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Abstract 
Genetic mutations that initiate and drive the progression of colorectal cancer cause defects in 
key signalling pathways that affect cell function. The Wnt signalling pathway is a key pathway 
that is disrupted in colorectĂů ĐĂŶĐĞƌĂŶĚɴ-ĐĂƚĞŶŝŶ ŝƐ ƚŚĞŬĞǇŵĞĚŝĂƚŽƌŽĨtŶƚ ƐŝŐŶĂůůŝŶŐ͘ɴ-
catenin is a multifunctional protein with roles in Wnt signalling and cell adhesion. I aimed to 
ƵŶĚĞƌƐƚĂŶĚ ƚŚĞ ƌĞůĂƚŝŽŶƐŚŝƉ ďĞƚǁĞĞŶ ƚŚĞ ŵĂŝŶ ŝŶƚĞƌĂĐƚŝŽŶƐ ĂŶĚ ĨƵŶĐƚŝŽŶƐ ŽĨ ɴ-catenin. 
SpecificaůůǇ͕/ŝŶǀĞƐƚŝŐĂƚĞĚŚŽǁĂƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶŝŶɴ-catenin, decreases in APC, E-cadherin 
ŽƌWdEĂůƚĞƌĞĚƚŚĞŝŶƚĞƌĂĐƚŝŽŶƐŽĨɴ-catenin and cell behaviour. 
I established that mutant, non-ĚĞŐƌĂĚĂďůĞ ɴ-catenin can be sequestered by APC and is less 
available for binding to and stabilising E-cadherin than wild-ƚǇƉĞ ɴ-catenin, which only 
ƚƌĂŶƐŝĞŶƚůǇŝŶƚĞƌĂĐƚƐǁŝƚŚW͘/ĨŽƵŶĚƚŚĂƚ͕ƐŝŵŝůĂƌƚŽƚŚĞɴ-catenin/E-cadherin protein complex, 
ƚŚĞɴ-catenin/APC complex also localises to the plasma membrane and cultured cells and tissue 
organoids. 
I also established a direct role for APC in directed cell migration that was independent of other 
genetic changes commonly found in colorectal cancer, including loss of PTEN, which on its own 
increased migration. To compare results from a cell culture to the situation in human tumours, 
ůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin was measured in adenomatous and serrated human colorectal polyps. 
/ŶĂůůƉŽůǇƉƐ͕ƚŚĞƉƌĞĚŽŵŝŶĂŶƚůŽĐĂƚŝŽŶŽĨɴ-catenin was the plasma membrane, even in polyps 
with a serrated histology and reduced PTEN signals. However, the changes in E-cadherin 
observed in cultured cells lacking PTEN were not reproduced in these tumours. I also discovered 
that changes in transcription did not always mirror changes in protein expression, suggesting a 
ŵƵĐŚŵŽƌĞĐŽŵƉůĞǆƌĞůĂƚŝŽŶƐŚŝƉďĞƚǁĞĞŶƚŚĞƚǁŽŵĂŝŶĨƵŶĐƚŝŽŶƐŽĨɴ-catenin than expected. 
Together, my data reveal that the distribution of E-catenin between its main functions as an 
adhesion or transcriptional regulator, cannot be predicted by tŚĞŵƵƚĂƚŝŽŶƐƚĂƚƵƐŽĨWŽƌɴ-
XIV 
 
catenin alone, but is affected by many other signalling pathways that are frequently dis-
regulated in cancer. 
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1 Introduction 
1.1 Colorectal Cancer 
Colorectal cancer is the fourth most common cancer in the United Kingdom with approximately 
41,600 diagnoses annually (CRUK 2015). In Scotland, around 3,500 patients are diagnosed with 
bowel cancer every year and it is the second most common cause of cancer death (COWG 
(2000)). Males in the United Kingdom have a 1 in 16 lifetime risk of a colorectal carcinoma 
diagnosis, while the risk in females is 1 in 20 (CRUK 2015). Bowel cancer risk increases with age 
and over 80% of diagnoses are in patients over the age of 60. A history of bowel cancer in close 
relatives is also associated with increased risk, as are lifestyle factors such as smoking, obesity 
and a western diet (CRUK 2015). 
Current treatment has variable success. Radical surgical excision can offer a cure if the disease 
is at an early stage, but unfortunately does not in patients with advanced or metastatic disease. 
Surgery is combined with chemotherapy and/or radiotherapy. Most chemotherapeutic agents 
interfere with DNA or RNA synthesis, (Dihlmann and von Knebel Doeberitz 2005) preferentially 
destroying rapidly dividing tumour cells, but side effects are common due to off-target effects 
on normal cells. Despite recognition that significant clinical and tumour heterogeneity exists in 
colorectal cancer, current therapy remains largely non-specific. Individualised, targeted 
therapies based on features of both the tumour and patient may prove beneficial. Currently, 
this strategy is unavailable in the majority of cases. 
Survival outcome in colon cancer is heavily influenced by disease stage and an overall five year 
survival rate of 60% is achieved. For lesions diagnosed at an early stage this increases to over 
95%, but for cancers diagnosed at an advanced stage, five year survival is less than 10%(CRUK 
2015). Colorectal cancers are thought to develop from benign precursor polyp lesions that 
undergo malignant transformation over time (Fearon and Vogelstein 1990). This presents an 
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opportunity for detection at an early stage, which has prognostic benefits. The potential benefits 
of early detection prompted the implementation of population-based bowel screening 
programmes using guaiac-based faecal occult blood testing (FOBt). Early studies assessing FOBt-
based bowel screening in the UK identified an increase in the proportion of early stage tumours 
(Hardcastle et al. 1996, Team 2003). The benefits of this screening modality have been 
confirmed in randomised controlled trials and a meta-analysis showed a 16% overall reduction 
in mortality for screened patients (Mandel et al. 1993, Kronborg et al. 1996, Towler et al. 1998, 
Hewitson et al. 2008, Mackay et al. 2014). 
The detection rate of early stage polyp cancers has increased as a result of the screening 
programme. Many of these lesions are resected endoscopically and found to have a focus of 
malignancy on pathological assessment, but as no lymph nodes are present in the resection 
specimen, full pathological staging cannot take place. These lesions are a management 
conundrum because predicting which patients have lymph node involvement and would 
therefore benefit from formal surgical resection is difficult. Studies to date have identified the 
presence of vascular invasion, tumour grade, tumour budding, depth of invasion and positive 
resection margins to be associated with lymph node involvement (Ueno et al. 2004, Mitchell and 
Haboubi 2008, Gill et al. 2013). A National Institute of Clinical Excellence (NICE) guideline in 2011 
attempted to identify which treatment was the best for patients that had undergone local 
excision of stage I colorectal cancer (including polyps) and subsequently found to have 
unfavourable pathological prognostic features. Based on current available evidence, no formal 
recommendation could be made (Poston et al. 2011). A large nationwide study is currently under 
way in an attempt to provide robust evidence that can guide therapeutic decision making. 
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1.2 General aims of the Thesis Project 
Mutations of APC and conƐĞƋƵĞŶƚ ĐŚĂŶŐĞƐ ŝŶ ɴ-catenin lie at the core of colorectal cancer. 
Dysfunction of the Wnt signalling pathway and cell adhesion are linked to the initiation and 
ƉƌŽŐƌĞƐƐŝŽŶŽĨ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͘ɴ-Catenin is central to both of these functions and does so 
through interaction with either APC or E-cadherin. 
 
E-Catenin forms complexes with both APC and E-cadherin. Formation of these two distinct 
complexes is mutually exclusive. It is unclear how the amounts or functions of APC and E-
cadherin influence each other. 
This thesis aims to measure the impact of mutations commonly implicated in colorectal cancer 
ŽŶƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin between complexes containing APC and complexes containing 
E-cadherin and how this impacts on cell function. Specifically, the mĂŶŝƉƵůĂƚŝŽŶŽĨɴ-catenin, 
WĂŶĚWdEǁĂƐƵƐĞĚƚŽŐĂŝŶĂĚĞĞƉĞƌƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨŚŽǁƚŚĞƌĞůĂƚŝŽŶƐŚŝƉƐŽĨɴ-catenin 
with its key binding partners (APC and E-cadherin) may change in cancer and what consequences 
this has for the function of the cell. 
A greater understanding of the molecular mechanisms that drive colorectal cancer may provide 
opportunities to develop improved diagnostic and screening modalities or specific targeted 
therapies. 
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1.3 The gastrointestinal tract 
1.3.1 Intestinal function 
The main function of the intestine is the digestion of food and absorption of nutrients. A 
specialised epithelial surface comprises a barrier between the body and the intestinal luminal 
content (Tortora 1995). Within the gut epithelium, there are several resident specialised cell 
types with functions related to secretion, hormone production and self-renewal. The most 
common cell type is the absorptive enterocyte. These cells are primarily responsible for the 
uptake of nutrients from the bowel lumen and their transport to the capillaries in the 
submucosa. The cells are polarised with microvilli at their luminal surface to increase absorptive 
surface area and organised cell–cell junctions where adhesion complexes are located (Brittan 
and Wright 2004b). Alongside the enterocytes are mucous secreting goblet cells and 
enteroendocrine cells, which release hormonal signals to regulate intestinal function(Heath 
2000) (Figure 1.1). 
In both the small and large intestines, the epithelium is characterised by invaginations called 
crypts of Lieberkuhn. In the small bowel, finger-like projections called villi extend into the lumen, 
which increases the surface area for nutrient absorption. There are no villi in the large intestine 
and the crypt opening, also referred to as the ‘collar,’ lies flush with the intestinal lumen. 
1.3.2 The colonic crypt 
The colonic crypt unit contains numerous specialised epithelial cell types as well as self-renewing 
stem cells. In total, a crypt contains approximately 250 cells (Marshman et al. 2002). Two 
populations of stem cells are thought to reside in the crypt and can be identified by the marker 
leucine-rich G protein-coupled receptor 5 (Lgr5).  A crypt base population as well as a slower 
cycling population of stem cells can be found in the +4 position in the crypt (Simons and Clevers 
2011)Self-renewing stem cells are resident at the crypt base and give rise to all cell types resident 
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in the crypt (Leushacke and Barker 2012). Daughters of the stem cells undergo cell division in 
the transient amplifying zone prior to terminal differentiation into terminal specialised epithelial 
cells(Brittan and Wright 2004a). Differentiated cells migrate up the crypt and are then shed into 
the lumen after 3–4 days(van der Flier and Clevers 2009). The Paneth and stem cells remain 
resident at the crypt base (Figure 1.1). 
Normal functioning of the crypt relies on the integrated co-ordination of proliferation, 
differentiation, migration, adhesion and exfoliation into the bowel lumen. Perturbations in any 
of these key cell functions can potentially lead to the initiation and subsequent progression of 
cancer. 
Genetic mutation can trigger disruption of the normal crypt function and architecture leading to 
the formation of early-stage precursor lesions termed aberrant crypt foci. An accumulation of 
genetic defects in these lesions can drive progression of carcinoma through the development of 
colonic polyps and eventually carcinoma. 
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Figure 1.1: Schematic depiction of an intestinal crypt. Stem cells (green) and Paneth cells (pink) 
are resident in the stem cell niche at the base of the crypt. Stem cell progeny undergo further cell 
divisions in the transit amplifying compartment prior to terminal differentiation into specialised 
epithelial cell types: enterocyte (white), goblet cell (blue) and endocrine cells (purple). Cells 
migrate up the crypt prior to being shed in the gut lumen. 
1.4.1 Pathogenesis of colorectal cancer 
The transformation of normal colonic epithelium into cancer is thought to progress via 
accumulation of genetic mutations that cause changes in the histological appearance and 
structure of the tissue. The earliest microscopic changes, termed aberrant crypt foci, progress 
into benign polyps, defined as abnormal protrusions of the mucosa into the bowel lumen 
(Williams et al. 2013). Early polyps are benign, but progression results in malignancy when cells 
breach the muscularis mucosa (Lipper et al. 1983, Morson et al. 1984). Approximately 10% of 
polyps will progress to cancer (Hisabe et al. 2014) and an estimated 35% of patients will develop 
further polyps following removal within five years (Neugut et al. 1985, Winawer et al. 1993). 
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Robust indices that could predict which polyps are likely to progress and/or recur would be 
clinically beneficial in both management and surveillance strategies. 
1.4.2 Classification of colorectal polyps 
Colorectal polyps are classified according to three main categories. The first is based on 
histological features of the polyp, the second is related to specific mutations in the polyp and 
the third relates to mechanisms of conferring genetic instability into tumours. 
The first classifier refers to the histological appearance of the polyp. In this thesis, reference is 
made to two main histological categories; conventional adenomatous polyps and serrated 
adenomas. Conventional adenomas are sometimes referred to as developing along the 
traditional or conventional pathway while serrated adenomas are described as being on the 
serrated or alternative pathway of carcinogenesis. 
Conventional adenomas can be further subdivided by histological type into tubular, tubulo-
villous or villous. End-stage carcinomas produced by this pathway are classified as 
adenocarcinomas. The second category is serrated adenomas, which are composed of sessile 
serrated adenomas, traditional serrated adenomas and hyperplastic polyps. The serrated 
adenoma pathway is sometimes referred to as the alternative pathway. 
The second main category of classification is based on specific molecular characteristics that 
refer to mutations in particular genes such as APC, P53, BRAF, KRAS or PTEN. 
The third category is based on more global molecular features of the lesion. This includes two 
mechanisms that confer genetic instability to a tumour. Chromosomal instability is the first of 
these and refers to aberrant rearrangements or duplications of chromosomes. The second is 
termed microsatellite instability. This is used to indicate genomic instability. This is often caused 
by mutation or methylation of DNA mismatch repair genes MLH1 or MSH2. This is sometimes 
referred to as the mutator phenotype. The last classification in this category is the CpG island 
8 
 
methylator genotype (CIMP). A CIMP-high tumour is characterised by extensive methylation, 
which can act to silence important tumour suppressor genes. 
The two main histological categories of colorectal polyps, conventional adenomatous polyps and 
serrated polyps, are broadly characterised by distinct features. Conventional adenomas are 
characterised by the accumulation of mutations in key tumour suppressors and oncogenes. This 
promotes progression of benign lesions to cancer and is termed the adenoma–carcinoma 
sequence(Fearon and Vogelstein 1990). These lesions are characterised by early mutations in 
adenomatous polyposis coli (APC) and subsequent mutations in P53, KRAS and 
SMAD4(Dickinson et al. 2015). These conventional lesions are characterised by chromosomal 
instability and are CIMP low (Figure 1.2). 
Serrated lesions are less common than conventional adenomas and debate exists as to their 
exact classification and characteristics. Approximately 10% of colorectal cancers are serrated 
carcinomas, derived from serrated polyps (Makinen et al. 2001). Precursor lesions in serrated 
carcinomas are serrated polyps and hyperplastic polyps (Goldstein 2006). Distinct histological 
subtypes exist in serrated adenomas with some lesions displaying serrated dysplasia while 
others are characterised by conventional adenomatous dysplasia (Tsai 2014). Common 
mutations associated with the serrated pathway are in the BRAF gene, present in an estimated 
80% of serrated cancers (Lochhead et al. 2014). K-ras mutation has also been associated with 
distal serrated lesions (Yamane et al. 2014). These lesions are also characterised by 
microsatellite instability (Jass 2007) and tend to be CIMP high (Jass 2007). 
Although common in conventional adenomas, APC mutation is an infrequent finding in studies 
so far in serrated lesions (Uchida et al. 1998, Dehari 2001, Sawyer et al. 2002, Fu et al. 2012) 
although methylation of APC may occur in some serrated lesions (Kim et al. 2011). 
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Murine studies have also linked phosphatase and tensin homologue deleted on chromosome 
ten (PTEN) with the development of serrated lesions and potential functional interaction of 
PTEN, KRAS and APC. Wild-type mice and mice with a predisposition to adenoma development 
(Apc fl/+) had intestinal specific deletion of PTEN and activation of KRAS. The (Apc fl/+) mice, 
predisposed to adenoma, had a significantly reduced lifespan compared with APC wild-type mice 
and lesions had evidence of invasive carcinoma but no metastasis. However, the APC wild-type 
mice with deletion of PTEN and activation of KRAS developed sessile serrated adenomas, 
hyperplastic polyps as well as metastasising serrated carcinomas, characteristic of the human 
pathway of serrated carcinogenesis (Davies et al. 2014). A study by the same group also 
implicates PTEN in the conventional pathway of carcinogenesis. Intestinal deletion of PTEN alone 
caused no change in intestinal architecture. However, PTEN deletion in APC heterozygous mice 
significantly reduced the lifespan and led to the development of invasive adenocarcinoma 
compared with only adenoma development in APC heterozygotes with PTEN (Marsh et al. 2008). 
PTEN mutation has also been associated with the serrated pathway in human cancers. An 
analysis of 489 cancers found PTEN mutation in 5.8%. Interestingly, the tumours with PTEN 
mutation were significantly associated with proximal tumours, microsatellite instability, CIMP 
high and BRAF mutation. These are all features associated with the sessile serrated pathway 
(Day et al. 2013). A recent genome wide analysis of 276 samples to characterise mutations found 
in colorectal cancer identified PTEN mutation in 4% of non hyper-mutated cancers (Cancer 
Genome Atlas 2012). 
A schematic of both the conventional and serrated pathways of colorectal carcinogenesis is 
shown in Figure 1.2. 
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Figure 1.2: A schematic of the adenoma to carcinoma sequence is shown. The top panel (orange) 
shows the conventional pathway and the genes commonly implicated in this progression along 
with chromosomal instability. The bottom panel (green) shows the serrated pathway and 
associated common mutations depicted with CpG Island methylator phenotype and 
microsatellite instability. This figure is a modification of (Dickinson et al. 2015). 
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1.5 Adenomatous Polyposis Coli (APC) 
1.5.1 The APC Protein 
The Apc gene was identified on chromosome 5q21 as the genetic defect responsible for familial 
adenomatous polyposis coli (FAP). This autosomal dominant condition results in hundreds to 
thousands of benign colonic polyps, of which some inevitably undergo malignant change via the 
conventional pathway of colorectal carcinogenesis necessitating prophylactic colectomy in the 
majority of patients. Positional cloning of the FAP locus then resulted in identification of the Apc 
gene (Kinzler et al. 1991, Su et al. 1992). 
2843 amino acids make up the large 312 kDa multifunctional APC protein. The N terminal 
domain contains two nuclear export sequences, binding sites for protein phosphatase 2a (PP2A) 
and microtubules (Nathke 2004). 
The central portion of APC contains elements vital for regulating proteins in the Wnt signalling 
pathway. This region contains three or four 15 amino acid repeats and seven 20 amino acid 
ƌĞƉĞĂƚƐ͘dŚĞƐĞƌĞƉĞĂƚƐďŝŶĚɴ-catenin (Rubinfeld et al. 1996). Interspersed within these repeats 
are SAMP sequences that can bind to Axin (Fagotto et al. 1999). This mid-portion of APC is also 
a binding site for GSK3E. The overlapping binding sites for these important interactors are in the 
same region on APC, suggesting that binding may be mutually exclusive. 
The C terminal end of APC contains two microtubule binding regions (Munemitsu et al. 1994, 
Smith et al. 1994, Dikovskaya et al. 2010) and is capable of binding to the microtubule end-
binding protein EB1 (Askham et al. 2000) (Figure 1.3). This region also binds to actin. 
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Figure 1.3: A schematic representation of the APC protein. Binding partners are colour coded 
according to their recognised binding locations. 
1.5.2 The Functions of APC 
Truncating mutations of APC are responsible for FAP and are also found in >90% of colorectal 
carcinomas (Fodde 2002). The high incidence of APC defects in colorectal cancers suggests that 
APC is vital in governing normal epithelial homeostasis. Mutations in this multifunctional protein 
may impact on many different cellular functions that can predispose to cancer if unregulated. 
1.5.2.1 APC in the canonical Wnt signalling pathway 
APC is an essential component of the Wnt ƐŝŐŶĂůůŝŶŐƉĂƚŚǁĂǇĂŶĚŵŽĚƵůĂƚĞƐɴ-catenin (Figure 
ϭ͘ϰͿ͘/ŶƚŚĞĂďƐĞŶĐĞŽĨĂtŶƚƐŝŐŶĂů͕ɴ-catenin is targeted for degradation by the proteasome. 
This relies on the formation of a destruction complex composed of casein kinase 1 (CK1), 
GSK3Eprotein phosphatase 2, the scaffold protein axin and APC. CK1 and GSK3E mediated 
phosphorylation of the scaffold protein axin, increases its binding affinity to E-catenin (Luo et al. 
2007), increasing the efficacy of E-catenin phosphorylation by CK1 (Dajani et al. 2003). CK1 
ƉŚŽƐƉŚŽƌǇůĂƚĞƐ ɴ-catenin at serine residue 45, priming it for subsequent sequential 
phosphorylation at serine residues 41, 37 and 33 by GSK3E (Yost et al. 1996, Liu et al. 2002). The 
ƉŚŽƐƉŚŽƌǇůĂƚĞĚɴ-catenin is targeted by E-TrCP E3 ubiquitin ligase and subsequently degraded 
by the proteasome (Hart et al. 1999). 
Upon binding of a Wnt ligand to its receptor Frizzled, the destruction complex is inhibited. This 
ƉƌĞǀĞŶƚƐɴ-catenin degradation allowing its accumulation and translocation to the cell nucleus. 
Here, its interaction with T-cell factor (TCF) and Lymphoid enhancer factor (LEF) transcription 
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factors (Brantjes et al. 2002), stimulates transcription of a plethora of Wnt target genes (He et 
al. 1998, van de Wetering et al. 2002, Sansom et al. 2004) affecting the proliferation and 
differentiation of cells. 
dƌƵŶĐĂƚŝŽŶŵƵƚĂƚŝŽŶƐŝŶWĐĂŶƌĞƐƵůƚŝŶƚŚĞůŽƐƐŽĨɴ-catenin regulation, and this plays a key 
role in the initiation and progression of colorectal cancer. 
1.5.2.2 APC and Cell migration 
APC also interacts with and stabilises microtubules via binding of its C-terminal region directly 
to microtubules or to the microtubule binding protein EB1 (Munemitsu et al. 1994, Nathke 
2004). Microtubule functioning is important to the cytoskeleton, such as cell division and co-
ordinated cell migration. APC mutation can negatively impact on these functions, contributing 
to cancer progression (Nelson and Nathke 2013) as co-ordinated, directional cell migration is 
required for normal function of the intestinal crypt. Normally, cells ascend the crypt and are 
shed into the intestinal lumen. Mutations causing migration defects can result in the cell having 
an increased residency in the crypt, allowing time for it to accumulate further mutations to drive 
cancer progression. 
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Figure 1.4: Schematic representation of APC in the canonical Wnt pathway. In the absence of a 
Wnt signal (a) the destruction complex sequentially phosphorylates E-catenin, which targets it 
for E-TrCP-mediated ubiquitination and subsequent proteosomal degradation. Upon binding of 
a Wnt ligand (b) to LRP6 an interaction between the Wnt receptor and Frizzled causes inhibition 
of the destruction complex. This leads to accumulation of E-catenin and translocation to the 
nucleus where it activates transcription of Wnt target genes causing cell proliferation. 
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ϭ͘ϲɴ-Catenin 
ɴ-Catenin is a multifunctional protein with key roles in embryonic development as well as tissue 
homeostasis, renewal and regeneration in adult organisms (Valenta et al. 2012). It was 
discovered independently twice in relation to two of its most important functions, cell adhesion 
and Wnt signalling. It was initially isolated along with proteins associated with Ca2+-dependent 
cell adhesion at adherens junctions, D-catenin, plakoglobin and E-cadherin (Ozawa et al. 1989). 
Studies of its Drosophila ŽƌƚŚŽůŽŐƵĞ ƌŵĂĚŝůůŽ ƌĞǀĞĂůĞĚ ƚŚĞ ƐŝŐŶĂůůŝŶŐ ĨƵŶĐƚŝŽŶ ŽĨ ɴ-catenin. 
Armadillo mutants in Drosophila fail to develop the organised segments of denticles and belts 
in the Drosophila embryonic cuticle characteristic of the wild-type embryo (Wieschaus E 1984). 
Further studies found that the function of Armadillo in segmentation of the embryonic cuticle is 
regulated by wingless (Wnt) (Riggleman et al. 1990) ƚŚƵƐŝĚĞŶƚŝĨǇŝŶŐƚŚĞƌŽůĞŽĨɴ-catenin in the 
Wnt signalling pathway. The nematode Caenorhabdidis elegans ŚĂƐƚŚƌĞĞĚŝƐƚŝŶĐƚɴ-catenins. 
One has an adhesion specific role (HMP-2) and two are for signalling (BAR-1) & (WRM-1) (Liu et 
al. 2008)͘dŚĞĂďŝůŝƚǇŽĨĂƐŝŶŐůĞɴ-catenin to carry out two important but disparate functions in 
humans may partly relate to the protein structure. 
ϭ͘ϲ͘ϭ^ƚƌƵĐƚƵƌĞŽĨɴ-catenin 
ɴ-Catenin is composed of 781 amino acid residues in humans. Twelve Armadillo repeats 
comprise the central region (Figure 1.5) with each repeat comprising 42 residues arranged in 
three helices. Together, the helices form a super helix that forms a positively charged groove 
providing a binding platform for APC, E-cadherin and TCF/Lef. This renders the binding of APC, 
E-ĐĂĚŚĞƌŝŶ ĂŶĚ d&ͬ>ĞĨŵƵƚƵĂůůǇ ĞǆĐůƵƐŝǀĞ ďĞĐĂƵƐĞ ƚŚĞŝƌ ďŝŶĚŝŶŐ ƐŝƚĞƐ ŽŶ ɴ-catenin overlap 
(Valenta et al. 2012). The central region is flanked by N and C terminal domains, which may be 
structurally flexible (Huber et al. 1997)͘dƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŝƐƉĞƌĨŽƌŵĞĚďǇŵŽŶŽŵĞƌŝĐɴ-
ĐĂƚĞŶŝŶǁŚĞƌĞĂƐĂɴ-catenin–D-catenin dimer associates with E-cadherin at adhesion junctions 
(Gottardi and Gumbiner 2004). E-Cadherin binding requires all 12 Armadillo repeats, whereas 
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interaction with TCF in the nucleus only requires the eight central repeats. Back folding of the 
flexible C-terminus could potentially impede binding to E-cadherin but not to TCF (Graham et al. 
2000, Huber and Weis 2001). The C terminal domain has been shown to be essential for 
signalling but dispensable for adhesive function (Xing et al. 2008). Specific mutations in the 
Drosophila orthologue Armadillo disrupt adhesive function but do not impact on Wnt/Wingless 
signalling activity or vice versa (Orsulic and Peifer 1996)͘dŚĞůŽĐĂƚŝŽŶŽĨɴ-catenin in the cell may 
also influence its function in either signalling or adhesion. Each of these functions will now be 
considered 
 
Figure 1.5: Schematic representation of the E-catenin protein showing central Armadillo repeats 
flanked by the N and C termini. Important phosphorylation sites at S33, S37, T41 and S45 that 
mediate E-catenin destruction are also represented. Binding regions of E-cadherin, APC, Axin and 
TCF /Lef show overlap implying mutual exclusivity in binding. 
ϭ͘ϲ͘Ϯ&ƵŶĐƚŝŽŶƐŽĨɴ-Catenin 
ϭ͘ϲ͘Ϯ͘ϭɴ-Catenin in cell adhesion 
ɴ-Catenin was first identified in conjunction with E-cadherin at adhesion junctions. These 
junctions are critical in the formation of polarised epithelial tissues and the maintenance of 
tissue organisation (Meng and Takeichi 2009). Cadherins are transmembrane proteins that 
function in Ca2+-dependent cell adhesion and are named according to the tissue in which they 
predominantly function. E-cadherin refers to epithelial cadherin, although other forms such as 
N-cadherin also exist (Meng and Takeichi 2009). 
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Interaction between E-ĐĂĚŚĞƌŝŶĂŶĚɴ-catenin is essential for effective formation of functional 
ĂĚŚĞƌĞŶƐũƵŶĐƚŝŽŶƐǁŝƚŚɴ-catenin binding to the cytoplasmic tail of E-cadherin. The catenin–
cadherin interaction is initiated while the newly synthesised cadherin is in the endoplasmic 
reticulum and the two proteins are transported as a unit to the plasma membrane (Hinck et al. 
1994). Its association with E-ĐĂĚŚĞƌŝŶ ĂůƐŽ ƐƚĂďŝůŝƐĞƐ ɴ-catenin, as this cadherin-bound pool 
cannot be targeted for destruction by the APC destruction complex (Huber and Weis 2001). 
Cadherin-ďŽƵŶĚɴ-catenin can also bind D-catenin at distal segments of the N-terminus (Pokutta 
and Weis 2000). This simultaneous binding functionally links the adherens junction to the actin 
cytoskeleton via D-ĐĂƚĞŶŝŶ͘dŚĞɴ-catenin–D-catenin interaction forms a heterodimer, while as 
a homodimer D-catenin interacts with actin, promoting bundling of actin filaments (Benjamin et 
al. 2010)͘dŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨɴ-catenin and D-catenin at adherens junctions therefore can impact 
on the dynamics of the actin cytoskeleton (Yamada et al. 2005). 
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ϭ͘ϲ͘Ϯ͘Ϯɴ-Catenin and the Wnt Signalling Pathway 
ɴ-Catenin is the key effector molecule of the Wnt signalling pathway. In the absence of a Wnt 
ůŝŐĂŶĚ͕ɴ-catenin is targeted for destruction by a multiprotein complex containing APC, axin, 
GSK3E and CK1 (Figure 1.4). Binding of a Wnt ligand to its receptor leads to inhibition of the 
destruction complĞǆ͕ƌĞƐƵůƚŝŶŐŝŶƐƚĂďŝůŝƐĂƚŝŽŶĂŶĚĂĐĐƵŵƵůĂƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶ͘dŚĞɴ-catenin can 
ƚŚĞŶ ƚƌĂŶƐůŽĐĂƚĞ ƚŽ ƚŚĞ ŶƵĐůĞƵƐ ĂŶĚ ďŝŶĚ ƚŽ d&ͬ>ĞĨ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ĨĂĐƚŽƌƐ͘ dŚĞ ďŝŶĚŝŶŐ ŽĨ ɴ-
catenin converts TCF/Lef from transcriptional repressors to transcriptional activators, 
stimulating transcription of specific Wnt target genes (Najdi et al. 2011, Archbold et al. 2012). 
1.6.2.2.1 Wnt signalling in intestinal carcinogenesis 
ɴ-Catenin is central in maintaining normal intestinal tissue homeostasis and ordered structure 
ŽĨƚŚĞĐŽůŽŶŝĐĐƌǇƉƚ;&ŝŐƵƌĞϭ͘ϭͿ͘ɴ-Catenin/TCF transduction of the Wnt signal is important in 
maintenance of the progenitor phenotype of crypt-base stem cells (Reya and Clevers 2005). 
Paneth cells are a source of Wnt (Farin et al. 2012) and establish a focused Wnt gradient in 
relation to the neighbouring stem cell (Sato 2013). The resultant high Wnt level in the stem-cell 
niche supports the self-renewing properties of the stem cells. Cells further up the crypt are 
exposed to a decreasing Wnt gradient, allowing escape from the self –renewing stem cell 
phenotype and differentiation into specialised epithelial-cell-type lineages (Sato 2013). In TCF4-
null mice the crypt progenitor compartment is lacking, implying that its existence is dependent 
on Wnt signalling and is responsible for maintenance of self-renewing stem cells at the crypt 
base (Korinek et al. 1998). This is supported by studies that inhibit the Wnt receptor in adult 
mice using Dickkopf-1, which results in loss of crypts (Pinto et al. 2003, Kuhnert et al. 2004). 
ǇƐĨƵŶĐƚŝŽŶŽĨɴ-catenin in the gut can have dire consequences and is tightly associated with 
ĐĂƌĐŝŶŽŵĂ͘ɴ-Catenin is usually implicated in carcinogenesis following loss of APC, occurring in 
>90% of colorectal cancers. Some tumours lacking APC mutation have been found to have 
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ĂĐƚŝǀĂƚŝŶŐŵƵƚĂƚŝŽŶƐŽĨɴ-catenin (Miyaki et al. 1999) (Johnson et al. 2005) and some authors 
ƐƵŐŐĞƐƚƚŚĂƚWĂŶĚɴ-catenin mutation in tumours is mutually exclusive (Morin et al. 1997) 
(Sparks et al. 1998). E-Catenin mutations are far less common than loss of APC and are 
characterised by point mutation of N-terminal residues or deletion of exon 3 (Ilyas et al. 1997, 
Morin et al. 1997, Johnson et al. 2005, Segditsas and Tomlinson 2006). Like APC loss, these 
mutations result in the loss of important phosphorylation sites (residues 33, 37, 41 & 45) that 
ĂƌĞǀŝƚĂůĨŽƌƚŚĞƚĂƌŐĞƚĞĚĚĞŐƌĂĚĂƚŝŽŶŽĨɴ-catenin and one may intuitively expect the functional 
consequences to be comparable. 
ɴ-Catenin mutations are particularly associated with HNPCC, an inherited autosomal dominant 
condition characterised with DNA mismatch repair defects and a predisposition to cancer. One 
ƐƚƵĚǇ ŝĚĞŶƚŝĨŝĞĚɴ-catenin mutations in 43% of HNPCC tumours. /ŶƚĞƌĞƐƚŝŶŐůǇ͕ŶŽŶĞŽĨ ƚŚĞɴ-
catenin mutant tumours had APC mutation (Miyaki et al. 1999), while a separate analysis found 
ϭϴйŽĨƐƚƵĚŝĞĚ,EWƚƵŵŽƵƌƐƚŽŚĂǀĞĂɴ-catenin mutation. 
In contrast, the mutation rate iŶƐƉŽƌĂĚŝĐĐĂŶĐĞƌƐŝƐůĞƐƐ͘EŽɴ-catenin mutations were identified 
ŝŶĂƐĞƌŝĞƐŽĨƐƉŽƌĂĚŝĐĐĂŶĐĞƌƐ͕ĂůƚŚŽƵŐŚϭ͘ϮйŽĨƐƚƵĚŝĞĚĂĚĞŶŽŵĂƐĐĂƌƌŝĞĚɴ-catenin mutations 
in the same series ((Johnson et al. 2005). Similarly, 12.5% of small adenomas were found to have 
Ăɴ-catenin mutation versus only 2.4% of large adenomas and 1.4% of sporadic cancers in a 
distinct series (Samowitz et al. 1999)͘ dŚŝƐ ƐƵŐŐĞƐƚƐ ƚŚĂƚ ůĞƐŝŽŶƐ ŚĂƌďŽƵƌŝŶŐŵƵƚĂƚŝŽŶƐ ŝŶ ɴ-
catenin may be less likely to progress than those with loss of APC. Considering that the functional 
ĐŽŶƐĞƋƵĞŶĐĞƐŽƵŐŚƚƚŽƌĞůĂƚĞƚŽƚŚĞƉƌĞƐĞŶĐĞŽĨƐƚĂďŝůŝƐĞĚɴ-catenin in both cases, the reasons 
fŽƌ ƚŚŝƐĂƌĞƵŶĐůĞĂƌ͘EŽŶĞƚŚĞůĞƐƐ͕ ƚŚĞƐĞ ĨŝŶĚŝŶŐƐ ƐƵŐŐĞƐƚ ƚƵŵŽƵƌƐǁŝƚŚĞŝƚŚĞƌŵƵƚĂƚŝŽŶŽĨɴ-
catenin or APC may progress along divergent paths with distinct outcomes.  
ůƚŚŽƵŐŚƵŶĐŽŵŵŽŶ ŝŶ ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ͕ŵƵƚĂƚŝŽŶ ŝŶ ɴ-catenin exon 3 is found with more 
frequency in other tumour types such as hepatocellular carcinoma and pseudo papillary 
tumours of the pancreas (Huels 2015). In colorectal cancer mutations out with exon 3  at the C-
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ƚĞƌŵŝŶƵƐŽĨɴ-catenin can also be identified (Cancer Genome Atlas 2012). These mutations do 
ŶŽƚĂĨĨĞĐƚĂŶǇŽĨƚŚĞŬĞǇƌĞƐŝĚƵĞƐƌĞůĞǀĂŶƚĨŽƌɴ-catenin stabilisation. It is unclear therefore if 
these are passenger mutations or if they can influence phenotype. 
>ŽƐƐŽĨWŽƌĂĐƚŝǀĂƚŝŶŐŵƵƚĂƚŝŽŶƐŝŶɴ-ĐĂƚĞŶŝŶďŽƚŚůĞĂĚƚŽƐƚĂďŝůŝƐĞĚɴ-catenin. However the 
frequencies of these mutations in colorectal cancer are markedly different. The reasons for this 
are unclear but it may relate to the levels of Wnt signalling required to initiate tumour genesis 
in the gut. The pattern of APC mutations appear to be selected to provide an optimal but not 
ŵĂǆŝŵĂů ůĞǀĞů ŽĨ ɴ-catenin transcriptional activation. This leads to favourable conditions to 
stimulate transformation (Fodde and Brabletz 2007, Buchert et al. 2010). Other authors have 
also suggested that in the presence of wild type APC an activating mutation may not be sufficient 
ƚŽĚƌŝǀĞĐĂƌĐŝŶŽŐĞŶĞƐŝƐĂƐƚŚĞɴ-catenin can be bound and sequestered by E-cadherin (Huels 
2015). 
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1.6.3 Crosstalk between Adhesion and Transcriptional regulation functions 
ɴ-Catenin has distinct roles in cell adhesion and transcriptional regulation. Interaction with E-
ĐĂĚŚĞƌŝŶ Žƌ W ƌĞŐƵůĂƚĞƐ ƚŚŝƐ ĨƵŶĐƚŝŽŶĂů ďĂůĂŶĐĞ ďƵƚ ƚŚĞŝƌ ďŝŶĚŝŶŐ ƚŽ ɴ-catenin is mutually 
ĞǆĐůƵƐŝǀĞ͘ ,Žǁ ƚŚĞ ĐĞůů ĚĞƚĞƌŵŝŶĞƐ ŚŽǁ ɴ-catenin is partitioned between adhesive and 
transcriptional functions is unclear, but crosstalk between the two is necessary (Figure 1.6). 
^ƚƵĚŝĞƐ ŝŶ ƚŚĞϭϵϵϬƐ ƐŚŽǁĞĚ ƚŚĂƚĂĚŚĞƐŝŽŶĂŶĚtŶƚ ƐŝŐŶĂůůŝŶŐĚƌĂǁŽŶ ƚŚĞ ƐĂŵĞƉŽŽůŽĨɴ-
catenin and a bias towards one function can impact on the other. 
Dorsal axis formation in the xenopus embryo is dependent on Wnt signalling, and this can be 
inhibited by overexpression of cadherins (Heasman et al. 1994). The wingless phenotype in 
drosophila, characterised by segment polarity defects, can be mimicked by overexpression of 
cadherin. This phenotype is due to an absence of wingless, which in turn leads to reduced levels 
ŽĨƌŵĂĚŝůůŽ ;ɴ-catenin), negatively impacting on its signalling function. These findings imply 
that E-ĐĂĚŚĞƌŝŶĐĂŶƐƚĂďŝůŝƐĞĂƉŽŽůŽĨƌŵĂĚŝůůŽ;ɴ-catenin) reducing its signalling role (Sanson 
et al. 1996)͘ƌŵĂĚŝůůŽ;ɴ-catenin) mutant drosophila have a less severe segment polarity defect 
if one E-cadherin allele is expressed compared with flies with two (Cox et al. 1996). The authors 
of this study proposed that expression of only one E-cadherin allele could free up wild-ƚǇƉĞɴ-
catenin, allowing it to play more of a signalling role, thus reducing phenotypic severity. In SW480 
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ĐĞůůƐ͕ ĐĂĚŚĞƌŝŶ ĞǆƉƌĞƐƐŝŽŶ ƚƌŝŐŐĞƌĞĚ Ă ƚƌĂŶƐůŽĐĂƚŝŽŶ ŽĨ ɴ-catenin from the 
nucleus to the plasma membrane with an associated reduction in LEF-mediated transcription 
(Sadot et al. 1998). In a similar fashion, embryonic stem cells lacking E-cadherin display an 
ĂĐĐƵŵƵůĂƚŝŽŶ ŽĨ ŶƵĐůĞĂƌ ɴ-catenin and increased transcription of Wnt target genes. This 
phenotype was rescued by expression of wild-type E-cadherin but not E-ĐĂĚŚĞƌŝŶůĂĐŬŝŶŐƚŚĞɴ-
catenin binding domain (Orsulic et al. 1999). 
The influence of E-ĐĂĚŚĞƌŝŶŽŶɴ-catenin-mediated transcription may be influenced by activity 
of the Wnt pathway. DLD-1 colorectal cancer cells contain a truncating mutation in APC causing 
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activation of the Wnt pathway. siRNA-mediated depletion of E-cadherin in these cells results in 
ĚŝƐƐŽĐŝĂƚŝŽŶŽĨĂĚŚĞƌĞŶƐũƵŶĐƚŝŽŶƐ͕ƚƌĂŶƐůŽĐĂƚŝŽŶŽĨɴ-catenin to the nucleus and augmentation 
of Wnt-mediated transcription. In contrast, the same treatment caused no effect on 
transcription in HaCaT keratinocytes, which lack Wnt activity. Forced expression of E-cadherin 
in fibroblasts that also lack Wnt activity alters cell morphology but does not impact on gene 
transcription (Kuphal and Behrens 2006)͘ dŚƵƐ͕ ƐƚĂďŝůŝƐĂƚŝŽŶ ŽĨ ɴ-catenin by binding to E-
ĐĂĚŚĞƌŝŶ Ăƚ ĐĞůů ũƵŶĐƚŝŽŶƐ ĐĂŶ ƉƌŽǀŝĚĞ Ă ƌĞƐĞƌǀŽŝƌ ĨŽƌ ĨƌĞĞ ĐǇƚŽƉůĂƐŵŝĐ ɴ-catenin to bind. 
Dissociation of the adherens junctions on the other hand can potentially ƌĞůĞĂƐĞɴ-catenin from 
its association with E-cadherin, increasing ƚŚĞƐŝŐŶĂůůŝŶŐĨƵŶĐƚŝŽŶŽĨɴ-catenin (Heuberger and 
Birchmeier 2010). 
dŚĞƉĂƌƚŝĐŝƉĂƚŝŽŶŽĨɴ-catenin in either a signalling or adhesion role may be influenced by specific 
phosphorylation signatures. Regulation by APC is reliant on the presence of several N-terminal 
residues that require phosphorylation for degradation to proceed. Likewise, stability of the 
adherens junctions is influenced by specific phosphorylation signatures. These residues are 
generally located towards the C-ƚĞƌŵŝŶƵƐŽĨɴ-catenin, the opposite end of the molecule to 
those phosphorylation sites important to the function of APC. Phosphorylation of residues 
ƐĞƌŝŶĞϲϴϲĂŶĚϲϵϮŝŶĐƌĞĂƐĞƐƚŚĞƐƚĂďŝůŝƚǇŽĨƚŚĞŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and E-cadherin 
(Huber and Weis 2001). Alternatively, phosphorylation of residue tyrosine 654 decreases the 
ĂĨĨŝŶŝƚǇŽĨɴ-catenin for E-cadherin, which may enhance signalling activity (Piedra et al. 2001). 
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Figure 1.6: Schematic representation of the dual functions of E-catenin in the Wnt signalling 
pathway and cell adhesion. E-catenin is the effector protein of the Wnt signalling pathway (left 
of figure). In the absence of a Wnt signal, E-catenin is marked for degradation by the APC 
destruction complex prior to degradation by the proteasome. A Wnt signal inhibits the 
destruction complex and cytoplasmic E-catenin accumulates and can translocate to the nucleus 
stimulating transcription of Wnt target genes via interaction with TCF/Lef transcription factors. 
E-Catenin forms a dimeric interaction with D-catenin, which interacts with the actin 
cytoskeleton. The E-catenin/D-catenin dimer binds to the junctional protein E-cadherin. Both 
functions draw on the same cellular pool of E-catenin and crosstalk exists between adhesion and 
Wnt signalling functions. 
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ϭ͘ϲ͘ϯZŽůĞŽĨɴ-Catenin in Epithelial to Mesenchymal Transition (EMT) 
ƌŽƐƐƚĂůŬ ďĞƚǁĞĞŶ ƚŚĞ ĂĚŚĞƐŝŽŶ ĂŶĚ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů ƌŽůĞƐ ŽĨ ɴ-catenin has relevance in the 
process of epithelial to mesenchymal transition (EMT), an important process in the progression 
of cancer. Tight regulation of cell adhesion is a requirement for normal tissue homeostasis and 
abnormalities are involved in carcinogenesis through the process of EMT. During EMT, highly 
organised polarised epithelial cells acquire a phenotype characteristic of more motile 
mesenchymal cells expressing N-cadherin, with a reduction in E-cadherin (Thiery et al. 2009, 
Zeisberg and Neilson 2009)͘ tŶƚ ƚĂƌŐĞƚ ŐĞŶĞƐ ƵŶĚĞƌ ƚŚĞ ĚŝƌĞĐƚ ŝŶĨůƵĞŶĐĞ ŽĨ ɴ-catenin are 
ŝŵƉůŝĐĂƚĞĚ ŝŶ ƚŚŝƐ ƉƌŽĐĞƐƐ͘ ɴ-Catenin directly upregulates Snail 2, whereas Wnt signalling-
mediated inhibition of GSK3E can cause an increase in the level of Snail 1 (Zhou et al. 2004, Yook 
et al. 2006). Both Snail 1 and 2 repress E-cadherin transcription (Barrallo-Gimeno and Nieto 
2005)͘ŶŝŶĐƌĞĂƐĞŝŶɴ-catenin signalling following APC loss in cancer could therefore enhance 
cancer progression by causing down regulation of E-cadherin in the EMT process. Other Wnt 
target genes can also promote EMT by either suppression of E-cadherin transcription (Slug) 
(Vallin et al. 2001), up regulation of N-cadherin (Twist) (Howe et al. 2003) or cleavage of E-
cadherin (ADAM10) (Maretzky et al. 2005) (Figure 1.7). 
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Figure 1.7: Schematic representation of the involvement of E-catenin in EMT. Wnt signalling and 
destabilisation of E-cadherin can increase the signalling function of E-catenin. This can lead to 
up regulation of E-cadherin transcriptional repressors Snail, Slug and Twist, which depress 
transcription of E-cadherin. EMT is also associated with an up regulation of N-cadherin and 
cleavage of E-cadherin by ADAM10. 
/ƚŝƐĐůĞĂƌƚŚĂƚƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin by two distinct complexes containing either APC or E-
cadherin is relevant for the initiation and progression of colorectal cancer. One of the main aims 
ŽĨŵǇ ƚŚĞƐŝƐ ŝƐ ƚŽ ƵŶĚĞƌƐƚĂŶĚ ŚŽǁ ƚŚŝƐ ŝƐ ĐŽŶƚƌŽůůĞĚ͘ DƵƚĂƚŝŽŶƐ ŝŶ ɴ-catenin or in APC are 
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associated with cancer, although the frequencies of these defects are different and they do not 
co-exist. It is unclear how mutations leading to seemingly comparable molecular defects, i.e. 
ƐƚĂďŝůŝƐĞĚɴ-catenin, can diverge in terms of disease progression. Determination of how these 
ŵƵƚĂƚŝŽŶƐ ƵƉƐĞƚ ƚŚĞ ďĂůĂŶĐĞ ŽĨ ŝŶƚĞƌĂĐƚŝŽŶƐ ďĞƚǁĞĞŶ ɴ-catenin and APC or E-cadherin may 
clarify the functional defects that influence cancer progression. 
1.7 PTEN 
1.7.1 PTEN and colorectal carcinoma 
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a tumour suppressor 
gene, located at chromosome 10q23. PTEN mutation is implicated in PTEN hamartomatous 
tumour syndrome, an autosomal dominant condition that predisposes to colorectal cancer. This 
is comprised of patients with either Cowden Syndrome or Bannayan–Riley–Ruvalcaba syndrome 
(Campos et al. 2015). Both syndromes carry risk of gastrointestinal polyps with malignant 
potential as well as extra intestinal manifestations. As many as 80% of patients with a PTEN 
mutation in Cowden’s syndrome will have intestinal polyps, with 18% developing colorectal 
cancer by age 60 (Nieuwenhuis et al. 2012). These patients also carry a risk of developing 
carcinoma in other organs, including breast, thyroid, endometrium and kidney (Tan et al. 2012). 
PTEN protein loss is also implicated in sporadic colorectal cancers. The frequency of reported 
loss varies between studies from 12–78% of cases (Parsons et al. 2005, Sartore-Bianchi et al. 
2009, Wiesweg et al. 2013, Yip et al. 2013, Chong et al. 2014). PTEN mutation has also been 
linked with the alternative serrated pathway of colorectal carcinogenesis. A large study 
examining 1,093 colorectal cancers identified PTEN mutation in 5.8% of tumours. Interestingly, 
these PTEN mutant tumours more commonly had BRAF mutation, MSI high, CIMP high and a 
proximal location. These are all features associated with sessile serrated tumours (Day et al. 
2013). 
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1.7.2 PTEN structure and function 
The PTEN gene encodes a 403 amino acid protein with both lipid and protein phosphatase 
activity. It is composed of a phosphatase domain and a C2 domain, which constitute the main 
functional units of the protein. In addition, the N-terminus has a binding region for 
phosphatidylinositol (PI) 4,5-bisphosphonate (PIP2), whereas the C-terminal end of the protein 
has a PDZ binding domain as well as a PEST sequence (Lee et al. 1999). 
 
 
 
 
Figure 1.8: The structure of PTEN protein. The 403 amino acid sequence is composed of 185 N-
terminal amino acids containing a PIP2 binding domain between residues 1–15 and a 
phosphatase domain (residues 25–185). A C-terminus, containing PEST motifs and a PDZ binding 
region at the C-terminal extreme is joined by the C2 domain (amino acids 185–351) to complete 
the C-terminal region. 
PTEN is a multifunctional protein with an important role as a tumour suppressor. It plays a key 
role in the negative regulation of the phosphatidylinositol (PI) 3, 4, 5-triphosphate (PIP3)-
mediated activation of the Akt signalling pathway. Ligand activation of receptor tyrosine kinases 
leads to phosphorylation of PIP2 by phosphoinositide 3-kinase (PIK3) creating PIP3. This 
activates the Akt pathway, stimulating cell proliferation, progression of the cell cycle, growth 
and survival (Koul et al. 2002, Fata et al. 2012, Song et al. 2012). PTEN’s lipid phosphatase activity 
directly antagonises PIK3 activity by dephosphorylation of PIP3. This PTEN-induced negative 
regulation of PIP3 and its downstream effectors can induce a tumour-suppressing effect. PTEN 
loss on the other hand can result in unrestrained activation of PI3K effectors (Di Cristofano and 
Pandolfi 2000, Cully et al. 2006) (Figure 1.9 h). PTEN mutation is commonly implicated in 
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prostate and endometrial carcinoma. Loss of the negative regulation of the Akt pathway is 
thought to account for tumour genesis following PTEN loss in these cancers (Kwak et al. 2013) 
 
Figure 1.9: A simplified schematic of PTEN involvement in the PI3K/Akt pathway. Binding of 
growth factor to tyrosine kinase receptor activates PI3K, which phosphorylates PIP2 to PIP3. The 
phosphatase activity of PTEN facilitates the reverse conversion of PIP3 to PIP2. PIP3 can then 
activate Akt via PDK1. Akt has multiple downstream effects. It positively influences cell growth, 
survival and proliferation while negatively impacting on apoptosis. It also inhibits GSK3E. This 
can lead to reduced function of the APC destruction complex resulting in increased levels of E-
catenin. Loss of PTEN leads to activation of the Akt pathway. Ras mutations also feed into this 
pathway by influencing the function of PI3K. 
Mutations affecting the C-terminal domain can also influence PTEN function and account for the 
majority of PTEN tumorigenic mutations. Aprroximately 40% of PTEN mutations are located in 
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exon 5 which contains the phosphatase domains, essential for the lipid and phosphatase 
functions of PTEN. These mutations result in truncation leading to loss of the phosphatase 
domain or missense mutations in the phosphatase motif leading to loss of function.(Waite and 
Eng 2002, Sansal and Sellers 2004). The C2 domain has been shown to play a role in cell migration 
and EMT in multiple systems. Loss of PTEN can result in increased cell migration, and this has 
been shown to be specifically related to loss of its protein phosphatase function (Leslie et al. 
2007). The role of PTEN in the EMT process may be related to an association with adherens 
junctions. 
  
30 
 
1.8 PhD Proposal 
Work in the Näthke laboratory is focused on cell biology of the gut, specifically related to the 
function of APC and colorectal cancer. In this proposal, I aim to establish factors that regulate 
ƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin between complexes containing APC and complexes containing E-
cadherin. 
Specifically, I will: 
ƐƚĂďůŝƐŚŚŽǁĂƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶŝŶɴ-catenin affects its involvement in complexes with either 
APC or E-cadherin. 
ĞƚĞƌŵŝŶĞŚŽǁƚŚĞĂďƐĞŶĐĞŽĨWdEŝŶĨůƵĞŶĐĞƐƚŚĞůĞǀĞůƐŽĨɴ-catenin, APC and E-cadherin and 
how it affects the ƌĞůĂƚŝǀĞŝŶƚĞƌĂĐƚŝŽŶŽĨɴ-catenin with either APC or E-cadherin. 
ƐƚĂďůŝƐŚ ŚŽǁ ŐĞŶĞƚŝĐ Žƌ ďŝŽĐŚĞŵŝĐĂů ŵĂŶŝƉƵůĂƚŝŽŶ ŽĨ ɴ-catenin, APC and PTEN affects the 
proliferation, migration and invasion of colorectal cancer cells. 
Determine if the expression patterns ŽĨ ɴ-catenin, E-cadherin and PTEN differ between 
conventional colorectal polyps and polyps with a serrated histology. 
&ŝŶĚŝŶŐƐĨƌŽŵƚŚŝƐƐƚƵĚǇǁŝůůĂĚĚƚŽŽƵƌŬŶŽǁůĞĚŐĞŽĨŚŽǁŵƵƚĂƚŝŽŶƐŝŶɴ-catenin and loss of 
APC or PTEN change the relative interactions ĂŶĚĨƵŶĐƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin. This may reveal 
reasons why tumours characterised by certain mutational signatures progress, while others with 
related but distinct mutations, may not. Insight into this could highlight opportunities for 
identifying high-risk patients that justify a more aggressive treatment or surveillance regime 
with the aim of improving prognosis. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Primary Antibodies 
Antibody Source Cat. No. Clonality Species Application Dilution 
(Biochemistry) 
Dilution 
(Imaging) 
ɴ-catenin Abcam AB16051 Monoclonal Mouse Biochemistry / 
Imaging 
1:500 1:500 
ɴ-catenin 74 Näthke 
Self-
Generated 
N/A Polyclonal Rabbit 
(C-
termnus) 
Biochemistry 1:500 1:500 
M-APC Näthke 
Self-
Generated 
N/A Monoclonal Mouse 
(aa 788-
1038) 
Imaging N/A 1:200 
N-APC Näthke 
Self-
Generated 
N/A Polyclonal Rabbit 
(aa 1-300) 
Biochemistry 1:500 N/A 
APC–ALI Näthke 
Self-
Generated 
N/A Monoclonal Mouse 
(aa135-
422) 
Biochemistry 1:500 N/A 
E-cadherin Cell Signalling 24E10 Polyclonal Rabbit Biochemistry / 
Imaging 
1:500 1:100 
PTEN Cell Signalling 9559 Monoclonal Rabbit Biochemistry 1:500 N/A 
PTEN Sigma Aldrich Ab-370 Polyclonal Rabbit Imaging N/A 1:50 
Phospho-Akt Cell Signalling 4060 Monoclonal Rabbit Biochemistry 1:500 N/A 
SNAIL Cell Signalling #3879 Monoclonal Rabbit Biochemistry 1:50 N/A 
GAPDH Life 
Technologies 
MA5-15738 Monoclonal Mouse Biochemistry 1:1000 N/A 
Rhodamine 
phalloidin 
Molecular 
Probes 
T-7471 N/A N/A Imaging N/A 1:50 
 
 
2.1.2 Secondary antibodies and nuclear stain 
 
All secondary antibodies were provided by molecular probes (Invitrogen, Oregon USA). The 
nuclear stain 4c,6-diamidino-2-phenylindole dihydrochloride (DAPI) was sourced from Sigma-
Aldrich (D9542). 
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2.1.3 Short interfering RNAs 
Product Company Symbol Modification Target Sequence 
E-catenin 
siRNA 
 
Qiagen CTNNB1 nil Sense 
5c-CGGGAUGUUCACAACCGAATT-3c 
Anti-sense 
5c-UUCGGUUGUGAACAUCCCGAG-3c 
E-catenin 
siRNA 
(Fluorescent tag) 
Qiagen CTNNB1 3cCy5 Sense 
5c-CGGGAUGUUCACAACCGAATT-3c 
Anti-sense 
5c-UUCGGUUGUGAACAUCCCGAG-3c 
E-cadherin 
siRNA 
Qiagen CDH1 nil Sense 
5c-AGGUAUUGUCUACUCUGAATT-3c 
Anti-sense 
5c-UUCAGAGUAGACAAUACCUAG-3c 
E-cadherin 
siRNA 
(Fluorescent tag) 
Qiagen CDH1 3cCy5 Sense 
5c-AGGUAUUGUCUACUCUGAATT-3c 
Anti-sense 
5c-UUCAGAGUAGACAAUACCUAG-3c 
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PTEN 3 
siRNA 
Qiagen PTEN nil Sense 
5c-ACGGGAAGACAAGTTCATGTA-3c 
Anti-sense 
5c-UACAUGAACUUGUCUUCCGT-3c 
PTEN 8 
siRNA 
Qiagen PTEN nil Sense 
5c-CGAUAGCAUUUGCAGUAUATT-3c 
Anti-sense 
5c-UAUACUGCAAAUGCUAUCGAT-3c 
D-catenin 1 
siRNA 
(Fluorescent tag) 
Qiagen CTNNA1 3cCy5 Sense 
5c-GUGGAUAAGCUGAACAUUATT-3c 
Anti-sense 
5c-UAAUGUUCAGCUUAUCCACTT-3c 
D-catenin 2 
siRNA 
(Fluorescent tag) 
Qiagen CTNNA2 3cCy5 Sense 
5c-CCAUUGUAUUCACUAACUATT-3c 
Anti-sense 
5c-UAGUUAGUGAAUACAAUGGTA-3c 
APC SiRNA 
DUPLEX 5 
Sigma APC NIL Sense 
5c-GAUGAUAUGUCGCGAACUUU-3c 
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Anti-sense 
5c-AAGUUCGCGACAUAUCAUCUU-3c 
APC SiRNA 
DUPLEX 6 
Sigma APC NIL Sense 
5c-GAGAAUACGUCCACACCUUUU-3c 
Anti-sense 
5c-AAGGUGUGGACGUAUUCUCUU-3c 
APC SiRNA 
DUPLEX 7 
Sigma APC NIL Sense 
5c-GAACUAGAUACACCAAUAAUU-3c 
Anti-sense 
5c-UUAUUGGUGUAUCUAGUUCUU-3c 
APC SiRNA 
DUPLEX 5 
(Fluorescent tag) 
Sigma APC 3cCy5 Sense 
5c-GAUGAUAUGUCGCGAACUUU-3c 
Anti-sense 
5c-AAGUUCGCGACAUAUCAUCUU-3c 
APC SiRNA 
DUPLEX 6 
(Fluorescent tag) 
Sigma APC 3cCy5 Sense 
5c-GAGAAUACGUCCACACCUUUU-3c 
Anti-sense 
5c-AAGGUGUGGACGUAUUCUCUU-3c 
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APC SiRNA 
DUPLEX 7 
(Fluorescent tag) 
Sigma APC 3cCy5 Sense 
5c-GAACUAGAUACACCAAUAAUU-3c 
Anti-sense 
5c-UUAUUGGUGUAUCUAGUUCUU-3c 
Negative 
Control 
Qiagen   All stars negative control 
Flexitube siRNA (20mmol) 
Product number:1027418 
 
36 
 
2.1.4 qPCR primers 
Gene Company 5c forward primer 3c 5c reverse primer 3c TM (°C) 
Actin Eurofins CTGGGAGTGGGTGGAGGC TCAACTGGTCTCAAGTCA 59.3 
AXIN2 Eurofins TGGCTATGTCTTTGCACCAG TGTTTCTTACTGCCCACACG 59.3 
ɴ-catenin Eurofins ATGGCTTGGAATGAGACTGC TTCCATCATGGGGTCCATAC 59.3 
E-cadherin Eurofins TGGAGGAATTCTTGCTTTGC CGTACATGTCAGCCAGCTTC 59.3 
 
2.1.5 Cell lines 
Cell lines were supplied by Horizon Discovery Ltd. Four HCT116 human colorectal cancer cell 
lines were ƐƚƵĚŝĞĚ͘dŚĞƐĞĐĞůůůŝŶĞƐĚŝĨĨĞƌĞĚŝŶƚŚĞŝƌɴ-catenin proteins. The parental cell line is 
ŚĞƚĞƌŽǌǇŐŽƵƐĨŽƌɴ-catenin ;ȴϰϱͬ+) and has one wild-ƚǇƉĞɴ-catenin allele and a corresponding 
ŵƵƚĂŶƚɴ-catenin allele that lacks serine 45. This residue is a target for phosphorylation by the 
APC destruction complex. Without phosphorylation of serine 45, subsequent phosphorylations 
Ăƚ ƌĞƐŝĚƵĞƐϰϭ͕ϯϳĂŶĚϯϯĐĂŶŶŽƚƚĂŬĞƉůĂĐĞ͘ƐĂ ƌĞƐƵůƚ͕ɴ-catenin cannot be degraded. This 
parental cell line was used to generate two fuƌƚŚĞƌĐĞůůůŝŶĞƐĚŝĨĨĞƌŝŶŐŝŶƚŚĞŝƌĞǆƉƌĞƐƐŝŽŶŽĨɴ-
catenin. This was done by insertion of Lox P sites and the Cre recombinase system.  
dŚĞƉĂƌĞŶƚĂůĐĞůůůŝŶĞŚĂƐƵŶĚĞƌŐŽŶĞŚĞƚĞƌŽǌǇŐŽƵƐĚĞůĞƚŝŽŶŽĨĞŝƚŚĞƌƚŚĞŵƵƚĂŶƚŽƌǁŝůĚƚǇƉĞɴ-
catenin to generate two further cell lines.  
The cell line referred to as “mutant” ŚĂƐ ŚĂĚ ƚŚĞǁŝůĚ ƚǇƉĞ ɴ-catenin deleted so exclusively 
ĞǆƉƌĞƐƐĞƐ ƚŚĞŵƵƚĂŶƚɴ-catenin ;ȴϰϱͬ-). Throughout this thesis I will refer to this cell line as 
“mutant” to reflect the fact that it only expresses mutant ;ȴϰϱͿɴ-catenin.  
The cell line referred to as “wild type” only expresses the wild-ƚǇƉĞɴ-catenin protein (-/+). It has 
had the mutant ;ȴϰϱͿĚĞůĞƚĞĚ͕ůĞĂǀŝŶŐŽŶůǇǁŝůĚƚǇƉĞɴ-catenin. Throughout the thesis this cell 
line will be referred to as wild type to reflect the fact that it only expresses one normal (wild 
ƚǇƉĞͿɴ-catenin protein.  
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The three cell lines described above all have wild type APC, E-cadherin and PTEN. 
The PTEN (-/-ͿĐĞůůƐĂƌĞĐŚĂƌĂĐƚĞƌŝƐĞĚďǇƚŚĞƐĂŵĞɴ-catenin expression as the parental cell line, 
but differ in that it has a homozygous deletion of PTEN. All of these cell lines carry an 
endogenous KRAS mutation (KRAS G13D/+). The PTEN (-/-) cells also have wild type APC and E-
cadherin.  
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Thawing of cells 
Cells were removed from cold storage in liquid nitrogen. A T75 tissue culture flask was prepared 
by addition of 15 ml of growth media. The vial containing the frozen cell pellet was immersed in 
a water bath at 37 °C briefly. Upon removal, 1 ml of prewarmed growth media was added to the 
vial and gently pipetted up and down. The media containing the cells were then added to the 
tissue culture flask. 
2.2.1.2 Cell passaging 
HCT116 human colorectal carcinoma cell lines were maintained in RPMI growth media 
supplemented with 10% FBS and penicillin/streptomycin under sterile conditions in tissue 
culture flasks. Cells were inspected daily. When cells had reached 70–80% confluence, they were 
passaged in the tissue culture hood. The cells were washed once in 1% trypsin. 4 ml of trypsin 
was then added to the flask and the flask returned to the incubator at 37 °C. After approximately 
5 minutes the cells were inspected for detachment from the culture vessel. 8 ml of culture media 
was added to the flask and an appropriate volume of this mixture was added to a new tissue 
culture vessel at an appropriate density as experiments dictated. 
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2.2.1.3 Cell counting 
A haemocytometer and cover slip were cleaned with 70% ethanol and left to dry in a tissue 
culture hood. A small volume of trypsinised cells in growth media was pipetted under the cover 
slip. Cells were visualised using a 20u microscope objective lens. Cells were counted in each of 
four quadrants and a mean count determined. This value was then used to determine the 
appropriate volume of cells required for each specified procedure. 
2.2.1.4 Cryopreservation of cells 
Cells were trypsinised and 8 ml of growth media was added. The mixture was pipetted into a 
falcon tube and centrifuged at 2000 rpm for 5 minutes. The supernatant was aspirated and 1 ml 
of freezing media (90% FBS, 10% DMSO) was added. The cells were resuspended and 100 Pl 
aliquots were added to cryovials. The vials were stored in a cryofreezing chamber at –80 °C for 
one night before being transferred to liquid nitrogen for long-term storage. 
2.2.2 Cell siRNA transfection 
siRNA transfections were carried out in T25 tissue-culture flasks. Cells were seeded the day prior 
to transfection to ensure they had reached a confluence of approximately 50% at the time of 
the transfection procedure. For each siRNA used, 8 Pl of 10 PM siRNA duplex was added to 200 
Pl of Opti-MEM and flick mixed. 16 Pl of INTERFERinTM (Polyplus TransfectionTM) was added to 
the mixture and homogenised for 10 seconds using a vortex. The same volumes were used for 
each siRNA duplex with the exception of APC in which 16 Pl of 10 PM siRNA, 32 Pl INTERFERin 
and 200 Pl of optimum were used. 
The mixtures were incubated for 10 minutes at room temperature. During the incubation period, 
growth medium was removed from each tissue culture flask and replaced with fresh prewarmed 
growth media. 200 Pl of the transfection mixture was added to each tissue culture flask. Cells 
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were incubated at 37 °C for 24 hours, at which point the transfection procedure was repeated 
as described above. A further 24 hour period of incubation was performed prior to cell 
harvesting. 
siRNA was chosen to perform down knock downs due to the reliability and reproducibility of 
results. In addition the system is straight forward to replicate in multiple experiments and fitted 
in well with the time constraints of the project.  
For each experiment involving targeted depletions using siRNA against specific genes negative 
control experiments were carried out in tandem. The control experiments were treated with 
scrambled siRNA. All other reagents used in the experimental conditions (interferin and 
optimum) were also used to treat cells under control conditions. This approach was taken 
whether the cells were to be used in protein experiments, RNA experiments or imaging. 
2.2.3 Microscopy 
2.2.3.1 Collagen coating of coverslips 
Cover slips were sterilised in 70% ethanol then each one placed in a well of a six-well plate prior 
to washing twice in PBS. 2 ml of collagen was added to the well and left for 4 hours in a sterile 
tissue culture hood. The collagen was aspirated from the well and the plate was left to incubate 
overnight under ultraviolet light in a tissue culture hood. 
2.2.3.2 Staining of cells 
Five hundred thousand cells were seeded onto collagen-coated cover slips and incubated at 37 
°C for 48 hours to achieve a confluence of approximately 80%. Growth medium was aspirated 
and cells were fixed in 4% paraformaldehyde (PFA) for 10 minutes, which was prepared prior to 
the procedure. Specifically, 1.85 g of PFA was dissolved in 3.7 ml doubly distilled H2O and 100 µl 
1 M potassium hydroxide was added. The solution was placed in a water bath at 60 °C. When 
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fully dissolved, the pH was adjusted to 7 and diluted to a final concentration of 4% in 1u PHEM 
buffer (60 mM Pipes, 4 mM MgSO4 25 mM (Formedium, Hepes 10), 10 mM EGTA, pH 6.9) and 
warmed to 37 °C prior to use. After fixation, cells were washed in wash buffer (0.02% sodium 
azide, 0.2% BSA in PBS). Cover slips were then transferred onto a parafilm sheet inside a dark 
humidified chamber for the remainder of the protocol. 
Cells were permeabilised in permeabilisation buffer (1% NP-40 in phosphate-buffered saline 
(PBS) for 10 minutes before repeated washing in wash buffer. Blocking buffer (5% normal goat 
serum, 2% bovine serum albumin (BSA), 0.02% sodium azide and 0.1% TX-100 in PBS) was added 
to coverslips for 30 minutes prior to a further wash. 
Primary antibodies were diluted at the appropriate concentration in incubation buffer (2% BSA, 
0.02% sodium azide, 0.1% TX-100 in PBS) and centrifuged for 5 minutes at 13,000g to remove 
aggregates before addition of 150 µl to each cover slip. Cells were incubated in primary antibody 
for 1 hour in the dark at 37 °C then washed in wash buffer for 3 u 5 minutes. 
Secondary antibodies attached to a fluorescent probe (Alexa Fluor 488, Alexa Fluor 568 or Alexa 
Fluor 647) (Molecular Probes, Invitrogen) were diluted in incubation buffer, centrifuged for 5 
minutes at 13,000g before addition of 150 µl to each cover slip and incubation in the dark for 1 
hour at 37 °C before washing in wash buffer for 3 u 5 minutes. 
Cells were then counterstained with 4,6-diamidino-2-phenylindole (DAPI) (1 µg/ml) for 10 
minutes followed by a further wash step. Cover slips were tilted to allow drying and were then 
inverted and placed on a drop of mountant (deoxygenated 90% v/v glycerol, 20 mM Tris pH 8.8, 
p-phenylenediamine). Coverslip edges were sealed with nail polish and left to dry in the dark for 
30 minutes prior to storage at –20 °C. Coverslips were thawed at room temperature and washed 
with ultra-pure water prior to imaging. 
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2.2.3.3 Staining of mouse tissue 
Tissue sections were placed in a slide holder at room temperature and rinsed twice in PBS for 
10 minutes prior to permeabilisation with 1% Triton for 20 minutes followed by a further PBS 
rinse. 
Sections were then blocked with blocking buffer (5% normal goat serum, 2% BSA, 0.02% sodium 
azide, 0.1% TX-100 in PBS) for 2 hours. They were incubated overnight with primary antibodies 
at 4 °C in working buffer (WB) (0.3% normal goat serum, 0.1% BSA, 0.2% TX-100 in PBS pH 7.4). 
Sections were then washed in WB five times for 5 minutes. Sections were then incubated in 
secondary antibodies diluted at a concentration of 1:500 for 1 hour at room temperature. 
The sections were then rinsed in WB for 5 u 5 minutes then 3 u 5 minutes in PBS prior to 
ĐŽƵŶƚĞƌƐƚĂŝŶŝŶŐǁŝƚŚW/ĂƚϭϬʅŐͬŵů;ϭ͗ϱϬͿƚŚĞŶĂŐĂŝŶƌŝŶƐĞĚŝŶW^͘ 
ƐŵĂůůĚƌŽƉ;ϭϬʅůͿŽĨŵŽƵŶƚĂŶƚ;WƌŽůŽŶŐŐŽůĚͿǁĂƐƉůĂĐĞĚŽŶƚŽƉŽĨƚŚĞƚŝƐƐƵĞƐĞĐƚŝŽŶĂŶĚĂ
number 1.5 22 u 22 mm coverslip was placed on top. These were allowed to harden at room 
temperature overnight and then sealed with nail polish the following day. Coverslips were 
washed with ultra-pure water prior to imaging. Samples were then stored at –20 °C. 
2.2.3.4 Staining of human tissue 
The same procedure described above was followed for staining human tissue slides. 
2.2.3.5 Confocal microscopy 
High-resolution images were captured using a Zeiss 710 confocal microscope. Images were 
acquired at 0.2 µm z-section intervals using a 40u objective lens. Images were processed using 
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the Zenn software imaging system. Further analysis was carried out using imageJ (Image 
processing and analysis in JAVA) and Imaris (Bitplane, Oxford Instruments). 
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2.2.4 Protein Analysis 
2.2.4.1 Cell lysis 
Cells were placed on ice for 5 minutes. Media was aspirated and the cells were washed three 
times with chilled PBS. Proteases; LPC (leupeptin, pepstatin A & chymostatin, each at 10 mg/ml 
in DMSO), sodium orthovanadate (0.1 M) and sodium fluoride (1 M) were added to MEBC lysis 
buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM NaEDTA, 5 mM NaEGTA, 40 mM E-
glycerophosphate and 0.5% NP-40) at a concentration of 1:100 (10 Pg/ml). 100 Pl of the mixture 
was spread over the base of a T25 flask and left on ice for 10 minutes. If the lysate was intended 
for incubation with phospho-specific antibodies, the same procedure was followed but with an 
alternative incubation buffer. In these cases the cells were incubated in (1u lysis buffer, 270 mM 
sucrose, 1 mM benzamide, 0.2 mM PMSF, 1 mM sodium orthovanadate, 0.1% 2-
mercaptoethanol, 0.1 µM microcystin LR, 1 tablet protease inhibitor and 4.2 ml deionised H2O). 
Material was then scraped from the dish and pipetted into a 1.5 ml Eppendorf tube. The tube 
was centrifuged for 20 minutes at 14,000 rpm at 4 qC. An 8 Pl aliquot was taken for 
determination of protein concentration while the remainder was snap frozen in liquid nitrogen, 
as was the pellet. Samples were stored at –80 qC. 
2.2.4.2 Protein concentration in lysates 
The Bradford assay was used to determine the protein concentration of cell lysate. Stock 
standards used were 0, 0.25, 0.5, 1, 1.5 and 2 mg/ml. Each standard was produced by adding 10 
Pl of the relevant stock standard to 790 Pl of water and 200 Pl of Bradford reagent. 
Protein samples were measured in triplicate. 2 Pl of each sample was added to 798 Pl of water 
and 200 Pl of Bradford reagent. Samples were vortexed prior to pipetting into a cuvette. They 
were then analysed using an OD595 spectrophotometer. 
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2.2.4.3 Cell fractionation 
The following cell fractionation protocol utilises a ProteoExtract® Subcellular Proteome 
Extraction Kit (EMD Biosciences). Cells were seeded at a density of 50% in a T25 flask and 
incubated at 37 qC under sterile conditions for 48 hours to achieve a cell density of 80–90% 
confluence. Buffers I–III and Benzonase® were kept on ice while Buffer IV and the protease 
inhibitor cocktail were stored at room temperature. Prior to extraction, buffers were mixed by 
vortexing. 
Growth media was aspirated from the cell culture vessel leaving approximately 500 Pl. The 
mixture was pipetted into a 1.5 ml Eppendorf tube containing 500 Pl of ice cold wash buffer. 
The tube was centrifuged at 300g for 10 minutes and the supernatant was carefully aspirated. 
This wash step was performed once more using 500 Pl of wash buffer. 
2.5 Pl of protease inhibitor was added to 500 Pl of extraction buffer I, and flick mixed in an 
Eppendorf tube. The cell pellet was gently resuspended in this mixture and incubated at 4 °C 
under gentle agitation for 10 minutes. The tube was then centrifuged for 10 minutes at 1000g. 
The supernatant was carefully pipetted into another Eppendorf tube as the Fraction 1 
(cytoplasmic) fraction and snap frozen in liquid nitrogen. 
500 µl of extraction buffer II was mixed with 2.5 µl of Protease Inhibitor cocktail and added 
immediately to the cell pellet. This was resuspended by gentle pipetting prior to incubation at 4 
qC for 30 minutes under gentle agitation. Insoluble material was sedimented by centrifugation 
at 6000g for 10 minutes at 4 qC. The supernatant was transferred to a separate tube as Fraction 
2 (Membrane) and snap frozen in liquid nitrogen. 
250 µl of extraction buffer III was mixed with 2.5 µl Protease Inhibitor cocktail and 0.75 µl of 
Benzonase®. This was immediately added to the cell pellet by pipetting up and down. It was then 
incubated for 10 minutes at 4 qC under gentle agitation. Insoluble material was sedimented by 
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centrifugation at 6800g for 10 minutes at 4 qC. The supernatant was transferred to a separate 
tube as Fraction 3 (Nucleus) and snap frozen in liquid nitrogen. 
250 µl of extraction buffer IV was mixed with 2.5 µl Protease Inhibitor cocktail and immediately 
added to the cell pellet. Residual particles were suspended by pipetting up and down. This was 
snap frozen in liquid nitrogen as Fraction 4 (Cytoskeleton). Samples were stored at –80 qC. 
2.2.5 Western blot 
2.2.5.1 SDS PAGE 
An appropriate volume of 4u loading buffer, protein sample and H2O were mixed in an 
Eppendorf tube. Samples were denatured by boiling for 10 minutes at 99 °C. After boiling, one 
twentieth the volume of DTT was added to each sample, flick mixed and briefly vortexed. 10 Pl 
of Benchmark protein ladder (Invitrogen 10747012) was added to the first well of the gel. An 
appropriate volume of sample was added to each well and the gel was run at 90 V in running 
buffer (outer chamber 475 ml H2O, 25 ml 20X MOPS-SDS, running buffer (FORMEDIUMTM MOPS-
SDS0500), inner chamber 190 ml H2O, 10 ml 20X MOPS-SDS running buffer with 500 Pl Nupage 
antioxidant (Invitrogen 162262)) until the gel had reached the bottom of the chamber. 
2.2.5.2 Electrophoretic transfer 
The gels were transferred to a 0.1 Pm Protran nitrocellulose membrane using a trans-blot 
transfer cell. Transfer buffer (200 ml 10u laemmli, 75 ml methanol and 1 ml 20% SDS in 1 L of 
H2O was used for transfer, which took place for 16 hours at 30 V. Transfers were carried out at 
4 °C. 
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2.2.5.3 Ponceau detection of proteins 
Membranes were submerged in Ponceau S solution to visualise all protein bands. This allowed 
marking of the protein ladder with a pen and cutting of the membrane as necessary. 
2.2.5.4 Detection of transferred proteins 
The membrane was washed in wash buffer (1 u TBS, 0.002% Triton X-100) to remove the 
Ponceau stain. Membranes were then blocked in blocking buffer (5% milk powder, 1 u TBS. 
0.02% Triton X-100 and 0.02% sodium azide) for 1 hour under gentle agitation at room 
temperature. Membranes were then transferred to a vessel containing blocking buffer with the 
appropriate primary antibody. Incubation time was antibody dependent and carried out at 4 °C. 
The membrane was then washed thoroughly for at least 3 u 5 minutes in wash buffer prior to 
incubation in blocking buffer containing the appropriate secondary antibody. Incubation in the 
secondary antibody lasted one hour at room temperature. A further 3 u 5 minute wash was 
carried out prior to imaging and quantification using the LI-COR Odyssey system. Protein signal 
intensity normalised to an appropriate loading control in the same sample was used to 
quantitate protein levels. 
2.2.6 Immunoprecipitation 
40 Pl of either sepharose protein A or G beads as appropriate were added to a 1.5 ml screw top 
Eppendorf tube on ice. Beads were washed u 2 in 750 Pl of MEBC prior to addition of 5 Pg of 
antibody or control IgG along with 200 Pl of MEBC and incubated overnight on a wheel rotator 
at 4 qC. The tubes were then centrifuged briefly and were again washed twice in MEBC. 50 Pg of 
lysate was kept for a pre-IP sample and 1 mg of lysate was then added to the beads and 
incubated for 2 hours at 4 qC. The volume of lysate used in the IP was approximately 500–750 
Pl. The beads were centrifuged briefly and a further 50 Pg of lysate was taken for a post-IP 
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sample. The beads were washed five times in MEBC with LPC, sodium orthovanadate (0.1 mM) 
and sodium fluoride (0.1 mM) on ice. 20 Pl of 1.3 u loading buffer was added to the beads and 
they were vortexed and snap frozen in liquid nitrogen. Samples were then loaded and separated 
using SDS PAGE and transferred as described above. 
2.2.7 Transfection of expression vectors 
Cells were grown in a well of a 6-well plate. When they were approximately 60% confluent the 
transfection procedure was performed. 2 ml of fresh growth media was placed in the well. The 
transfection mix was then prepared as follows. For each well to be transfected, 1 Pg of the 
appropriate vector was added to 200 Pl of optimum transfection media. To this, FuGENE 6 
(Promega UK©) transfection reagent was added in a volume exactly double the volume of the 
vector. For example, if 1 Pg of vector equalled 1 Pl then 2 Pl of FuGENE 6 was used. 
The appropriate volume of vector was added to the 200 Pl of Opti-MEM and flick mixed. The 
FuGENE 6 was then added to the mixture before vortexing. This was left to incubate at room 
temperature for 15 minutes. 200 Pl of the transfection mixture was then added dropwise to 
each well. Cells were incubated at 37 °C and harvested after 48 hours. The PTEN vectors were a 
kind gift from Dr Nick Leslie, Heriot Watt University, Edinburgh, Scotland. E-Catenin constructs 
encoding wild-type E-ĐĂƚĞŶŝŶƉƌŽƚĞŝŶĂŶĚĂŵƵƚĂŶƚɴ-catenin with the deletion of serine residue 
45 were used. Both had a myc tag. These constructs were available in-house and were originally 
developed by Dr Rolf Kemler described in (Aberle et al. 1997). 
2.2.8 Flow Cytometry 
2.2.8.1 FACS assisted cell counting 
Adherent cells were washed twice using PBS. Cells were then trypsinised and incubated at 37 °C 
until detached from the culture vessel. Trypsin was deactivated by addition of growth media and 
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cells were transferred to a Falcon tube. DAPI was diluted at a concentration of 1:500 in PBS and 
630 Pl was added to a FACS tube. The cell containing mixture was flick mixed and 70 Pl added 
to the PBS/DAPI solution. Cells were counted using a Verse flow cytometer. 
2.2.8.2 FACS staining 
Cells were suspended at approximately 5 u 105 cells/ml in PBS and washed twice in PBS + 1% 
w/v BSA (1 g/100 ml PBS) and pelleted by centrifugation at 2000 rpm for 5 minutes prior to 
aspiration of the supernatant. The cells were then resuspended in 500 Pl of staining buffer (50 
Pg/ml of propidium iodide and 50 Pg/ml ribonuclease A in PBS + 1% BSA) The cells were then 
incubated at room temperature, protected from light for 20 minutes prior to cell cycle 
assessment using a Verse flow cytometer. 
2.2.9 Cell Function Assays 
2.2.9.1 Cell proliferation assay 
Cells were counted using a Verse flow cytometer. Two thousand cells were seeded per well of a 
96-well plate. Each well was imaged once every 24 hours using the Incucyte Zoom live cell 
imaging system (Essen Bioscience). Cell confluence was calculated using the automated Incucyte 
zoom image analysis software. 
2.2.9.2 Cell migration assay 
Fifty thousand cells were seeded per well of a 96-well ImageLockTM plate and incubated at 37 qC 
for 24 hours achieving a confluence of 90–100%. A wound 700–800 Pm wide was created in each 
well using the Essen Bioscience WoundMaker™. Each well was washed u3 in PBS prior to 
addition of 100 Pl of growth media. Plates were incubated at 37 qC in the Incucyte Zoom live cell 
imaging system. Each well was imaged at two hourly intervals for 48 hours. Relative wound 
density was calculated using the Cell migration analysis software platform (Essen Bioscience). 
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2.2.9.3 Cell Invasion assay 
Fifty thousand cells were seeded per well of a 96 well ImageLockTM plate and incubated at 37 qC 
for 24 hours achieving a confluence of 90–100%. A wound 700–800 Pm wide was created in each 
well using the Essen Bioscience WoundMaker™. Each well was washed u3 in PBS prior to 
addition of 50 Pl of matrigel. Plates were placed in an incubator at 37 qC for 30 minutes to allow 
the matrigel to set. 100 Pl of growth media was then added to each well. Plates were incubated 
at 37 qC in the Incucyte Zoom live cell imaging system. Each well was imaged at two hourly 
intervals for 48 hours. Relative wound density was calculated using the Cell invasion analysis 
software platform (Essen Bioscience). The invasion assay differs from the migration assay by the 
presence of the matrigel. This forms a barrier that the cells have to invade through in order to 
cross the wound. 
2.2.10 Quantitative real-time PCR (qPCR) 
RNA was isolated from cells using a Nucleospin kit (Machery Nagel) according to the 
manufacturer’s instructions. The concentration of extracted RNA was determined using a 
NANODROP 1000 spectrophotometer (Thermo Scientific) and 1 µg was used for synthesis of 
cDNA. A qscriptTM cDNA synthesis kit (Quanta Biosciences) was used according to the 
manufacturer’s instructions along with a mastercycler gradient (Eppendorf). 5 µg of cDNA was 
used for analysis with a CFX connect real-time qPCR system (BIORAD) and PerfeCta SYBR Green 
FastMix for iQTM (Quanta Biosciences) according to the manufacturer’s instructions. 
For each cDNA amplification reaction, the time required to reach the exponential phase was 
normalised to a housekeeping gene (Actin) of the same cDNA sample and calculated relative to 
the control cell samples. To account for the difference in efficiency of each amplification 
reaction, the calibration for each qPCR reaction was achieved by measuring the point of 
temporary exponential DNA amplification in a set of serially diluted cDNA samples. For each 
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qPCR experiment Actin was used as a reference gene control. All changes in target gene 
transcript were measured relative to Actin. Actin was unchanged following any of the 
treatments in any of the cell lines used. 
2.2.11 Histological assessment of tissue slides 
The aim of assessing staining pattern on immuno-histochemistry slides was to determine if the 
locĂƚŝŽŶ ŽĨ ɴ-catenin and E-cadherin differed between polyps of conventional and serrated 
histology. The cells were divided into three regions, Membrane, cytoplasm and nucleus. A semi-
quantitative approach was taken to assessing the slides. The predominant loĐĂƚŝŽŶŽĨɴ-catenin 
and E-ĐĂĚŚĞƌŝŶǁĂƐĐůĂƐƐŝĨŝĞĚĂƐŵĞŵďƌĂŶĞ͕ĐǇƚŽƉůĂƐŵŽƌŶƵĐůĞƵƐ͘͘EƵĐůĞĂƌɴ-catenin stain was 
classified as present or absent. To compare stain intensity of PTEN between areas of 
conventional and serrated histology a score of low, medium or high was applied to indicate stain 
intensity. Slides were scored in conjunction with a consultant pathologist. A semi-quantitative 
approach to classification of signal intensity from immuno-histochemical slides in colorectal 
cancer is a recognised approach (Brown et al. 2014) (Huels et al. 2015). 
2.2.12 Statistical Analysis 
Unless otherwise stated t-test was undertaken to determine statistical significance. Significance 
level was set at p<0.05. Statistical values are only quoted where the result is discussed in the 
text. Results that are not addressed by further discussion will not have a quoted p value applied 
to them. 
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ϯWŽŝŶƚDƵƚĂƚŝŽŶŝŶɴ-Catenin Stabilises It and Affects Its Interaction with 
APC and E-cadherin 
3.1 Introduction 
ɴ-Catenin is a multifunctional protein, with roles in cell adhesion and in transcriptional 
regulation responsive to Wnt signalling (Figure 1.6). Function in the Wnt pathway is regulated 
by APC. dŚĞƌŽůĞŽĨɴ-catenin in adhesion is dependent on the interaction with E-cadherin to 
form functional adhesion junctions. Both APC and E-cadherin compete for overlapping binding 
ƌĞŐŝŽŶƐ ŽŶ ɴ-catenin, so their binding is mutually exclusive. However, adhesive and 
transcriptional functions have been shown to rely on the sĂŵĞƉŽŽůŽĨɴ-catenin. 
Overexpression of E-ĐĂĚŚĞƌŝŶĐĂŶ ƌĞĚƵĐĞ ƚŚĞĐŽŶƚƌŝďƵƚŝŽŶŽĨɴ-catenin to the Wnt signalling 
pathway in both Xenopus (Heasman et al. 1994) and Drosophila (Sanson et al. 1996), whereas a 
reduction in E-ĐĂĚŚĞƌŝŶĞǆƉƌĞƐƐŝŽŶĐĂŶĂƵŐŵĞŶƚƚŚĞƐŝŐŶĂůůŝŶŐĨƵŶĐƚŝŽŶŽĨɴ-catenin (Cox et al. 
1996). ƌĞĚƵĐƚŝŽŶŝŶtŶƚƚĂƌŐĞƚŐĞŶĞĞǆƉƌĞƐƐŝŽŶĂŶĚƚŚĞƚƌĂŶƐůŽĐĂƚŝŽŶŽĨɴ-catenin from the 
cell nucleus to the membrane can be achieved by expression of cadherin in SW480 colorectal 
cancer cells (Sadot et al. 1998). 
>ŽƐƐ ŽĨ W͕ ŽŶ ƚŚĞ ŽƚŚĞƌ ŚĂŶĚ͕ ƌĞƐƵůƚƐ ŝŶ ŝŶĐƌĞĂƐĞĚ ɴ-catenin due to loss of a degradative 
function with subsequent translocation to the cell nucleus and transcription of Wnt target genes 
(He et al. 1998, van de Wetering et al. 2002, Sansom et al. 2004). This process is implicated as 
an early and very common event in colorectal cancer (Miyaki et al. 1994, Fodde 2002). 
DƵƚĂƚŝŽŶƐŝŶɴ-catenin may also influence its ability to function in either a signalling or adhesive 
role. A study in human colorectal cancer cells (HCT116) found that exclusive expression of a 
mutant-ƐƚĂďŝůŝƐĞĚɴ-catenin decreased the strength of the bonds with E-cadherin compared with 
cells with only wild-ƚǇƉĞɴ-catenin. Single cells were brought into contact very briefly (1–300 ms) 
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then one was pulled away using a cantilever. Bond strength was measured using atomic force 
microscopy. Cells with one wild type and one mutant protein also exhibited a weaker E-
cadherin–cadherin bond than cells with only wild-ƚǇƉĞɴ-catenin. This signifies that the mutant 
ɴ-catenin may act in a dominant negative fashion ǁŚĞƌĞďǇƚŚĞƉƌĞƐĞŶĐĞŽĨŵƵƚĂŶƚɴ-catenin 
can impact negatiǀĞůǇŽŶďŽŶĚƐƚƌĞŶŐƚŚĚĞƐƉŝƚĞƚŚĞƉƌĞƐĞŶĐĞŽĨƚŚĞǁŝůĚƚǇƉĞɴ-catenin protein.. 
Comparable amounts of E-ĐĂĚŚĞƌŝŶǁĞƌĞ͕ŚŽǁĞǀĞƌ͕ŝĚĞŶƚŝĨŝĞĚŝŶĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚɴ-catenin. The 
effects of the mutations on interaction with APC were not assessed (Bajpai et al. 2013). A 
decrease in the association between N-ƚĞƌŵŝŶĂůůǇĚĞƉůĞƚĞƐƚĂďŝůŝƐĞĚɴ-catenin and E-cadherin 
has been identified previously, but again no assessment of the interaction with APC was made 
(Chan et al. 2002). 
/ƚŝƐĐůĞĂƌƚŚĂƚƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin in complexes with either APC or E-cadherin is central 
to the balance of its function in cell adhesion and transcriptional regulation. Disruption of these 
interactions is critical in the pathogenesis of colorectal cancer. I aim to explore the factors 
ƌĞŐƵůĂƚŝŶŐ ƚŚĞƐĞ ɴ-catenin complexes and the consequences of a point mutation leading to 
ƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-catenin. 
Specifically I will: 
1) Compare total protein levels of APC, ɴ-catenin and E-cadherin in parental, mutant and 
wild-type HCT116 cells. 
2) DĞĂƐƵƌĞƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin, E-cadherin and AXIN2 in these three cell lines. 
3) ƐƚĂďůŝƐŚǁŚĞƌĞŝŶƚŚĞĐĞůůɴ-catenin is located and if this changes in response to 
depletion ŽĨW͕ɴ-catenin, E-cadherin or PTEN. 
4) ĞƚĞƌŵŝŶĞŚŽǁƐƚĂďŝůŝƐĞĚɴ-ĐĂƚĞŶŝŶĂĨĨĞĐƚƐƚŚĞƌĞůĂƚŝǀĞůĞǀĞůŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-
catenin in complexes containing APC and those containing E-cadherin. 
5) ƐƚĂďůŝƐŚŝĨŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨɴ-catenin can cause changes in protein level of APC or E-
cadherin or affect transcription of AXIN2 and E-cadherin. 
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3.2 Results 
ϯ͘Ϯ͘ϭ͘ϭ^ ƚĂďŝůŝƐŝŶŐɴ-ĐĂƚĞŶŝŶĂĨĨĞĐƚƐƚŚĞĂďƵŶĚĂŶĐĞŽĨW͕ɴ-catenin and E-cadherin in HCT116 
cells 
I determined the total protein levels of APC, E-catenin and E-cadherin in the three HCT116 
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌĐĞůůůŝŶĞƐ͕ĚĞĨŝŶĞĚŝŶDĂƚĞƌŝĂůĂŶĚDĞƚŚŽĚƐ;WĂƌĞŶƚĂů;ȴϰϱͬнͿ͕ŵƵƚĂŶƚ;ȴϰϱͬ-) 
and wild type (-/+)). 
Cell lysis and western blot analyses showed differential expression of APC, E-catenin and E-
cadherin in the cell lines studied (Figure 3.1). 
 
Figure 3.1: Stabilising E-catenin mutations are associated with different expression levels of APC, 
E-catenin and E-cadherin. Whole-cell lysates from parental, mutant and wild-type HCT116 cells 
were subjected to western blot and probed with antibodies against APC, E-catenin and E-
cadherin. Total protein levels were normalised to GAPDH. Protein levels of APC (a), E-catenin (b) 
and E-cadherin (c) are plotted. Data represent the mean and standard deviation of three 
independent experiments. A representative western blot is shown in (d). 
 
E-cadherin expression is much higher in the wild-type cells compared with both the parental and 
mutant cell lines. ɴ-Catenin and APC levels are highest in the mutant cells and lowest in the wild 
types with the parental cell line showing intermediate expression levels. 
Statistical values quoted are based on t-tests unless otherwise stated. Statistical significance 
level is set at p < 0.05). APC levels are approximately two times greater in the mutant compared 
with parental cells (p < 0.05) while the wild-type cells express an APC level equivalent to the 
parental cells (p = 0.395). 
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dŚĞĐĞůůƐĂůƐŽĚŝĨĨĞƌŝŶƚŚĞŝƌĞǆƉƌĞƐƐŝŽŶůĞǀĞůŽĨɴ-catenin (p < 0.05 in comparison of both mutant 
and wild-type cells to the parental cell line). Expression of E-cadherin also differs between the 
parental, mutant and wild-type HCT116 cells (p < 0.05 for each comparison). E-cadherin 
expression in the parental and mutant cells is very low compared with the wild-type cell line. 
The low E-cadherin and higher APC in the mutant cells is the opposite pattern to the wild-type 
cells. This suggests that a point mutĂƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶŵĂǇĂůƚĞƌƚŚĞĚŝĨĨĞƌĞŶƚŝĂůŝŶƚĞƌĂĐƚŝŽŶŽĨɴ-
catenin with either APC or E-cadherin. dŚĞ ƐƚĂďŝůŝƐĞĚɴ-catenin cannot be degraded. This, in 
combination with very low levels of E-cadherin may lead one to hypothesise that the mutant cell 
line ŵĂǇŚĂǀĞŚŝŐŚĞƌůĞǀĞůƐŽĨɴ-catenin mediated transcriptional output. 
ϯ͘Ϯ͘ϭ͘Ϯ ^ƚĂďŝůŝƐĞĚ ɴ-ĐĂƚĞŶŝŶ ĂĨĨĞĐƚƐ ƚŚĞ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŽĨ ɴ-catenin and E-cadherin but not 
AXIN2. 
ĨƚĞƌ ĚĞĨŝŶŝŶŐ ƚŚĞ ƚŽƚĂů ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŽĨ ɴ-catenin, APC and E-cadherin, I measured the 
ƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin and E-cadherin. In addition, I also measured the transcription of 
y/EϮ͕Ăɴ-catenin target gene in each of the three cell lines (Figure 3.2). 
 
Figure 3.2: Stabilising E-catenin mutations affect transcription of E-catenin, AXIN2 and E-
cadherin in HCT116 cells. Transcript levels of E-catenin (a), AXIN2 (b) and E-cadherin (c) were 
measured using qPCR in whole-cell lysates of parental, mutant and wild-type HCT116 cells. 
Plotted values represent the mean and standard deviation of three independent experiments for 
each condition and levels are plotted relative to the parental cell line. 
E-cadherin transcript levels are significantly higher in the wild-type cell than the parental and 
mutant cell lines. ɴ-Catenin levels are lower in the mutant compared with both parental and 
wild-type cells while AXIN2 transcription is similar in all three cell lines. 
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The elevated E-cadherin protein in the wild type compared with the mutant and parental cells 
reflects the pattern of transcript expression. dƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin in the mutant cell line 
were significantly lower than the other two cell lines (p < 0.005 for both comparisons). This does 
ŶŽƚƌĞĨůĞĐƚƚŚĞƐůŝŐŚƚůǇŚŝŐŚĞƌůĞǀĞůŽĨɴ-catenin protein in the mutant cells. Perhaps because the 
stabilised protein is non-ĚĞŐƌĂĚĂďůĞ͕ƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨŶĞǁɴ-catenin is subdued to control overall 
levels. 
AXIN2 transcription was not significantly different between the three cell lines studied. This is 
surprising as the mutant and parental cell lines each express a non-ĚĞŐƌĂĚĂďůĞ ɴ-catenin 
protein, and intuitively one may expect this to be reflected by a greater degree of AXIN2 
transcription compared with the wild-type cells. In addition, the very low levels of E-cadherin 
ĂǀĂŝůĂďůĞ ƚŽ ďŝŶĚ ɴ-catenin in the parental and mutant cells may have been expected to 
ĞǆĂĐĞƌďĂƚĞɴ-catenin transcriptional activity, but it did not. 
dŚĞƐĞĨŝŶĚŝŶŐƐŵĂǇŝŶĚŝĐĂƚĞƚŚĂƚƐƚĂďŝůŝƐĞĚɴ-catenin is bound to and sequestered by APC in the 
mutant and parental cells, although this hypothesis requires further experiments for 
clarification͘dŚĞƐĞƌĞƐƵůƚƐĂůƐŽŝŶĚŝĐĂƚĞƚŚĂƚĂƉŽŝŶƚŵƵƚĂƚŝŽŶĐĂƵƐŝŶŐƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-catenin 
may affect cellular levels of E-cadherin. Figure 3.3 shows a schematic representation of the 
ƌĞůĂƚŝŽŶƐŚŝƉďĞƚǁĞĞŶɴ-catenin, APC and e- in the mutant and wild-type cell lines. 
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Figure 3.3: Stabilised E-catenin may be sequestered by APC in parental (a) and mutant (b) 
HCT116 cells while wild-type E-catenin is degraded by the APC destruction complex in wild-type 
cells (c). E-cadherin levels are much higher in the wild type (c) compared with the parental and 
mutant cells (a & b). 
 
3.2.1 Summary of Key Findings: 
x Wild-type cells have far more E-cadherin protein and transcript than mutant cells 
x Cells expressing only stabiliƐĞĚɴ-catenin have more APC and less E-cadherin than cells 
with only wild-ƚǇƉĞɴ-catenin. 
x y/EϮƚƌĂŶƐĐƌŝƉƚŝŽŶŝƐŶŽƚĂĨĨĞĐƚĞĚďǇĞǆƉƌĞƐƐŝŽŶŽĨƐƚĂďŝůŝƐĞĚɴ-catenin. 
 
The key differences in protein levels between cells are summarised in Table 3.1. 
Cell Line APC ɴ-catenin E-cadherin 
Parental - - - 
Mutant Increased Increased Unchanged 
Wild Type Decreased Unchanged Increased 
 
Table 3.1: Summary of expression levels of APC, E-catenin and E-cadherin in HCT116 cells. Levels 
in the mutant and wild-type cells are tabulated relative to the level in the parental cells. 
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ϯ͘Ϯ͘Ϯ͘ϭǆƉƌĞƐƐŝŽŶůĞǀĞůƐŽĨɴ-catenin, APC and E-cadherin respond to depletion of each of the 
three proteins. 
&ŝŐƵƌĞϯ͘ϭƌĞǀĞĂůĞĚƚŚĂƚƐƚĂďŝůŝƐŝŶŐɴ-catenin mutations impact on total levels of both APC and 
E-cadherin. I next wanted to provide further insight into the relationships between these three 
proteins. /ĂŝŵĞĚƚŽĂƐƐĞƐƐƚŚĞĞĨĨĞĐƚŽŶůĞǀĞůƐŽĨɴ-catenin, APC and E-cadherin after depletion 
of each of these proteins in turn (Figure 3.4). 
I alsŽĂƐƐĞƐƐĞĚƚŚĞĞĨĨĞĐƚŽĨWdEĚĞƉůĞƚŝŽŶŽŶƚŚĞůĞǀĞůƐŽĨɴ-catenin, APC and E-cadherin. The 
rationale for these experiments is as follows. APC is commonly mutated in colorectal cancer at 
an early stage in tumour development. The cancer cell however, accumulates further mutations 
as it progresses from a benign, to malignant and metastatic lesion. PTEN is also commonly 
mutated in colorectal cancer, implicated in both the conventional and serrated pathways of 
carcinogenesis. The combination of mutations in a tumour may influence tumour behaviour and 
impact on outcome. I wanted to assess if loss of PTEN could ĂůƚĞƌƚŚĞƌĞůĂƚŝŽŶƐŚŝƉƐďĞƚǁĞĞŶɴ-
catenin, APC and E-cadherin. This may indicate potential crosstalk between pathways affected 
by loss of APC or PTEN. Tumours with mutations in APC or PTEN in isolation may behave 
differently from tumours with these mutations combined. I aimed to assess changes at a 
molecular level that may explain differences in tumour features. 
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Figure 3.4: siRNA targeted depletion of APC, E-catenin, E-cadherin or PTEN can influence 
expression levels of APC, E-catenin and E-cadherin. APC, E-catenin, E-cadherin or PTEN were 
depleted in Parental (top panel), Mutant (middle panel) and Wild-Type (bottom panel) HCT116 
cells. Whole-cell lysates were then subjected to western blot and probed with antibodies against 
APC, E-cadherin, E-catenin and GAPDH. Protein levels were measured relative GAPDH. Plotted 
values represent the mean and standard deviation of three independent experiments are 
presented relative to levels under control conditions. Levels of APC are plotted in (a, e & i), E-
catenin in (b, f & j) and E-cadherin in (c, g & k). Representative western blots are shown in (d, h 
& l). 
 
The most striking findings from these experiments are that depletion of PTEN causes an increase 
in E-cadherin in all cell lines studied. APC depletion only causĞƐŵŽĚĞƐƚŝŶĐƌĞĂƐĞƐŝŶɴ-catenin 
protein levels in the parental and wild-type cells with no change in the mutant cell line. 
^ƵƌƉƌŝƐŝŶŐůǇWůĞǀĞůƐĨĂůůĨŽůůŽǁŝŶŐĚĞƉůĞƚŝŽŶŽĨɴ-catenin in all cell lines. 
E-cadherin levels rose significantly in all cell lines following knockdown of PTEN (c, g & k). The 
magnitude of the rise here should be interpreted with caution in the parental and mutant cells 
as they both had very low baseline levels so a degree of measurement artefact is possible. 
DŽĚĞƐƚŝŶĐƌĞĂƐĞƐŝŶɴ-catenin were also detected following PTEN depletion so perhaps some of 
the increase in E-cadherin can be explained by stabilisation of the protein. dŚĞ ɴ-catenin 
increase following PTEN loss could potentially relate to activation of the Akt pathway and 
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subsequent inhibition of GSK3E, which may negatively impact on the function of the APC 
destruction complex (Maurer et al. 2014). PTEN was only blotted under control and PTEN knock 
down conditions. This was done to show that the PTEN knock down worked. It was not relevant 
for inclusion under the other conditions studied. 
Despite siRNA treatment causing APC levels to fall to 5-10% of control levels, APC depletion 
caƵƐĞĚŽŶůǇĂŵŽĚĞƐƚƌŝƐĞŝŶɴ-catenin in the parental and wild-type cells and no change in the 
mutant cells (b, f & j). EŽƌŝƐĞŝƐĞǆƉĞĐƚĞĚĨŽůůŽǁŝŶŐůŽƐƐŝŶƚŚĞŵƵƚĂŶƚĐĞůůƐĂƐƚŚĞƐƚĂďŝůŝƐĞĚɴ-
catenin is degradation resistant and the changes in the other two cell lines are in keeping with a 
ůŽƐƐŽĨɴ-catenin degradation.  
^ƵƌƉƌŝƐŝŶŐůǇ W ůĞǀĞůƐ ĂůƐŽ ĨĞůů ĨŽůůŽǁŝŶŐ ɴ-catenin depletion in all cell lines (a, e & i). The 
mechanisms for this are unclear but may represent a feedback loop. /ĨůĞƐƐɴ-catenin is available 
ĨŽƌWƚŽĚĞŐƌĂĚĞŽƌƐĞƋƵĞƐƚĞƌ͕ƉĞƌŚĂƉƐůĞƐƐWŝƐƌĞƋƵŝƌĞĚƚŽƌĞŐƵůĂƚĞɴ-catenin, potentially 
explaining the reduction in APC protein level. 
 
ϯ͘Ϯ͘Ϯ͘Ϯ dƌĂŶƐĐƌŝƉƚŝŽŶ ůĞǀĞůƐ ŽĨ ɴ-catenin, AXIN2 and E-ĐĂĚŚĞƌŝŶ ƌĞƐƉŽŶĚ ƚŽ ĚĞƉůĞƚŝŽŶŽĨ ɴ-
catenin, E-cadherin APC or PTEN 
/ŶĞǆƚĂŝŵĞĚƚŽĞƐƚĂďůŝƐŚŝĨƚŚĞŵĞĂƐƵƌĞĚĐŚĂŶŐĞƐŝŶƉƌŽƚĞŝŶůĞǀĞůƐŽĨɴ-catenin and E-cadherin 
were reflected by changes in transcript level. In addition, I measured the transcriptional output 
ŽĨɴ-catenin by quantifying transcription of AXIN2 (Figure 3.5). 
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Figure 3.5: Transcript levels of E-catenin, E-cadherin and AXIN2 are responsive to depletion of 
APC, E-catenin, E-cadherin and PTEN. Transcript levels of E-catenin (a–c)), E-cadherin (d–f) and 
AXIN2 (g–i) were measured using qPCR in whole-cell lysates of parental, mutant and wild-type 
HCT116 cells. Plotted values represent the mean and standard deviation of three independent 
experiments for each condition and levels are plotted relative to the parental cell line. 
 
E-cadherin transcript level increases significantly following PTEN depletion in all cell lines. AXIN2 
transcription increases significantly in all cell lines following APC depletion. In all cell lines, the 
ƚƌĂŶƐĐƌŝƉƚůĞǀĞůŽĨɴ-catenin increases following APC depletion. 
dƌĂŶƐĐƌŝƉƚŝŽŶĂů ŝŶĐƌĞĂƐĞƐ ŝŶ ɴ-catenin following APC depletion are surprising. The accepted 
ŵĞĐŚĂŶŝƐŵŽĨɴ-catenin increase after APC loss is attributed to a loss of degradative function. 
These data suggest that de novo transcription may also contribute. This increase in transcript 
ĨŽůůŽǁƐƚŚĞŝŶĐƌĞĂƐĞŝŶɴ-catenin levels observed in the parental and wild-type cells. The mutant 
cell line showed no increase in protein following APC depletion, although the transcript level is 
increased slightly. 
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The increase in E-cadherin transcript reflects the increased E-cadherin protein level in all cell 
lines following depletion of PTEN. This indicates that the increase in E-cadherin protein level is 
at least in part due to new transcription as opposed to stabilisation of the E-cadherin protein. 
The mechanisms responsible for this increase are unclear and require further experiments for 
clarification. 
AXIN2 transcript increases following APC depletion in all cell lines. This may be stimulated by a 
ƐůŝŐŚƚ ŝŶĐƌĞĂƐĞ ŝŶ ɴ-catenin under these conditions in the parental and wild-type cells. The 
ŵƵƚĂŶƚĐĞůůƐŚĂĚŶŽ ŝŶĐƌĞĂƐĞ ŝŶɴ-catenin protein level following APC loss so these data may 
support ƚŚĞ ŚǇƉŽƚŚĞƐŝƐ ƚŚĂƚ ƐƚĂďŝůŝƐĞĚ ɴ-catenin is sequestered by APC. Release of this 
sequestered pool could contribute to AXIN2 transcriptional increases in the parental and mutant 
cell line. 
Changes in protein and transcriptional levels of the proteins under study are summarised in 
Table 3.2. 
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Table 3.2: Summary of directional changes relative to the control in levels of protein (blue) and 
ƚƌĂŶƐĐƌŝƉƚ;ŐƌĞĞŶͿůĞǀĞůƐŽĨW͕ɴ-catenin, E-cadherin and AXIN2 in response to depletion of APC, 
ɴ-catenin, E-cadherin or PTEN are presented. Red text indicates results of interest. 
Parental 
Cells 
Control 
– 
APC KD ɴ-cat KD E-cad KD PTEN KD 
Protein Transcript Protein Transcript Protein Transcript Protein Transcript 
APC – Down – Down – Up – Down – 
ɴ-catenin – Up Up Down No 
change 
Up No 
change 
Up No 
change 
E-
cadherin 
– Up No 
change 
No 
Change 
Up Down Down Up Up 
AXIN2 – – Up – Down – Up – Up 
Mutant 
Cells 
Control 
– 
APC KD ɴ-cat KD E-cad KD PTEN KD 
Protein Transcript Protein Transcript Protein Transcript Protein Transcript 
APC – Down - Down – Up – Up – 
ɴ-catenin – No 
Change 
Up Down No change Up No change Up Up 
E-
cadherin 
– Up No change No 
Change 
No change Down Down Up Up 
AXIN2 – – Up - Down – Up – Up 
Wild-
Type 
Cells 
Control 
– 
APC KD ɴ-cat KD E-cad KD PTEN KD 
Protein Transcript Protein Transcript Protein Transcript Protein Transcript 
APC – Down – Down – Up – Up – 
ɴ-catenin – Up Up Down No 
change 
Up No 
change 
Up No 
change 
E-
cadherin 
– No 
Change 
No 
change 
No Change No 
change 
Down Down Up Up 
AXIN2 – – Up – Down – No 
change 
– No 
Change 
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3.2.2 Summary of Key Findings: 
x WƉƌŽƚĞŝŶůĞǀĞůƐĚĞĐƌĞĂƐĞĨŽůůŽǁŝŶŐɴ-catenin depletion in all cell lines studied. 
x APC depletion caused a modest increase in E-catenin protein level in cells with wild-type 
ɴ-catenin but caused no ĐŚĂŶŐĞ ŝŶ ƚŚŽƐĞ ǁŝƚŚ ŽŶůǇ ŵƵƚĂŶƚ ɴ-ĐĂƚĞŶŝŶ͖ ŚŽǁĞǀĞƌ͕ ɴ-
catenin transcript level increased in all cell lines. 
x APC depletion caused a significant increase in AXIN2 transcription in all cell lines. 
x E-cadherin protein and transcript levels rose in response to PTEN depletion in all cell 
lines. 
 
3.2.3 Depletion of APC and E-ĐĂĚŚĞƌŝŶĐĂƵƐĞƐĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the plasma 
membrane to the cytoplasm 
/ŶĞǆƚĂŝŵĞĚƚŽŵĞĂƐƵƌĞǁŚĞƌĞŝŶƚŚĞĐĞůůɴ-catenin was located, both under control conditions 
and folloǁŝŶŐĚĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin, E-cadherin and PTEN. I first studied the cells under 
control conditions using immunofluorescence microscopy. This allowed visual comparison of the 
ŽǀĞƌĂůůůĞǀĞůƐŽĨɴ-catenin and E-cadherin. It also generated a picture of where in the cell these 
proteins were localised (Figure 3.6). 
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Figure 3.6: Immunoflourescent microscopy shows a predominantly membrane-associated E-
catenin in all cell lines studied. Parental (a–e), mutant (f–j) and wild type (k–o) HCT116 cells were 
fixed and stained with DAPI (a, f & k) and phalloidin (b, g & l) to identify the cell nucleus and cell 
periphery. Antibodies against E-cadherin (c, h & m) and E-catenin (d, I & n) were used to indicate 
their location. Composite images (e, j & o) were generated by combinations of DAPI, phalloidin, 
E-cadherin and E-catenin images. Scale bar represents 50 Pm. 
 
dŚĞŝŵĂŐĞƐƐŚŽǁĂƉƌĞĚŽŵŝŶĂŶƚŵĞŵďƌĂŶĞůŽĐĂůŝƐĂƚŝŽŶĨŽƌɴ-catenin in all cell lines. Very low 
levels of E-cadherin were detected in the parental and mutant (c & h) cells with slightly more in 
the wild-type (m) cells. This supports biochemical data in Figure 3.1. 
/ŶĞǆƚĂŝŵĞĚƚŽĚĞƚĞƌŵŝŶĞƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin biochemically by fractionating cells into 
cytoplasmic, membrane, nuclear and cytoskeletal pools. In addition, I established if the 
ůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶĐŽƵůĚďĞĐŚĂŶŐĞĚďǇĚĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin, E-cadherin or PTEN 
(Figure 3.7). Prior to cell fractionation the cells were treated with siRNa to deplete target 
proteins. This was carried out in exactly the same manner as the experiment above that assessed 
total protein levels following depletion of target proteins 
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Figure 3.7: Cellular location of E-catenin is affected by depletion of APC (b, g & l) and E-cadherin 
(d, I & n) in all cell lines studied. Cells were fractionated into cytoplasmic, membrane, nuclear 
and cytoskeletal compartments. Lysates were then subjected to western blot and probed with 
antibody against E-catenin. Proportional distribution between cell compartments was then 
plotted. Data represent the mean and standard deviation of three independent experiments 
except E-cadherin depletion, which represents a single experiment. Results obtained from the 
parental cell line are shown (top row), mutant (middle row) and wild type (bottom row). 
 
hŶĚĞƌĐŽŶƚƌŽůĐŽŶĚŝƚŝŽŶƐɴ-catenin is located mainly at the cell membrane and all cell lines show 
a similar distribution throughout the cell compartments. Depletion of APC caused a 
ƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the cell membrane to the cytoplasm in all cell lines studied. E-
cadherin knockdown led to a similar cytoplasmic redistribution. 
dŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin under control conditions (a, f & k) is reasonably consistent in all 
three cells. Approximately 50–ϲϬйŽĨƚŽƚĂůɴ-catenin resides in the membrane compartment of 
the cells with 20–30% in the cytoplasm. The cytoskeletal compartment contains approximately 
ϮϬйŽĨɴ-ĐĂƚĞŶŝŶ͕ǁŚŝůĞŶƵĐůĞĂƌɴ-catenin accounts for 10%. The exception to this is the mutant 
cells, in which the cytoskeletal and nuclear pools make up 30% and 20%, respectively. 
ĂƐĞĚŽŶƚŚĞƐĞĨŝŐƵƌĞƐ͕ƚŚĞŐƌĞĂƚĞƐƚƉƌŽƉŽƌƚŝŽŶŽĨɴ-catenin appears to be associated with E-
cadherin at the cell membrane under control conditions. It is worth recollecting that the parental 
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and mutant cell lines have low levels of E-ĐĂĚŚĞƌŝŶ͕ƐƵŐŐĞƐƚŝŶŐƚŚĂƚƚŚĞɴ-catenin is recruited to 
the membrane region by alternative binding partners, other than E-cadherin. 
W ŬŶŽĐŬĚŽǁŶ ůĞĚ ƚŽ Ă ŵĂƌŬĞĚ ƌĞĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ ɴ-catenin from the membrane to the 
cytoplasm in all cell lines. The redistribution in the parental and mutant cells was statistically 
significant but did not reach significance in the wild-type cells (b, j & l). Loss of APC in the mutant 
ĐĞůůƐĚŽĞƐŶŽƚĂĨĨĞĐƚƚŽƚĂůɴ-catenin levels as degradation is not altered. The redistribution here 
ŵĂǇ ƚŚĞƌĞĨŽƌĞ ďĞ ĚƵĞ ƚŽ ƌĞůĞĂƐĞ ŽĨ ƐĞƋƵĞƐƚĞƌĞĚ ɴ-catenin from APC. This implies that the 
ŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶWĂŶĚɴ-catenin occurs in the membrane region of the cell. 
E-ĐĂĚŚĞƌŝŶĚĞƉůĞƚŝŽŶĐĂƵƐĞĚĂĐǇƚŽƉůĂƐŵŝĐƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the membrane in all 
cell lines (d, I & n). dŚŝƐƌĞƐƵůƚĞĚŝŶĂŶĂƉƉƌŽǆŝŵĂƚĞŵĂƚĐŚŝŶŐŽĨĐǇƚŽƉůĂƐŵŝĐĂŶĚŵĞŵďƌĂŶĞɴ-
catenin proportions in all cell lines. The redistribution may be expected, as loss of E-cadherin 
leads to dissociation of the adheƌĞŶƐ ũƵŶĐƚŝŽŶƐ ĂŶĚ ƌĞůĞĂƐĞ ŽĨ ɴ-catenin. This matched very 
closely the proportional redistribution seen after APC depletion. The exception to this was the 
mutant cell line, where the cytoplasmic pool was greater after APC KD than E-cadherin 
depletion. This may reflect the finding that the mutant cell line has very low levels of E-cadherin. 
In support of the cell fractionation data, I also obtained Immunoflourescent images of all three 
cell lines following APC depletion to compare visually the localisation oĨɴ-catenin to control 
conditions (Figure 3.8). 
68 
 
 
69 
 
 
70 
 
 
Figure 3.8: APC depletion causes a redistribution of E-catenin from the plasma membrane to the 
cytoplasm in all cell lines. HCT116 cells were fixed and stained with DAPI (a–f) and probed with 
E-catenin antibody (g–l). Composite images (m–r) were generated by combination of the DAPI 
and E-catenin images. Scale bar represents 50 Pm. 
 
/ŶĂůůĐĞůůƐůŝŶĞƐ͕WĚĞƉůĞƚŝŽŶĐĂƵƐĞĚĂƌĞĚƵĐƚŝŽŶŝŶƚŚĞŝŶƚĞŶƐŝƚǇŽĨƚŚĞɴ-catenin signal at the 
cell periphery. This waƐĂĐĐŽŵƉĂŶŝĞĚďǇĂŶ ŝŶĐƌĞĂƐĞŽĨɴ-catenin signal in the cytoplasm, in 
support of the cell fractionation data. 
/ŚĂǀĞƐƵŐŐĞƐƚĞĚƚŚĂƚƐƚĂďŝůŝƐĞĚɴ-catenin may be sequestered by APC. It is possible that if much 
ŽĨ ƚŚĞĐĞůů͛ƐW ŝƐŽĐĐƵƉŝĞĚďǇƐĞƋƵĞƐƚĞƌĞĚɴ-catenin then it will be unavailable to perform 
71 
 
alternative functions. To investigate this, I measured the location of APC using 
immunofluorescent microscopy under control conditions and compared this with cells in which 
ɴ-catenin had been depleted (Figure 3.9). 
 
Figure 3.9: Depletion of E-catenin in HCT116 cells causes APC to localise in distinct clusters 
characteristic of localisation at microtubule ends. Mutant HCT116 cells were probed with 
antibody against APC under control (a) and E-catenin depleted (b) conditions. Scale bar 
represents 20 Pm. 
 
&ŽůůŽǁŝŶŐ ɴ-catenin depletion, APC localises in clusters in keeping with localisation at 
microtubule ends. APC has been reported in this location previously (Nathke et al. 1996). This 
result highlights how the contribution of APC to one role in the cell may be affected by another. 
/ŶƚŚĞŵƵƚĂŶƚĐĞůůůŝŶĞĞǆĂŵŝŶĞĚ͕WƐĞƋƵĞƐƚĞƌƐɴ-catenin. ĞƉůĞƚŝŽŶŽĨɴ-catenin results in a 
dramatic shift of APC to microtubule ends. This indicates that if APC is relieved of a specific role 
;ŝŶ ƚŚŝƐĐĂƐĞƐĞƋƵĞƐƚƌĂƚŝŽŶŽĨɴ-catenin) it may then be available to participate in alternative 
functions. 
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3.2.3 Summary of Key Findings: 
x dŚĞŝŶƚĞƌĂĐƚŝŽŶƐɴ-catenin/E-ĐĂĚŚĞƌŝŶĂŶĚɴ-catenin/APC occur in the membrane 
region of the cell. 
x WĚĞƉůĞƚŝŽŶĐĂƵƐĞƐĂŵĂƌŬĞĚƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the membrane to the 
cytoplasm. 
x E-ĐĂĚŚĞƌŝŶĚĞƉůĞƚŝŽŶĐĂƵƐĞƐĂŵĂƌŬĞĚƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the membrane 
to the cytoplasm. 
x ĞƉůĞƚŝŽŶŽĨɴ-catenin results in the accumulation of APC at microtubule ends. 
 
ϯ͘Ϯ͘ϯ^ƚĂďŝůŝƐĞĚɴ-catenin binds more tightly to APC and less tightly to E-cadherin 
/ŚĂǀĞƐƵŐŐĞƐƚĞĚƚŚĂƚĂƉŽŝŶƚŵƵƚĂƚŝŽŶĐĂƵƐŝŶŐƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-catenin results in sequestration 
by APC. The binding sites for APC and E-cadherin ŽŶɴ-catenin overlap, so interaction with each 
of these two partners is mutually exclusive (Valenta et al. 2012). I next aimed to determine if 
ŵŽƌĞƐƚĂďŝůŝƐĞĚɴ-catenin could be found in association with APC than wild-ƚǇƉĞɴ-catenin. In 
addition, I measured the level of interaction between both mutant and wild-ƚǇƉĞɴ-catenin with 
E-cadherin.  ɴ-catenin co-immunoprecipitation (Co-IP) was used to investigate these 
interactions (Figure 3.10). 
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Figure 3.10: Stabilising E-catenin mutations increases its interaction with APC. E-Catenin was co-
immunoprecipitated and western blot against APC, E-catenin and E-cadherin performed on the 
IP and lysates. Representative blots are shown in parental (a), mutant (b) and wild-type cells (c). 
The ratio of E-catenin/APC in the IP and lysates for each cell line are plotted in (d–f) and the E-
catenin/E-cadherin ratio is plotted in (g–i). Plots represent the mean and standard deviation of 
three independent experiments. Residual APC in the post-IP lysate is plotted in (j). Tabulated data 
are shown below the graphs. 
Parental ɴ-cat/APC 
ratio (IP) 
ɴ-cat /E-
cad     
ratio (IP) 
ɴ-cat/APC 
ratio 
(lysate) 
ɴ-cat /E-
cad 
(lysate) 
Mean 10 125.2 9.4 40 
SD 1.6 29.3 0.9 9 
Mutant ɴ-cat/APC 
ratio (IP) 
ɴ-cat /E-
cad     
ratio (IP) 
ɴ-cat/APC 
ratio 
(lysate) 
ɴ-cat /E-
cad 
(lysate) 
Mean 8.2 159 6.3 94 
SD 1.3 46 1.4 74 
Wild Type E-cat /APC 
ratio (IP) 
ɴ-cat/E-
cad ratio 
(IP) 
ɴ-cat/APC 
ratio 
(lysate) 
ɴ-cat /E- 
cad 
(lysate) 
Mean 15.3 62.6 4.7 12 
SD 0.2 1 1.2 2 
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^ƚĂďŝůŝƐĞĚɴ-catenin interacts more with APC than does wild-ƚǇƉĞɴ-catenin. More E-cadherin is 
found in association with wild-ƚǇƉĞɴ-catenin than wŝƚŚƐƚĂďŝůŝƐĞĚɴ-catenin. 
^ƚĂďŝůŝƐĞĚɴ-catenin in the parental and mutant cells has a greater interaction with APC than the 
ɴ-catenin in the wild-ƚǇƉĞĐĞůůƐ͘dŚĞɴ-catenin/APC ratios in the IP of parental and mutant cells 
are similar at 10 and 8.2, respectively, which are similar to the ratios in the lysate of these cells 
(9.4 and 6.3). These are both lower than the ratio of 15.3 in the wild-ƚǇƉĞ ĐĞůůƐ͛ /W͘ dŚĞ ɴ-
catenin/APC ratio in the wild-type lysate is also lower at 4.7 than the ratio in the wild-type IP 
;ϭϱ͘ϯͿ͘ dŽŐĞƚŚĞƌ͕ ƚŚĞƐĞ ƌĞƐƵůƚƐ ŝŶĚŝĐĂƚĞ ƚŚĂƚ ŵŽƌĞ W ŝƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ɴ-catenin in the 
parental and mutant cells compared with the wild-ƚǇƉĞĐĞůůƐ͘ŽŶƐŝĚĞƌŝŶŐƚŚĂƚƚŚĞƐƚĂďŝůŝƐĞĚɴ-
catenin cannot be degraded by APC, these data indicate that the relationship between APC and 
ƐƚĂďŝůŝƐĞĚɴ-catenin serves a sequestration function ǁŚĞƌĞďǇɴ-catenin can be bound by APC but 
not degraded. ŐƌĞĂƚĞƌĚĞŐƌĞĞŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶƐƚĂďŝůŝƐĞĚɴ-catenin and APC is reflected 
by the higher level of residual APC left in the post-IP lysate of the wild-type cells. This indicates 
ƚŚĂƚ ŝŶ ƚŚĞƐĞĐĞůůƐŶŽƚĂůůW ŝƐƐĂƚƵƌĂƚĞĚǁŝƚŚɴ-ĐĂƚĞŶŝŶ͕ǁŚĞƌĞĂƐ ŝŶ ĐĞůůƐǁŝƚŚ ƐƚĂďŝůŝƐĞĚɴ-
catenin it largely is. 
The interaction between wild-ƚǇƉĞ ɴ-catenin and E-cadherin is greater than that between 
ƐƚĂďŝůŝƐĞĚɴ-catenin and E-cadherin reflected by the findings of the IP. The parental and mutant 
cells express very low levels of E-ĐĂĚŚĞƌŝŶƐŽƚŚĞůŽǁůĞǀĞůƐŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and 
E-cadherin could be a reflection of the fact that there is little E-cadherin available to which to 
ďŝŶĚ͘ŶĂůƚĞƌŶĂƚŝǀĞĞǆƉůĂŶĂƚŝŽŶŝƐƚŚĂƚŵƵĐŚŽĨƚŚĞƐƚĂďŝůŝƐĞĚɴ-catenin is associated with APC, 
so is therefore unavailable to bind to E-ĐĂĚŚĞƌŝŶ͘ŶŽƚŚĞƌŚǇƉŽƚŚĞƐŝƐ ŝƐƚŚĂƚƚŚĞƐƚĂďŝůŝƐĞĚɴ-
catenin may be unable to bind efficiently to E-cadherin, resulting in low levels of interaction and 
a low expression of E-cadherin. 
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To investigate these relationships further, I immunoprecipitated APC and measured the amount 
of E-catenin that was recovered in the different cell types (Figure 3.11). 
 
 
 
 
Figure 3.11: Stabilising E-catenin mutations increases its interaction with APC. APC was co-
immunoprecipitated with western blot against APC, E-catenin and E-cadherin. Representative 
western blots for the IP and lysate in parental (a), mutant (b) and wild-type cells (c). E-
Catenin/APC ratios in the lysate and IP are plotted for each cell line in (d–f) with tabulated data 
shown below the graphs. 
 
dŚĞƌĞŝƐŵŽƌĞɴ-catenin bound to APC in the mutant cells compared with wild type, with the 
parental cells showing an intermediate result that is more aligned with the mutant cells. These 
results suppoƌƚƚŚŽƐĞŽďƚĂŝŶĞĚŝŶƚŚĞɴ-ĐĂƚĞŶŝŶ/WĂŶĚƚŚĞŚǇƉŽƚŚĞƐŝƐƚŚĂƚƐƚĂďŝůŝƐĞĚɴ-catenin 
ŝƐƐĞƋƵĞƐƚĞƌĞĚďǇW͘ǀŝĚĞŶĐĞŽĨƚŚĞŵƵƚƵĂůĞǆĐůƵƐŝǀŝƚǇŽĨƚŚĞďŝŶĚŝŶŐŽĨɴ-catenin to either 
APC or E-cadherin was also confirmed here. No E-cadherin was present in the IP, although it was 
detected in the pre- and post-IP lysate. 
Next, I aimed to see if I could recover different pools of E-catenin bound to either APC or E-
cadherin. I first precipitated APC Co-/W͕ĂŶĚƚŚĞŶƉƌĞĐŝƉŝƚĂƚĞĚɴ-catenin from the post-IP lysates. 
ThŝƐĂůůŽǁĞĚŵĞƚŽĚĞƚĞƌŵŝŶĞŝĨĂŶǇ͕ŽƌĂůůŽĨƚŚĞɴ-catenin that remained after removing APC 
Parental Lysate IP 
E-cat/APC 
ratio 
10.6 4.3 
Mutant Lysate IP 
E-cat/APC 
ratio 
8 5 
Wild Type Lysate IP 
E-cat/APC 
ratio 
3.15 1 
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was found bound to E-cadherin. In addition, I wanted to determine the relationship between 
ƚŚĞƌĞůĂƚŝǀĞĂŵŽƵŶƚƐŽĨɴ-catenin bound to APC and E-cadherin (Figure 3.12). 
 
Cell Parental Mutant Wild Type 
E-
cat/APC 
ratio 
2.61 4.15 0.2 
 
Figure 3.12: Recovering APC-associated E-catenin reveals differential binding of E-catenin to E-
cadherin in HCT116 cells. APC was co-immunoprecipitated then E-catenin was co-
immunoprecipitated on the post-IP lysate cleared of APC-bound E-catenin. Western blots for 
APC, E-cadherin and E-catenin in parental (a), mutant (b) and wild-type cells (c) are shown. The 
E-catenin/APC ratio from the APC IP is plotted in (d) and the E-catenin/E-cadherin ratio from the 
E-catenin IP is plotted in (e). Ratio data are tabulated below. 
 
ZĞůĂƚŝǀĞůǇ ůĞƐƐ ɴ-catenin is bound to APC in the wild type compared with mutant cell lines, 
whereas relatiǀĞůǇŵŽƌĞɴ-catenin is associated with E-cadherin in the wild type compared with 
the mutant cells. These results add further support to conclusions from the comparative single 
immunoprecipitations described above. 
These experiments revealed that stabilisinŐ ɴ-ĐĂƚĞŶŝŶŵƵƚĂƚŝŽŶƐ ƐŚŝĨƚƐ ƚŚĞ ĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ ɴ-
catenin to an APC-associated pool. This increased interaction with APC comes at the detriment 
of interaction with E-cadherin. This is especially apparent in the parental and mutant cell lines. 
The converse is true in the wild-ƚǇƉĞ ĐĞůůƐ͕ ǁŚĞƌĞ ƉƌŽƉŽƌƚŝŽŶĂůůǇ ůĞƐƐ ɴ-catenin is found in 
Cell Parental Mutant Wild Type 
E-cat 
/E-cad 
ratio 
4.71 9.13 3.15 
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association with APC, but more is identified bound to E-cadherin. These interactions are 
schematically represented for a mutant and a wild-type cell (Figure 3.13). 
 
Figure 3.13: E-Catenin is sequestered by APC in the mutant cell line (a) and little is associated 
with E-cadherin, which is expressed at a low level. The interaction of E-catenin with APC in the 
wild-type cells (b) is transient and serves a degradative function. Higher levels of E-cadherin are 
expressed in the wild-type cells and a higher proportion of E-catenin is identified in conjunction 
with E-cadherin. 
 
3.2.4 Summary of Key Findings: 
x ZĞůĂƚŝǀĞůǇŵŽƌĞƐƚĂďŝůŝƐĞĚɴ-catenin is found in association with APC compared with 
wild-ƚǇƉĞɴ-catenin 
x Relatively more wild-ƚǇƉĞɴ-catenin is identified bound to E-ĐĂĚŚĞƌŝŶƚŚĂŶƐƚĂďŝůŝƐĞĚɴ-
catenin 
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ϯ͘Ϯ͘ϱKǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨɴ-catenin in HCT116 cells 
I next wanted to assess what impact overexpression of either a mutant non-degradable or wild-
ƚǇƉĞɴ-catenin allele had on both mutant and wild-type HCT116 cells. 
The aim of these experiments was to measure if the level of APC or E-cadherin proteins was 
responsive to over-ĞǆƉƌĞƐƐŝŽŶŽĨɴ-catenin. In addition, I wanted to determine where in the cell 
ĞǆŽŐĞŶŽƵƐɴ-ĐĂƚĞŶŝŶ ůŽĐĂůŝƐĞĚĂŶĚ ŝĨƚŚŝƐĐŚĂŶŐĞĚƚŚĞ ůŽĐĂůŝƐĂƚŝŽŶŽĨĞŶĚŽŐĞŶŽƵƐɴ-catenin. I 
also measured the expression level of Snail because it has been implicated in the down-
regulation of E-cadherin in the process of EMT (Barrallo-Gimeno and Nieto 2005). This 
transcriptional repression of E-ĐĂĚŚĞƌŝŶďǇ^ŶĂŝůĐĂŶďĞĐĂƵƐĞĚďǇĞůĞǀĂƚĞĚɴ-catenin (Zhou et 
al. 2004, Yook et al. 2006)͘/ĨŝƌƐƚƋƵĂŶƚŝĨŝĞĚƚŚĞůĞǀĞůƐŽĨW͕ɴ-catenin and E-cadherin following 
transfection of either a mutant or wild-ƚǇƉĞɴ-catenin allele (Figure 3.14). 
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Figure 3.14: Expression of exogenous mutant and wild-type E-catenin proteins causes a 
differential response in protein expression levels between wild-type and mutant HCT116 cells. 
Mutant (top panel) and wild-type (bottom panel) HCT116 cells were transfected with either 
mutant or wild-type E-catenin with a myc tag. Western blot of whole-cell lysate was probed with 
antibodies directed against APC, E-cadherin, E-catenin and GAPDH. Representative western blots 
of the mutant (a) and wild-type (b) cells are shown. Protein levels were quantified relative to 
GAPDH. Protein levels under the different treatment conditions are plotted in (b, c, d & e) for 
mutant cells and (g, h, I & j) for wild type. Data represent the mean and standard deviation of 
three independent experiments. 
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An increase in the level of E-caĚŚĞƌŝŶĂŶĚɴ-catenin protein was measured following transfection 
of both the mutant and wild-ƚǇƉĞɴ-ĐĂƚĞŶŝŶŝŶƚŚĞŵƵƚĂŶƚĐĞůůůŝŶĞ͘KŶůǇɴ-catenin levels rose in 
the wild-type cells. 
In the mutant cell line, no significant differences in the levels of APC or Snail (p>0.05) were 
observed following transfection of either mutant or wild-ƚǇƉĞɴ-catenin, although a slight up-
regulation of APC was noted. I measured the expression level of Snail because it has been 
implicated in the down-regulation of E-cadherin in the process of EMT. This transcriptional 
repression of E-ĐĂĚŚĞƌŝŶďǇ^ŶĂŝůĐĂŶďĞĐĂƵƐĞĚďǇĞůĞǀĂƚĞĚɴ-catenin. A statistically significant 
rise in E-ĐĂĚŚĞƌŝŶ ůĞǀĞůǁĂƐŶŽƚĞĚĂĨƚĞƌƚƌĂŶƐĨĞĐƚŝŽŶŽĨďŽƚŚɴ-catenin proteins (p<0.05). This 
could potentially relate to stabilisation of the E-ĐĂĚŚĞƌŝŶƉƌŽƚĞŝŶďǇƚŚĞĞǆƚƌĂɴ-catenin or could 
represent transcription of new E-cadherin. The increase in E-cadherin protein may function to 
ďŝŶĚƐŽŵĞŽĨƚŚĞĞǆŽŐĞŶŽƵƐɴ-catenin. This may be an attempt to control levels ŽĨĨƌĞĞɴ-catenin 
as the APC in the mutant cells may be saturated with sequestered non-ĚĞŐƌĂĚĂďůĞɴ-catenin. 
Any rise in E-cadherin in the mutant cell line may be especially noticeable as baseline levels are 
very low under control conditions. 
No significant differences in the expression levels of any protein in response to transfection of 
ĞŝƚŚĞƌɴ-catenin were measured in the wild-type cell line (p>0.05). The wild-type cells’ capability 
ƚŽĚĞŐƌĂĚĞŽƌƐĞƋƵĞƐƚĞƌɴ-catenin may be sufficient to regulate levels ŽĨĨƌĞĞɴ-catenin without 
an increase in either APC or E-cadherin. This hypothesis is outlined schematically in Figure 3.15. 
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Figure 3.15: Wild-type (a) and mutant cells (b) are shown under control conditions. Wild-type 
cells express more E-cadherin than the mutant cells and E-catenin can undergo degradation by 
the APC destruction complex. The mutant cells express little E-cadherin and the E-catenin is 
resistant to degradation, but can be sequestered by APC. Upon transfection of exogenous E-
catenin (green), the wild-type cells (c) can respond by degrading both endogenous and 
exogenous wild-type E-catenin using available APC. This function is possible without additional 
APC or E-cadherin. Transfection of the mutant E-catenin causes a larger rise in E-catenin in the 
wild-type cells. This may be explained by APC binding sites becoming occupied in the 
sequestration of the mutant E-catenin. The mutant cell line destruction complex can sequester 
but not degrade endogenous E-catenin. This may reduce the number of available APC binding 
sites for exogenously expressed E-catenin. In addition, the mutant cells have low levels of E-
cadherin. Upregulation of APC and E-cadherin (d) in response to exogenous E-catenin aims to 
limit the magnitude of the free unbound poll of E-catenin. 
 
/ŶĞǆƚĚĞƚĞƌŵŝŶĞĚǁŚĞƌĞŝŶƚŚĞĐĞůůĞǆŽŐĞŶŽƵƐůǇĞǆƉƌĞƐƐĞĚɴ-catenin localised and whether this 
ŝŵƉĂĐƚĞĚŽŶƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨĞŶĚŽŐĞŶŽƵƐɴ-catenin or E-cadherin (Figure 3.16). The relative 
proportional distribution between the Cytoplasm, Membrane, Nucleus and cytoskeleton was 
ĂƐƐĞƐƐĞĚ͘ dŚĞ ĞǆŽŐĞŶŽƵƐ ɴ-catenin could be identified by its greater molecular weight in 
ĐŽŵƉĂƌŝƐŽŶƚŽĞŶĚŽŐĞŶŽƵƐɴ-catenin due to the presence of a myc tag. 
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Figure 3.16: Exogenously expressed mutant or wild-type E-catenin predominantly localises in the 
cytoplasm but does not change the localisation of endogenous E-catenin or E-cadherin. Mutant 
(top panel) and wild-type (bottom panel) HCT116 cells were transfected with either mutant or 
wild-type E-catenin and fractionated into cytoplasm, membrane, nuclear and cytoskeletal 
compartments. The proportional localisation of both endogenous and exogenous E-catenin was 
measured using western blot with antibodies against E-catenin and E-cadherin. The proportional 
distribution of endogenous E-catenin was measured by quantification of the lower E-catenin 
band and the mean and standard deviation were plotted in (b &c) for the mutant and (j & k) for 
the wild-type cells. The proportional localisation of exogenous E-catenin was measured by 
quantification of the upper E-catenin band and plotted in (d & e) for mutant and (l & m) for wild-
type cells. E-cadherin distribution was quantified and plotted in (f, g, h, n, o & p). Blot of E-
cadherin following transection was done only once. 
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The dŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin in both the mutant and wild-type cells does not change significantly 
following transfection of either mutant or wild-type ɴ-catenin. Similarly, no change in the 
pattern of E-ĐĂĚŚĞƌŝŶĚŝƐƚƌŝďƵƚŝŽŶǁĂƐŵĞĂƐƵƌĞĚ͘ǆŽŐĞŶŽƵƐɴ-catenin predominantly localises 
in the cytoplasm of the wild-type cell lines following transfection of either mutant or wild-type 
ɴ-ĐĂƚĞŶŝŶ͘dŚĞĞǆŽŐĞŶŽƵƐɴ-catenin also shows a shift to the cytoplasm in the mutant cells but 
some exogenous wild-type ɴ-catenin localises to the membrane in these cells. 
EŽ ĚƌĂŵĂƚŝĐ ĐŚĂŶŐĞ ŝŶ ƚŚĞ ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ ĞŶĚŽŐĞŶŽƵƐ ɴ-catenin is measured following 
ƚƌĂŶƐĨĞĐƚŝŽŶ ŽĨ ĞǆŽŐĞŶŽƵƐ ɴ-ĐĂƚĞŶŝŶ ŝŶ ĞŝƚŚĞƌ ĐĞůů ůŝŶĞ͘ dŚŝƐ ƐƵŐŐĞƐƚƐ ƚŚĂƚ ƚŚĞ ĞǆŽŐĞŶŽƵƐ ɴ-
catenin does not competitively move endogeŶŽƵƐɴ-catenin from its binding sites during the 
time course of this experiment. 
In the wild-type ĐĞůůƐƚŚĞĞǆŽŐĞŶŽƵƐɴ-catenin localised largely in the cytoplasm, suggesting it 
was free and unbound. No increase in either APC or E-cadherin levels was noted in these cells 
following transfection that may have increased the number of binding partners for the 
ĞǆŽŐĞŶŽƵƐɴ-catenin. 
/ŶƚŚĞŵƵƚĂŶƚĐĞůůƐ͕ƚŚĞŵƵƚĂŶƚĞǆŽŐĞŶŽƵƐɴ-catenin localises predominantly in the cytoplasm. 
The wild-type ĞǆŽŐĞŶŽƵƐɴ-catenin, however, is located at the membrane. The differences in 
ůŽĐĂůŝƐĂƚŝŽŶďĞƚǁĞĞŶƚŚĞƚǁŽĞǆŽŐĞŶŽƵƐɴ-catenin proteins in these cells may indicate that the 
ŵƵƚĂŶƚɴ-catenin cannot interact as well with E-cadherin as does the wild type. 
Having determined the localisĂƚŝŽŶŽĨĞǆŽŐĞŶŽƵƐɴ-catenin, I next aimed to measure its impact 
on transcription of AXIN2 and E-cadherin (Figure 3.17). 
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Figure 3.17: Over-expression of E-catenin causes an increase in AXIN2 transcription in both 
mutant and wild-type HCT116 cells, while the effect on E-cadherin is variable. Wild-type and 
mutant HCT116 cells were transfected with either mutant or wild-type E-catenin. Cell lysates 
were processed and analysed for levels of AXIN2 and E-cadherin transcription using qPCR. Data 
represent the means and standard deviations of two independent experiments and transcript 
levels are plotted relative to the control (empty vector) for mutant (a & b) and wild-type cells (c 
& d). 
 
Over-expression of both mutant and wild-ƚǇƉĞɴ-catenin caused an increase in the transcription 
of AXIN2 in both cell lines. E-cadherin transcript reduced slightly following transfection of the 
ŵƵƚĂŶƚɴ-catenin in the mutant cells and increased in the wild-type cells following transfection 
of the wild-ƚǇƉĞɴ-catenin. 
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AXIN2 transcription increased in both cell lines in response to transfection of both mutant and 
wild-ƚǇƉĞĞǆŽŐĞŶŽƵƐɴ-ĐĂƚĞŶŝŶ͘dŚŝƐĨŝŶĚŝŶŐŝƐĐŽŶƐŝƐƚĞŶƚǁŝƚŚƚŚĞŝŶĐƌĞĂƐĞĚůĞǀĞůƐŽĨɴ-catenin 
following transfection. It also supports previous findings that associated a cytoplasmic 
ůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin with an increase in AXIN2 transcription. 
E-cadherin protein levels increased in the mutant cell line following transfection of both mutant 
and wild-ƚǇƉĞ ɴ-catenin. Transcript levels did not reflect this and E-cadherin transcript was 
ƌĞĚƵĐĞĚ ĨŽůůŽǁŝŶŐ ƚƌĂŶƐĨĞĐƚŝŽŶ ŽĨ ƚŚĞ ŵƵƚĂŶƚ ɴ-catenin. This indicates that the increase in 
protein level may have been due to stabilisation. 
E-cadherin transcript level increased in the wild-type cells following transfection of wild-type ɴ-
catenin. This contradicts findings at the protein level, which did not change significantly. Reasons 
for this are unclear and further experiments are required for clarification. 
3.2.5 Summary of Key Findings: 
x Overexpression of both mutant and wild-ƚǇƉĞɴ-catenin protein causes a rise in E-
ĐĂĚŚĞƌŝŶƉƌŽƚĞŝŶŝŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐƐƚĂďŝůŝƐĞĚĞŶĚŽŐĞŶŽƵƐɴ-catenin. 
x ǆŽŐĞŶŽƵƐɴ-catenin localises to the cytoplasm in the wild-type cells but some wild-
ƚǇƉĞĞǆŽŐĞŶŽƵƐɴ-catenin is retained at the membrane in the mutant cell. 
x ǆƉƌĞƐƐŝŽŶŽĨĞǆŽŐĞŶŽƵƐɴ-catenin stimulates an increase in AXIN2 transcription in 
both mutant and wild-type cells. 
 
3.3 Discussion 
/ŶƚŚŝƐĐŚĂƉƚĞƌ͕ /ĂŝŵĞĚƚŽĚĞƚĞƌŵŝŶĞŚŽǁĂƉŽŝŶƚŵƵƚĂƚŝŽŶĐĂƵƐŝŶŐƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-catenin 
affects its interaction with APC and E-ĐĂĚŚĞƌŝŶ͘/ŚĂǀĞĞƐƚĂďůŝƐŚĞĚƚŚĂƚƐƚĂďŝůŝƐĞĚɴ-catenin has 
ŝŶĐƌĞĂƐĞĚ ďŝŶĚŝŶŐ ƚŽ W ĂŶĚ ƚŚŝƐ ƐĞƌǀĞƐ ƚŽ ƐĞƋƵĞƐƚĞƌ ƐƚĂďŝůŝƐĞĚ ɴ-catenin. This affects the 
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ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin as measured by AXIN2 transcription. Despite the mutant cell 
ůŝŶĞŚĂǀŝŶŐŚŝŐŚĞƌůĞǀĞůƐŽĨɴ-catenin and very low levels of E-cadherin compared with the wild-
type cells, AXIN2 transcription does not differ significantly between the cell lines. This indicates 
ƚŚĂƚƐĞƋƵĞƐƚƌĂƚŝŽŶŽĨɴ-catenin by APC can limit thĞƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĨƵŶĐƚŝŽŶŽĨɴ-catenin. 
Depletion of APC in all cell lines stimulated a rise in AXIN2 transcription. This was despite only 
ŵŽĚĞƐƚŝŶĐƌĞĂƐĞƐŝŶƚŽƚĂůɴ-catenin level in the parental and wild-type cells and no change in the 
mutant cells. A rĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin to the cytoplasm followed APC depletion in all cell 
lines. This signifies that loss of both degradative and sequestration functions can stimulate an 
ŝŶĐƌĞĂƐĞŝŶƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin by not only impacting on total levels, but also 
ŽŶƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶǁŝƚŚŝŶƚŚĞĐĞůů͘/ďĞůŝĞǀĞƚŚŝƐĐǇƚŽƉůĂƐŵŝĐƉŽŽůŽĨɴ-catenin to be 
“free”, unbound, and able to activate transcription. These data highlight the importance of both 
the presence and functional integrity of APC and E-ĐĂĚŚĞƌŝŶ ŝŶƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin to 
maintain its “free” levels and transcriptional output within acceptable limits. These results also 
raise some potential insights into how tumour behaviour may differ even if the molecular 
defects appear to be similar, at least on the surface. APC loss in tumours results in the lack of 
ĂďŝůŝƚǇ ƚŽ ĚĞŐƌĂĚĞ ɴ-catenin, which becomes stabilised and can activate a transcriptional 
ƉƌŽŐƌĂŵŵĞ͘ƉŽŝŶƚŵƵƚĂƚŝŽŶĐĂƵƐŝŶŐƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-catenin also results in the loss of ability 
ƚŽĚĞŐƌĂĚĞɴ-ĐĂƚĞŶŝŶ͕ďƵƚƚŚĞĨƵŶĐƚŝŽŶĂůĐŽŶƐĞƋƵĞŶĐĞƐŽĨƚŚŝƐĂƌĞĚŝĨĨĞƌĞŶƚ͘WŽŝŶƚŵƵƚĂƚĞĚɴ-
catenin can be sequestered by APC, thus minimising transcriptional activation. As long as 
subsequent mutations are not acquired, this mutation may have reasonably benign 
consequences for the cell and may not be enough to initiate or progress neoplastic change in 
ŝƐŽůĂƚŝŽŶ͘dŚŝƐŵĂǇƉĂƌƚůǇĞǆƉůĂŝŶǁŚǇƚƵŵŽƵƌƐǁŝƚŚƐƚĂďŝůŝƐŝŶŐɴ-catenin mutations are far less 
common than those with APC loss. 
I also ĞƐƚĂďůŝƐŚĞĚƚŚĂƚĐĞůůƐĞǆƉƌĞƐƐŝŶŐƐƚĂďŝůŝƐĞĚɴ-catenin have very low levels of E-cadherin 
protein and transcript compared with wild-type cells. It is unclear if the high level of interaction 
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ďĞƚǁĞĞŶƐƚĂďŝůŝƐĞĚɴ-ĐĂƚĞŶŝŶĂŶĚWƌĞƐƵůƚƐŝŶĂůĂĐŬŽĨɴ-catenin being available to bind to E-
cadherin. This scenario could mean that there is no requirement for a high level of E-cadherin 
ĂƐƚŚĞƌĞŝƐĂůŝŵŝƚĞĚƉŽŽůŽĨɴ-ĐĂƚĞŶŝŶĂǀĂŝůĂďůĞƚŽďŝŶĚ͘ůƚĞƌŶĂƚŝǀĞůǇ͕ƚŚĞƐƚĂďŝůŝƐĞĚɴ-catenin 
may not be able to bind to E-cadherin as efficiently as the wild-type protein. I attempted to 
clarify this by over-expressing mutant and wild-ƚǇƉĞɴ-catenin in both cell lines. I had expected 
responsive increases in E-ĐĂĚŚĞƌŝŶƚŽĂĐĐŽŵŵŽĚĂƚĞƚŚĞƌŝƐĞŝŶɴ-catenin. Expression of the wild-
ƚǇƉĞɴ-catenin in the mutant cell line caused it to localise mainly at the membrane with some in 
the cytoplasm. This could signify that the wild-type protein is able to interact with E-cadherin 
more efficiently than the mutant protein, which favoured a cytoplasmic localisation. Exogenous 
mutant and wild-ƚǇƉĞɴ-catenin both localised to the cytoplasm in the wild-type cells. Co-IP 
ƐƚƵĚŝĞƐŝĚĞŶƚŝĨŝĞĚĂŚŝŐŚůĞǀĞůŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and E-cadherin. This may indicate 
that E-cadherin is saturated and given that no increase in E-cadherin was observed following 
over-ĞǆƉƌĞƐƐŝŽŶ͕ƚŚĞɴ-catenin may have localised in the cytoplasm due to the lack of available 
E-cadherin binding sites. Further co-/WƐƚƵĚŝĞƐŽĨɴ-catenin and E-cadherin following transfection 
ŽĨĞǆŽŐĞŶŽƵƐɴ-catenin may help to clarify these relationships. 
/ ŝŶĐůƵĚĞĚ ĂŶĂůǇƐŝƐ ŽĨ ƚŚĞ ĞĨĨĞĐƚƐ ŽĨ ĚĞƉůĞƚŝŶŐ WdE ŽŶ ƚŚĞ ůĞǀĞůƐ ŽĨ W͕ ɴ-catenin and E-
cadherin. In all cell lines, PTEN knockdown caused significant increases in levels of E-cadherin 
pƌŽƚĞŝŶĂŶĚƚƌĂŶƐĐƌŝƉƚ͘DŽĚĞƐƚ ŝŶĐƌĞĂƐĞƐ ŝŶɴ-catenin were measured under these conditions 
that may be due to activation of the Akt pathway, which can inhibit GSK3E. This would negatively 
ŝŵƉĂĐƚŽŶƚŚĞĨƵŶĐƚŝŽŶŽĨƚŚĞWĚĞƐƚƌƵĐƚŝŽŶĐŽŵƉůĞǆ͘dŚĞƌŝƐĞŝŶɴ-catenin may cause some 
stabilisation of E-cadherin, contributing to the observed rise, but the increase in E-cadherin 
transcript signifies that new E-cadherin is likely to be the main contributor to the increase. The 
reasons for increased E-cadherin transcription following PTEN depletion are unclear and require 
further experiments for clarification. The findings are consistent between all cell lines studied, 
signifying that the mechanism is independent of whether stabilised or wild-ƚǇƉĞɴ-catenin is 
expressed. 
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ϰ dŚĞ ŝŶĨůƵĞŶĐĞ ŽĨ WdE ŽŶ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶƐ ŽĨ ɴ-catenin, APC and E-
cadherin 
4.1 Introduction 
PTEN is a multifunctional protein with an important role as a tumour suppressor. It plays a key 
role in the negative regulation of the Akt signalling pathway. Activation of the Akt pathway 
follows PTEN loss, stimulating cell proliferation, progression of the cell cycle, growth and 
survival. Homeostasis of these functions are critical for normal gut function and defects in these 
are linked to cancer.(Song, 2012, Koul, 2002, Fata, 2012) (Figure 1.9). PTEN is also implicated in 
crohns disease. Reactive oxygen species are thought to be able to activate nuclear NF-kB via the 
PTEN/Akt pathway leading to inflammation linked to crohns (Tokuhira et al. 2015) 
Potential crosstalk between PTEN and the adhesion jƵŶĐƚŝŽŶĂů ĐŽŵƉůĞǆ ŽĨ ɴ-catenin and E-
cadherin also exists. PTEN and PI3-kinase have been identified in association with E-cadherin 
ĂŶĚɴ-catenin at the adherens junctions (Vogelmann, 2005) and PTEN has been detected in co-
immunoprecipitates of both E-cadheƌŝŶĂŶĚɴ-catenin in MDCK cells (Kotelevets, 2005) 
In the previous chapter, Ilammatio ĨŽƵŶĚƚŚĂƚĂƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶŝŶɴ-catenin can affect its 
interaction with APC and E-cadherin. In addition, I measured the impact of PTEN depletion on 
the levels of these three proteins. I found that PTEN knockdown caused significant increases in 
the level of E-cadherin transcript and protein irrespective of whether the cell expressed wild-
ƚǇƉĞŽƌƐƚĂďŝůŝƐĞĚɴ-catenin. 
Analysis of the effects of PTEN were included because PTEN loss is commonly implicated in 
colorectal cancer and has been associated with tumours developing on the serrated pathway of 
colorectal carcinogenesis (Day et al. 2013, Davies et al. 2014). In addition, PTEN defects are also 
found in tumours developing on the conventional pathway of colorectal cancer, which are 
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characterised by APC mutations. I aimed to determine if there was potential crosstalk between 
these two pathways. Experiments in Chapter 1 have shown a rise in E-cadherin at both the 
transcriptional and protein level following PTEN loss in HCT116 colorectal cancer cells. In 
conjunction with APC, E-ĐĂĚŚĞƌŝŶƉůĂǇƐĂŬĞǇƌŽůĞŝŶƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin. Disturbances in 
ƚŚĞďĂůĂŶĐĞŽĨŚŽǁɴ-catenin interacts with APC and E-cadherin are central to the development 
of colorectal cancer and usually occur following loss of APC. I aimed to explore further how loss 
of one gene commonly implicated in cancer, PTEN, could impact on E-cadherin, a protein tightly 
linked to the important tumour suppressor gene, APC. 
In this chapter I aim to: 
1) ŽŵƉĂƌĞƚŽƚĂůƉƌŽƚĞŝŶůĞǀĞůƐŽĨW͕ɴ-catenin and E-cadherin in PTEN (+/+) and PTEN 
(-/-) cells. 
2) DĞĂƐƵƌĞƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin, E-cadherin and AXIN2 in these two cell lines. 
3) ƐƚĂďůŝƐŚŝĨWdEƐƚĂƚƵƐĂĨĨĞĐƚƐƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin and if this changes in 
ƌĞƐƉŽŶƐĞƚŽĚĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin, E-cadherin or PTEN. 
4) ĞƚĞƌŵŝŶĞŚŽǁWdEĂĨĨĞĐƚƐƚŚĞƌĞůĂƚŝǀĞůĞǀĞůŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin in 
complexes containing APC and those containing E-cadherin. 
5) Establish if expression of PTEN proteins in PTEN (-/-) cells can cause changes in protein 
ůĞǀĞůŽĨW͕ɴ-catenin and E-cadherin or affect transcription of AXIN2 and E-cadherin. 
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4.2 Results 
ϰ͘Ϯ͘ϭWdEůŽƐƐĂĨĨĞĐƚƐůĞǀĞůƐŽĨW͕ɴ-catenin and E-cadherin in HCT116 cells 
I first measured if PTEN nƵůůĐĞůůƐĚŝƐƉůĂǇĞĚĂĚŝĨĨĞƌĞŶƚĞǆƉƌĞƐƐŝŽŶƉƌŽĨŝůĞŽĨW͕ɴ-catenin and 
E-cadherin proteins using HCT116 human colorectal cancer cells. I compared two cell lines. First, 
a PTEN wild-type cell line PTEN (+/+) that expresses one wild-ƚǇƉĞɴ-catenin allele (+) and one 
ŵƵƚĂŶƚ;ȴϰϱͿĂůůĞůĞ;нͬȴϰϱͿ͘dŚĞŵƵƚĂŶƚĂůůĞůĞƌĞŶĚĞƌƐƚŚĞɴ-catenin protein non-degradable by 
ƚŚĞWĚĞƐƚƌƵĐƚŝŽŶĐŽŵƉůĞǆĚƵĞƚŽĚĞůĞƚŝŽŶŽĨƌĞƐŝĚĞƐĞƌŝŶĞϰϱ;ȴƐĞƌŝŶĞϰϱͿ͘dŚĞƐĞĐŽŶĚĐĞůů
line is a PTEN null cell PTEN (-/-) with the same complĞŵĞŶƚŽĨɴ-catenin as the PTEN (+/+) cell 
line. The cells are genetically identical other than the differences in PTEN. Cell lysis and western 
ďůŽƚ ĂŶĂůǇƐĞƐ ;&ŝŐƵƌĞ ϰ͘ϭͿ ƐŚŽǁĞĚ ĚŝĨĨĞƌĞŶƚŝĂů ĞǆƉƌĞƐƐŝŽŶ ŽĨ W͕ ɴ-catenin and E-cadherin 
between the cell lines studied. 
 
Figure 4.1: PTEN status influences the levels of APC, E-catenin and E-cadherin. Whole-cell lysate 
of PTEN (+/+) and PTEN (-/-) cells were subjected to western blot with antibodies against APC, E-
catenin and E-cadherin. Protein levels were quantified relative to GAPDH. Plots show protein 
levels APC in (a), E-catenin in (b) and E-cadherin in (c) plotted relative to the level in the PTEN 
(+/+) cells. Data represent the mean and standard deviation of three independent experiments. 
 
PTEN (-/-) cells ĞǆƉƌĞƐƐŵŽƌĞɴ-catenin and E-cadherin than PTEN (+/+) cells. No difference exists 
in the expression levels of APC. 
PTEN (-/-ͿĐĞůůƐŚĂǀĞŚŝŐŚĞƌůĞǀĞůƐŽĨɴ-catenin. This could potentially be due to activation of the 
Akt pathway, which can inhibit GSK3Eand ŶĞŐĂƚŝǀĞůǇ ŝŶĨůƵĞŶĐĞƚŚĞ ĨƵŶĐƚŝŽŶŽĨƚŚĞɴ-catenin 
destruction complex (Song, 2012, Koul, 2002, Fata, 2012) (Figure 4.2b.) 
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Figure 4.2: A simplified representation of the PTEN Akt pathway and its potential mechanism of 
influence on E-catenin level. Cell a) represents the phosphorylation of PIP2 to PIP3 by PIP3 kinase 
and its subsequent dephosphorylation by PTEN. This results in unphosphorylated Akt, uninhibited 
GSK3Eand an APC destruction complex with normal E-catenin degradative function. Cell b) 
signifies PTEN loss, phosphorylation of Akt with resultant inhibition of GSK3E. This negatively 
impacts on the function of the APC destruction complex and can allow accumulation of E-catenin. 
 
The higher levels of E-cadherin in PTEN (-/-) cells support findings in Chapter 1 that showed PTEN 
depletion resulted in an increase in both E-cadherin transcript and protein level. 
The PTEN (+/+) and PTEN (-/-ͿĐĞůůƐĞǆƉƌĞƐƐƚŚĞƐĂŵĞĨŽƌŵƐŽĨɴ-catenin. Some can be degraded 
by APC and some will be sequestered by APC in both cell lines. However, the PTEN (-/-) cells 
ĐŽŶƚĂŝŶŵƵĐŚŵŽƌĞƚŽƚĂůɴ-ĐĂƚĞŶŝŶ͘WĞƌŚĂƉƐƚŚĞĂĚĚŝƚŝŽŶĂůɴ-catenin saturates the ability of APC 
ƚŽƌĞŐƵůĂƚĞŝƚ;ĨŽƌŝŶƐƚĂŶĐĞďĞĐĂƵƐĞƚŽŽŵƵĐŚŵƵƚĂŶƚɴ-catenin is stably associated with APC). 
The resulting excess may be too much to be sequestered or controlled so that once a threshold 
is exceeded, more E-ĐĂĚŚĞƌŝŶ ŝƐ ĞǆƉƌĞƐƐĞĚ ƚŚĂƚ ĐĂŶ ƐĞƋƵĞƐƚĞƌ ƚŚŝƐ ɴ-catenin to regulate the 
ĂŵŽƵŶƚŽĨĨƌĞĞɴ-catenin in the cell (Figure 4.3). 
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Figure 4.3: In PTEN (+/+) cells (a) E-catenin levels are lower and can therefore be either degraded 
(Wild Type (yellow)) or sequestered (Mutant (red)) by APC to maintain free cytoplasmic levels 
within reasonable limits. Only a small amount of E-cadherin is required to sequester some of this 
E-catenin at adherens junctions. PTEN (-/-) cells (b) have far more E-catenin. This may saturate 
the capabilities for APC to either sequester or degrade, resulting in increased free E-catenin in 
the cytoplasm. An unknown mechanism may upregulate E-cadherin to bind this free E-catenin 
at the plasma membrane. 
 
dŽƚĞƐƚǁŚĞƚŚĞƌƚŚĞĞĨĨĞĐƚƐŽĨWdEůŽƐƐŽŶɴ-catenin and E-cadherin related to protein stability 
ŽƌŝŶĐƌĞĂƐĞĚƚƌĂŶƐĐƌŝƉƚŝŽŶ͕/ŵĞĂƐƵƌĞĚƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin and E-cadherin. In addition, 
I measuƌĞĚƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨy/EϮ͕Ăɴ-catenin target gene (Figure 4.4). 
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Figure 4.4: Differences exist in the transcription of AXIN2 and E-cadherin between PTEN (+/+) and 
PTEN (-/-) cells while E-catenin transcription is similar. Transcript levels of E-catenin (a), AXIN2 
(b) and E-cadherin (c) were assessed on whole-cell lysate by qPCR. Plotted data show the 
transcript level relative to the PTEN (+/+) cells and represent the mean and standard deviation 
of three independent experiments. Plotted values represent the mean and standard deviation of 
three independent experiments for each condition. 
 
EŽƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞǁĂƐŵĞĂƐƵƌĞĚďĞƚǁĞĞŶƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin in PTEN (+/+) and 
PTEN (-/-) cells. Transcription of AXIN2 and E-cadherin was significantly higher in PTEN (-/-) cells 
compared with PTEN (+/+) cells. 
This indicates that the excĞƐƐ ɴ-catenin protein in the PTEN (-/-) cells is not the result of 
increased transcription but likely due to increased protein stability caused by decreased 
degradation. 
E-cadherin transcription is much higher in the PTEN (-/-) than in the PTEN (+/+) cells. This 
indicates that the higher E-cadherin protein level in PTEN (-/-) cells is at least in part due to 
increased transcription rather than stabilisation of the E-cadherin protein. Whether higher E-
ĐĂĚŚĞƌŝŶƚƌĂŶƐĐƌŝƉƚŝŽŶŝƐĂĚŝƌĞĐƚƌĞƐƉŽŶƐĞƚŽŚŝŐŚĞƌɴ-catenin levels is unclear. 
AXIN2 transcript level is approximately four times higher in the PTEN (-/-) cells than in the PTEN 
;нͬнͿĐĞůůůŝŶĞ͘dŚĞɴ-catenin protein level is also in the region of four times higher in the PTEN (-
/-) cells than in the PTEN (+ͬнͿĐĞůůƐ͘dŚŝƐĨŝŶĚŝŶŐĐŽƵůĚƐŝŵƉůǇƌĞĨůĞĐƚƚŚĂƚƚŚĞŚŝŐŚĞƌůĞǀĞůŽĨɴ-
catenin present in the PTEN (-/-) cells stimulates AXIN2 transcription. 
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4.2.1 Summary of Key Findings: 
x PTEN (-/-ͿĐĞůůƐŚĂǀĞŵŽƌĞɴ-catenin and E-cadherin protein than PTEN (+/+) cells. 
x PTEN (+/+) and PTEN (-/-ͿĐĞůůƐŚĂǀĞĂƐŝŵŝůĂƌƚƌĂŶƐĐƌŝƉƚůĞǀĞůŽĨɴ-catenin but PTEN (-/-) 
cells have a higher transcript level of both E-cadherin and AXIN2. 
ϰ͘Ϯ͘Ϯ͘ϭɴ-catenin, APC and E-cadherin are responsive to depletion of each other in PTEN (-/-) 
cells. 
Figure 4.1 revealed that PTEN can affect the total level of APC and E-cadherin in HCT116 cells. I 
ŶĞǆƚǁĂŶƚĞĚ ƚŽƉƌŽǀŝĚĞ ĨƵƌƚŚĞƌ ŝŶƐŝŐŚƚ ŝŶƚŽ ƚŚĞƌĞůĂƚŝŽŶƐŚŝƉƐďĞƚǁĞĞŶW͕ɴ-catenin and E-
cadherin, and determine how they are influenced by PTEN. I ĐŽŵƉĂƌĞĚůĞǀĞůƐŽĨɴ-catenin, APC 
and E-cadherin after depletion of each of these proteins in PTEN (+/+) and PTEN (-/-) HCT116 
cells (Figure 4.5). 
 
Figure 4.5: Depletion of APC, E-catenin, E-cadherin or PTEN can influence expression levels of 
APC, E-catenin and E-cadherin in PTEN (+/+) and PTEN (-/-) HCT116 cells. Cells were treated with 
the appropriate siRNA then whole-cell lysate was subjected to western blot with antibodies 
directed against APC, E-catenin or E-cadherin. Protein levels were quantified relative to GAPDH. 
Protein levels of APC (a & e), E-catenin (b & f) and E-cadherin (c & g) are plotted relative to the 
control levels in PTEN (+/+) cells (top panel) and PTEN (-/-) cells (bottom panel). Representative 
western blots are shown in (d & h). Measurements represent the mean and standard deviation 
of three separate experiments and representative western blots are displayed for each condition. 
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E-cadherin levels increase following PTEN depletion in PTEN (+/+) cells and after APC depletion. 
Levels of WĂŶĚɴ-ĐĂƚĞŶŝŶĚĞĐƌĞĂƐĞĨŽůůŽǁŝŶŐĚĞƉůĞƚŝŽŶŽĨWĂŶĚɴ-catenin while E-cadherin 
levels are lower following all treatments in PTEN (-/-) cells. 
The increase in E-cadherin following PTEN depletion is in keeping with the higher level of E-
cadherin expression in PTEN (-/-) cells. The causative mechanism for this is unclear and requires 
further experiments. These data should be interpreted with caution as very low levels of E-
cadherin are expressed in these cells. This may have the effect of amplifying even small changes 
due to measurement artefacts. 
dŚĞWůĞǀĞůĚĞĐƌĞĂƐĞĚŝŶďŽƚŚĐĞůůůŝŶĞƐĨŽůůŽǁŝŶŐɴ-catenin depletion. This supports findings 
in Chapter 3 and appears to be independent of PTEN status. This may represent part of a 
ĨĞĞĚďĂĐŬůŽŽƉďĞƚǁĞĞŶWĂŶĚɴ-catenin. 
There was a reduction in E-cadherin level following all treatments in the PTEN (-/-) cells, which 
contrasts with findings in the PTEN (+/+) cells. The reasons for this are not apparent from these 
experiments. 
4.2.2.2 Depletion of APC, E-catenin and E-cadherin causes differential effects on transcription 
ŽĨɴ-catenin, E-cadherin and AXIN2 in PTEN (+/+) and PTEN (-/-) cells 
EĞǆƚ͕/ǁĂŶƚĞĚƚŽĂƐƐĞƐƐŝĨƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin and E-cadherin reflected the changes in 
ƉƌŽƚĞŝŶ ůĞǀĞůƐ ĨŽůůŽǁŝŶŐĚĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin, E-cadherin and PTEN in PTEN (+/+) and 
PTEN (-/-) HCT116 cells. In addition, I aimed to assess the impact of these treatments on the 
ƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨɴ-catenin target gene AXIN2 (Figure 4.6). 
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Figure 4.6: Transcript levels of AXIN2, E-catenin and E-cadherin are differentially responsive to 
depletion of APC and PTEN in PTEN (+/+) and PTEN (-/-) cells. Cells were treated with siRNA 
against APC, E-catenin, E-cadherin or PTEN, then the transcript level of AXIN2 (a & b), E-catenin 
(c & d) and E-cadherin (e & f) was measured using qPCR. Transcript levels are plotted relative to 
a control. Data represent the mean and standard deviation of three independent experiments. 
 
y/EϮƚƌĂŶƐĐƌŝƉƚŝŽŶŝŶĐƌĞĂƐĞƐƐŝŐŶŝĨŝĐĂŶƚůǇĨŽůůŽǁŝŶŐWĚĞƉůĞƚŝŽŶŝŶďŽƚŚĐĞůůůŝŶĞƐ͘ɴ-Catenin 
transcript increases following APC depletion in PTEN (-/-) cells and to a lesser extent in PTEN 
(+/+) cells under the same conditions. E-cadherin transcript level increases in PTEN (+/+) cells 
following PTEN depletion. 
AXIN2 transcription increases in both cell lines in response to APC depletion. This supports the 
findings in Chapter 3. This is most likely due to loss of degradation of the wild-ƚǇƉĞɴ-catenin in 
ƚŚĞƐĞĐĞůůƐĂŶĚƌĞůĞĂƐĞŽĨƚŚĞƐĞƋƵĞƐƚĞƌĞĚŵƵƚĂŶƚɴ-catenin in both cell lines. 
This may be supported by somĞŶĞǁƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨɴ-catenin, which is shown following APC 
depletion, especially in the PTEN (-/-ͿĐĞůůƐ͘dŚĞŝŶĐƌĞĂƐĞĚɴ-catenin transcript does not reflect 
ƚŚĞĚĞĐƌĞĂƐĞŝŶɴ-catenin protein in the PTEN (-/-) cells following APC depletion. The modest 
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ŝŶĐƌĞĂƐĞ ŝŶ ƚƌĂŶƐĐƌŝƉƚ ŝŶ ƚŚĞWdE ;нͬнͿ ĐĞůůƐ ƐƵƉƉŽƌƚƐĂ ƐŝŵŝůĂƌŵŽĚĞƐƚ ŝŶĐƌĞĂƐĞ ŝŶɴ-catenin 
protein in PTEN (+/+) cells after APC knockdown. 
The increased in E-cadherin protein in PTEN (+/+) cells after PTEN knockdown is supported by 
an increase in E-cadherin transcript level. This indicates that new transcription is responsible for 
the increased expression levels as opposed to stabilisation. 
4.2 Summary of Key Findings: 
x Both E-cadherin protein and transcript increase in PTEN (+/+) cells following PTEN 
knockdown. 
x AXIN2 transcription increases in both PTEN (+/+) and PTEN (-/-) cells following APC 
depletion. 
  
98 
 
4.2.2.3 Depletion of APC and E-ĐĂĚŚĞƌŝŶĐĂƵƐĞƐĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the plasma 
membrane to the cytoplasm 
/ŶĞǆƚǁĂŶƚĞĚƚŽĚĞƚĞƌŵŝŶĞŚŽǁĚĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin, E-cadherin or PTEN affects the 
ĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin in both PTEN (+/+) and PTEN (-/-) cells. 
I fractionated cells into pools representing different cellular components: cytoplasm, 
ŵĞŵďƌĂŶĞ͕ŶƵĐůĞƵƐĂŶĚĐǇƚŽƐŬĞůĞƚŽŶ͕ĂŶĚŵĞĂƐƵƌĞĚƚŚĞƉƌĞƐĞŶĐĞŽĨɴ-catenin in each fraction. 
Graphically displayed data and representative blots are in Figure 4.7. 
 
Figure 4.7: Cellular location of E-catenin is altered by depletion of APC and E-cadherin in both 
cell lines studied. Cells were fractionated into cytoplasmic, membrane, nuclear and cytoskeletal 
compartments and localisation of E-catenin was assessed by western blot using antibody 
directed against E-catenin following depletion of APC (b & g), E-catenin (c & h), E-cadherin (d & 
i), PTEN (e) or under control conditions (a & f). Data represent the mean and standard deviation 
of three independent experiments, except E-cadherin knockdown, where n = 1. 
 
PTEN is predominantly located at the plasma membrane in both PTEN (+/+) and PTEN (-/-) cells. 
Depletion of APC or E-ĐĂĚŚĞƌŝŶĐĂƵƐĞƐĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin to the cytoplasm in both cell 
lines. 
dŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin under control conditions shows a similar trend in both cell lines. In 
the PTEN (+/+) cell line, approximately 50–ϲϬй ŽĨ ƚŽƚĂů ɴ-catenin resides in the membrane 
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compartment of the cells with 20–30% in the cytoplasm. The cytoskeletal compartment contains 
ĂƉƉƌŽǆŝŵĂƚĞůǇϮϬйŽĨɴ-ĐĂƚĞŶŝŶ͕ǁŚŝůĞŶƵĐůĞĂƌɴ-catenin accounts for 10%. A similar distribution 
is found in the PTEN (-/-) cells. The main difference from the PTEN (+/+) cells is that around 65% 
ŽĨɴ-catenin is membrane associated at the expense of the cytoplasmic compartment, which has 
15%. The difference between the membrane proportion in PTEN (+/+) compared with PTEN (-/-
) cells was statistically significant (p<0.05). 
ĂƐĞĚŽŶƚŚĞƐĞĨŝŐƵƌĞƐ͕ƚŚĞŐƌĞĂƚĞƐƚƉƌŽƉŽƌƚŝŽŶŽĨɴ-catenin appears to be associated with E-
cadherin at the cell membrane under control conditions. Perhaps the much higher level of E-
cadherin in the PTEN (-/-ͿĐĞůůƐĐĂŶĞǆƉůĂŝŶƚŚĞŚŝŐŚĞƌƉƌŽƉŽƌƚŝŽŶŽĨɴ-catenin in the membrane 
region. 
Depletion of APC causes a ƌĞĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ ɴ-catenin to the cytoplasm from the plasma 
membrane in both cell lines. This supports findings from Chapter 3. This is likely due to release 
ŽĨƐĞƋƵĞƐƚĞƌĞĚŵƵƚĂŶƚɴ-catenin from APC and loss of degradation of wild-ƚǇƉĞɴ-catenin. The 
cytŽƉůĂƐŵŝĐɴ-catenin represents a free unbound pool. 
E-ĐĂĚŚĞƌŝŶ ĚĞƉůĞƚŝŽŶ ĐĂƵƐĞƐ Ă ƐŝŵŝůĂƌ ƌĞĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ ɴ-catenin to the cytoplasm from the 
plasma membrane. This would be expected following dissociation of adherens junctions and 
occurred in both cell lines. 
4.3 Summary of Key Findings: 
x ^ŝŐŶŝĨŝĐĂŶƚůǇŵŽƌĞɴ-catenin is located at the plasma membrane in PTEN (-/-) cells 
compared with PTEN (+/+) cells. 
x Depletion of APC or E-ĐĂĚŚĞƌŝŶƌĞƐƵůƚƐŝŶĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the plasma 
membrane to the cytoplasm irrespective of PTEN status. 
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ϰ͘ϰdŚĞƐƐŽĐŝĂƚŝŽŶŽĨɴ-ĂƚĞŶŝŶǁŝƚŚWŝƐhŶĂĨĨĞĐƚĞĚďǇWdE^ƚĂƚƵƐtŚŝůĞDŽƌĞɴ-Catenin 
is Bound to E-cadherin in PTEN Cells Compared with PTEN (+/+) Cells 
/Ŷ ŚĂƉƚĞƌ ϯ͕ / ƐŚŽǁĞĚ ƚŚĂƚ ƐƚĂďŝůŝƐŝŶŐ ŵƵƚĂƚŝŽŶƐ ŽĨ ɴ-catenin can influence its relative 
interaction with APC or E-cadherin. Based on the effects of PTEN on E-cadherin in particular, I 
ĂŝŵƚŽĂƐƐĞƐƐŝĨWdEŝŵƉĂĐƚƐŽŶƚŚĞƐĞƌĞůĂƚŝŽŶƐŚŝƉƐƵƐŝŶŐɴ-catenin Co-IP (Figure 4.8). 
 
Figure 4.8: The distribution of E-catenin between complexes containing APC or E-cadherin is 
different in PTEN (+/+) cells compared with PTEN (-/-) cells. E-Catenin was co-
immunoprecipitated from PTEN (+/+) and PTEN (-/-) cells. Western blot of the IP and lysate was 
probed with antibodies against APC, E-catenin and E-cadherin. Representative western blots of 
IP and lysate are shown for PTEN (+/+) (a) and PTEN (-/-) cells (b). Values of E-catenin/APC are 
tabulated (c) and plotted (e) for PTEN (+/+) and (f) for PTEN (-/-) cells. E-catenin/E-cadherin ratios 
are tabulated in (d) and plotted in (g) for PTEN (+/+) and (h) for PTEN (-/-) cells. Data represent 
the mean and standard deviation of three independent experiments. 
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dŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨɴ-catenin with APC is not significantly different between the PTEN (+/+) and 
PTEN (-/-) cells (p сϬ͘ϯϮϰͿ͘DŽƌĞɴ-catenin is found associated with E-cadherin in the PTEN (-/-) 
cells compared with PTEN (+/+) cells. 
ƐŝŵŝůĂƌůĞǀĞůŽĨɴ-catenin binds to APC in the PTEN (+/+) compared with the PTEN (-/-) cells 
reflectĞĚ ďǇ ɴ-ĐĂƚĞŶŝŶͬW ƌĂƚŝŽƐ ŽĨ ϭϬ͘ϳ ĂŶĚ ϭϲ͘Ϯ͘ ŽƚŚ ƚŚĞƐĞ ĨŝŐƵƌĞƐ ĂƌĞ ƐŝŵŝůĂƌ ƚŽ ƚŚĞ ɴ-
catenin/APC ratios in the lysate of these cells (8.3 in PTEN (+/+) and 25 in PTEN (-/-)). A similar 
ĚĞŐƌĞĞŽĨWͬɴ-catenin interaction may be expected as both cell lines express one mutant and 
one wild-ƚǇƉĞɴ-catenin protein. 
^ŝŐŶŝĨŝĐĂŶƚůǇŵŽƌĞɴ-catenin is found in association with E-cadherin in the PTEN (-/-) compared 
ǁŝƚŚ ƚŚĞWdE ;нͬнͿ ĐĞůůƐ ƌĞĨůĞĐƚĞĚďǇɴ-catenin/E-cadherin ratios of 7.1 and 125.2 in the IP 
respectively (p < 0.01). The higher level of interaction may simply reflect the fact that the PTEN 
(-/-ͿĐĞůůƐŚĂǀĞŵŽƌĞɴ-catenin and E-cadherin, so there is more opportunity for binding. 
To investigate these relationships further, I also immunoprecipitated APC and measured the 
amount of E-catenin that was recovered in the different cell types (Figure 4.9). 
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Figure 4.9: The level of E-catenin in complexes containing APC or E-cadherin differs between 
PTEN (+/+) cells and PTEN (-/-) cells with more E-catenin associated with E-cadherin in PTEN (-/-
) cells. APC Co-IP using APC-ALI antibody was carried out in PTEN (+/+) and PTEN (-/-) cells. 
Western blot on the IP and lysate was performed with antibodies directed at APC and E-catenin. 
Representative blots of the PTEN (+/+) (a) and PTEN (-/-) (b) cells are shown. The E-catenin/APC 
ratios for the IP and lysate are tabulated in (c) and plotted for the PTEN (+/+) cells in (d) and PTEN 
(-/-) cells in (e). Data represent the mean and standard deviation of three independent 
experiments. 
 
ƐŝŵŝůĂƌĚĞŐƌĞĞŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and APC is evident in PTEN (+/+) versus PTEN 
(-/-Ϳ ĐĞůůƐ ƌĞĨůĞĐƚĞĚ ďǇ ƐŝŵŝůĂƌ ɴ-catenin/APC ratios in the IP of 4.3 and 3.09, respectively. A 
greater difference in ratios determined from the lysate reflects the fact that the PTEN (-/-) cells 
ŚĂǀĞƌĞůĂƚŝǀĞůǇŵŽƌĞɴ-catenin and less APC than the PTEN (+/+) cells. 
dŚĞƐĞĨŝŶĚŝŶŐƐƐƵƉƉŽƌƚƚŚŽƐĞŽĨƚŚĞɴ-catenin Co-IP and are in line with expectations of two cell 
lines expressing the same complement of ɴ-catenin. 
I next aimed to see if I could distinguish different pools of E-catenin bound to either APC or E-
ĐĂĚŚĞƌŝŶŝŶƚŚĞĚŝĨĨĞƌĞŶƚĐĞůůůŝŶĞƐ͘/ĨŝƌƐƚƉƌĞĐŝƉŝƚĂƚĞĚW͕ĂŶĚƚŚĞŶƉƌĞĐŝƉŝƚĂƚĞĚɴ-catenin from 
the remaining, post-IP, lysates. This allowed ŵĞƚŽĚĞƚĞƌŵŝŶĞŝĨĂŶǇŽƌĂůůŽĨƚŚĞɴ-catenin that 
remained after removing APC was bound to E-cadherin (Figure 4.10). 
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Figure 4.10: Removing APC-associated E-catenin reveals differential binding of E-catenin to E-
cadherin in PTEN (+/+) and PTEN (-/-) cells. APC Co-IP was performed, and then the post-IP lysate 
was used for a E-catenin Co-IP. Western blot was carried out in PTEN (+/+) cells (a) and PTEN (-
/-) cells (b) with antibody against APC, E-catenin and E-cadherin. Ratios of E-catenin/APC in the 
APC-Co-IP were calculated and plotted in (c). E-Catenin/E-cadherin ratios were calculated from 
the E-catenin Co-IP and plotted in (d). Tabulated data are in (e). One replicate of this experiment 
was performed. 
 
^ŝŵŝůĂƌ ůĞǀĞůƐŽĨɴ-catenin are bound to APC in boƚŚĐĞůů ůŝŶĞƐ͘^ŝŐŶŝĨŝĐĂŶƚůǇŵŽƌĞɴ-catenin is 
associated with E-cadherin in the PTEN (-/-) compared with PTEN (+/+) cells. 
These results give support to findings from the single APC immunoprecipitations described 
above. Similar ratios (2.61 in PTEN (+/+) and 2.9 in PTEN (-/-ͿͿŽĨɴ-catenin/APC were obtained 
ŝŶƚŚĞW/W͘ůƚŚŽƵŐŚƚŽƚĂůůĞǀĞůƐŽĨɴ-catenin and APC differ between the two cell lines, the 
ƉƌŽƉŽƌƚŝŽŶŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶWĂŶĚɴ-catenin is similar between the two cell lines. This 
interaction appears to function independently of PTEN status. 
dŚĞƌĂƚŝŽƐŽĨɴ-catenin/E-ĐĂĚŚĞƌŝŶŝŶƚŚĞƐƵďƐĞƋƵĞŶƚɴ-catenin IP (4.71 in PTEN (+/+) and 1.1 in 
PTEN (-/-ͿͿ ŝŶĚŝĐĂƚĞ ƚŚĂƚ ƚŚĞƌĞ ŝƐŵŽƌĞ ɴ-catenin bound to E-cadherin in the PTEN (-/-) cells 
compared with PTEN (+/+) cells. This may relate to the fact that there are higher levels of both 
E-ĐĂĚŚĞƌŝŶĂŶĚɴ-catenin in the PTEN (-/-) cells (Figure 4.1). 
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4.4 Summary of Key Findings: 
x WƌŽƉŽƌƚŝŽŶĂƚĞůǇƐŝŵŝůĂƌĂŵŽƵŶƚƐŽĨɴ-catenin bind to APC in PTEN (+/+) cells as in PTEN 
(-/-) cells. 
x DŽƌĞɴ-catenin is found in association with E-cadherin in PTEN (-/-) cells compared 
with PTEN (+/+) cells. This may reflect the higher expression levels of these two 
proteins in PTEN (-/-) cells. 
4.5 Assessment of the Effects of Expression of PTEN Constructs in PTEN (-/-) Cells 
/ĚĞƚĞƌŵŝŶĞĚƚŚĂƚůĂĐŬŽĨWdEŝŶ,dϭϭϲĐĞůůƐůĞĂĚƐƚŽŚŝŐŚĞƌĞǆƉƌĞƐƐŝŽŶŽĨďŽƚŚɴ-catenin and 
E-cadherin with an associated increased interaction between them. I next aimed to measure if 
reintroducing PTEN into PTEN (-/-ͿĐĂŶĐĂƵƐĞĐŚĂŶŐĞƐŝŶƚŚĞůĞǀĞůƐŽĨɴ-catenin or E-cadherin. 
I transfected PTEN (-/-) cells with a panel of PTEN proteins that vary in the specific phosphatase 
functions of the expressed protein. This allows distinction of whether a specific catalytic function 
of the PTEN protein or its simple physical presence is involved in the effects observed. 
I compared a wild-type PTEN vector, which encodes the full length PTEN protein with normal 
lipid and protein phosphatase function, with protein C124S, which encodes full length PTEN 
lacking all phosphatase activity. I also assessed the effect of protein G129E, which encodes PTEN 
lacking lipid phosphatase but retains protein phosphatase activity. Lastly, protein Y138L, which 
encodes PTEN with lipid phosphatase activity but no protein phosphatase activity, was 
reintroduced into PTEN (-/-) cells (Davidson, 2010). 
First, I determined the level of PTEN protein following transfection of the PTEN (-/-) cells with 
the wild-type vector and compared expression levels with those in the PTEN wild-type PTEN 
(+/+) cell line (Figure 4.12). 
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Figure 4.11: Expression of wild-type PTEN in PTEN (-/-) cells leads to higher levels of PTEN than is 
present in PTEN (+/+) cells. PTEN (-/-) cells were transfected with either wild-type PTEN or control 
(empty vector). Whole-cell lysate was subjected to western blot and targeted with antibodies 
against APC, E-cadherin, E-catenin, PTEN and GAPDH. 
 
Transfection of wild-type PTEN into PTEN (-/-) cells achieved expression of PTEN protein. The 
expression level was higher than that of endogenously expressed PTEN in the PTEN (+/+) cell 
line. 
/ŶĞǆƚŵĞĂƐƵƌĞĚƚŚĞĞĨĨĞĐƚƐŽĨƚŚĞWdEĞǆƉƌĞƐƐŝŽŶŽŶůĞǀĞůƐŽĨW͕ɴ-catenin and E-cadherin 
(Figure 4.13). 
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Figure 4.12: Expression of PTEN protein in PTEN (-/-) cells causes minimal change in the levels of 
APC, E-cadherin, E-catenin or Snail, while phospho-Akt is responsive. PTEN (-/-) cells were 
transfected with a panel of PTEN proteins. Whole-cell lysate was probed with antibody against 
APC, E-cadherin, E-catenin, phospho-Akt, PTEN and Snail (a). Protein levels were quantified 
relative to GAPDH. Protein levels were plotted relative to levels in the control (empty vector) (b–
g). Data represent mean and standard deviation of three independent experiments except those 
for phospho-Akt and Snail, which represent one replicate. 
 
PTEN expression in PTEN (-/-) cells causes no change in the protein level of APC, E-ĐĂĚŚĞƌŝŶ͕ɴ-
catenin or Snail. Phospho-Akt levels are reduced following expression of PTEN with lipid 
phosphatase activity (wild type and Y138L). 
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APC levels are unchanged following transfection of any of the PTEN vectors (Graph (b) Figure 
4.14) (p > 0.05 for each vector versus control). APC levels in the PTEN (-/-) cells are slightly lower. 
I expected ĂĨĂůů ŝŶɴ-catenin following transfection of both the wild type and Y138L vectors, 
which have active lipid phosphatase activity. Re-expression of PTEN with lipid phosphatase 
activity may have been expected to down regulate Akt and the inhibition of GSK3E. This could 
potentially result in increased functional efficiency of the APC destruction complex with 
ƌĞƐƵůƚĂŶƚĚĞĐƌĞĂƐĞŝŶɴ-catenin. This did happen. 
Similarly, there was little difference in E-cadherin protein level following expression of any of 
the PTEN proteins (p > 0.05 for each vector versus control). 
Expression levels of phospho-Akt are altered as expected in PTEN transfected cells (f). As 
expected, little change compared with the control was observed following transfection of either 
C124S or G129E as these both lack lipid phosphatase activity. A reduction to 20% and 30% of p-
Akt compared with control levels is observed in cells expressing the wild type and Y138L PTEN, 
respectively. Both these PTEN proteins retain lipid phosphatase activity and are active in the 
PTEN/Akt pathway consistent with the decrease in p-Akt in cells expressing these PTEN proteins. 
I also measured the effect of different PTEN proteins on the expression of Snail. Snail is 
ŝŵƉůŝĐĂƚĞĚŝŶƚŚĞDdƉƌŽĐĞƐƐ͘ŚŝŐŚůĞǀĞůŽĨɴ-catenin can lead to Snail-mediated repression 
of E-cadherin transcription (Barrallo-Gimeno, 2005). No change in Snail expression was 
measured following transfection of any of the PTEN proteins. 
To determine if PTEN re-expression altered the transcription of the proteins of interest, I 
ŵĞĂƐƵƌĞĚƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨɴ-catenin, AXIN2 and E-cadherin in cells transfected with different 
PTEN proteins (Figure 4.15). 
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Figure 4.13: Transfection of PTEN protein into PTEN (-/-) cells causes changes in the transcription 
of E-catenin, AXIN2 and E-cadherin. PTEN proteins were transfected into PTEN (-/-) cells. 
Transcript levels of E-catenin (a), AXIN2 (b) and E-cadherin (c) were measured using qPCR. 
Transcript levels are plotted relative to the control and data reflect the mean and standard 
deviation of three independent experiments except (c), which represents the mean and standard 
deviation of seven separate experiments. 
 
dŚĞƚƌĂŶƐĐƌŝƉƚůĞǀĞůŽĨɴ-catenin (a) is reduced following transfection of all PTEN proteins. AXIN2 
transcript is reduced significantly following transfection of PTEN that retains lipid phosphatase 
activity and E-cadherin transcript is significantly reduced in response to all PTEN proteins. 
dƌĂŶƐĐƌŝƉƚůĞǀĞůŽĨɴ-catenin is reduced significantly following transfection of all PTEN proteins. 
dŚŝƐ ĚŽĞƐ ŶŽƚ ƌĞĨůĞĐƚ ƚŚĞ ƌĞƐƉŽŶƐĞ ŽĨ ɴ-catenin protein, which was unchanged under all 
conditions. The time course of the experiment may have been too short for the transcriptional 
changes to be translated into changes in protein level. It is surprising that a reduction was 
observed in response to all proteins as the expectation would have been that a change would 
have occurred only following transfection of PTEN with lipid phosphatase activity. 
E-cadherin transcript was reduced significantly following expression of any of the PTEN proteins. 
This is an unexpected finding considering that this does not correspond to a reduction in E-
cadherin protein. It is possible that the 48 hour time point may not be sufficient for a reduction 
in transcripts to produce a reduction in E-cadherin protein. 
Nonetheless, the reduced E-cadherin transcript is puzzling. All PTEN proteins have this effect, 
suggesting that this effect is unrelated to either phosphatase activity of PTEN and raising the 
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question of whether the physical presence of the PTEN protein is somehow involved. 
Alternatively, the effect of PTEN on E-cadherin may be specific to HCT116 cells and may be 
related to other genetic defects in these cells. Further analysis is required to clarify this finding. 
No significant change in AXIN2 transcription is observed following expression of C124S or G129E. 
However, Axin transcription is significantly reduced in cells expressing PTEN proteins that have 
lipid phosphatase activity. Given that chaŶŐĞƐ ŝŶ ɴ-catenin were not detected under these 
conditions, it is possible that changes in the availability of E-catenin for transcriptional activation 
of Axin are responsible. To assess this hypothesis, co-ŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚŝŽŶŽĨɴ-catenin could be 
carried out to assess if its binding with either APC or E-cadherin changed following PTEN 
transfection in future experiments. Previous experiments showed that a cytoplasmic 
ƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin was associated with an increase in AXIN2 transcription. This was not 
ŶĞĐĞƐƐĂƌŝůǇĂĐĐŽŵƉĂŶŝĞĚďǇĂŶŝŶĐƌĞĂƐĞŝŶƚŽƚĂůɴ-catenin level. 
dŽĚĞƚĞƌŵŝŶĞŝĨƚŚĞWdEĞĨĨĞĐƚƐ/ŽďƐĞƌǀĞĚĂƌĞƌĞůĂƚĞĚƚŽƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin and E-
cadherin in cells, I next measured their distribution between different cellular compartments in 
cells after transfection with different PTEN proteins (Figure 4.16). 
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Figure 4.14: Transfection of PTEN proteins into PTEN (-/-) cells causes no redistribution of E-
catenin or E-cadherin. PTEN (-/-) cells were transfected with a panel of PTEN proteins. They were 
then fractionated into cytoplasmic, membrane, nuclear and cytoskeletal compartments prior to 
western blot. Membranes were probed with antibodies against E-catenin, E-cadherin and PTEN. 
The proportional distribution of E-catenin and E-cadherin was calculated and plotted as control 
(a & b), wild type (d & e), C124S (g & h), G129E (j & k) and Y138L (m & n). Blots are shown in (c, 
f, i, l and o). The data represent results from one experiment. 
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Transfection of all tested PTEN vectors caused no cŚĂŶŐĞ ŝŶ ƚŚĞ ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ ɴ-catenin 
compared with control cells. Similarly, no redistribution was observed for E-cadherin, which was 
almost exclusively present in the membrane and cytoskeleton fractions. Slightly more E-
cadherin was present in the cytoplasmic fraction following expression of PTEN Y138L. This 
experiment was only performed once and requires repeating prior to drawing firm conclusions. 
Summary of Key Findings: 
x Reintroduction of PTEN into PTEN (-/-) cells caused no change in the level of APC͕ɴ-
catenin or Snail, while levels of phospho-Akt were significantly reduced following 
transfection of PTEN with lipid phosphatase activity. 
x dƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin and E-cadherin were reduced when PTEN protein was 
reintroduced into PTEN (-/-) cells, while AXIN2 transcript reduced only in response to 
PTEN protein with active lipid phosphatase activity. 
4.3 Discussion 
In Chapter 4, I have established that PTEN (-/-ͿĐĞůůƐĞǆƉƌĞƐƐŚŝŐŚĞƌůĞǀĞůƐŽĨɴ-catenin and E-
cadherin than (PTEN +/+) cells. The incƌĞĂƐĞĚůĞǀĞůŽĨɴ-catenin in the PTEN (-/-) cells is likely to 
ďĞĚƵĞƚŽĂůĂĐŬŽĨĚĞŐƌĂĚĂƚŝŽŶĂƐɴ-catenin transcription is similar in both cell lines. This could 
be mediated by activation of the Akt pathway in the absence of PTEN. This in turn can inhibit 
GSK3E, which could negatively impact on the function of the APC destruction complex. This 
ƉŽƚĞŶƚŝĂůůǇĞǆƉůĂŝŶƐ ƚŚĞŚŝŐŚĞƌ ůĞǀĞůƐŽĨɴ-ĐĂƚĞŶŝŶ͘dŚĞŚŝŐŚĞƌ ůĞǀĞůƐŽĨɴ-catenin protein are 
reflected by elevated AXIN2 transcript in the PTEN (-/-) cells indicĂƚŝŶŐ ƚŚĞ ɴ-catenin is 
transcriptionally active. 
The PTEN (-/-) cells were also characterised by higher levels of E-cadherin protein. I initially 
ƐƵƐƉĞĐƚĞĚƚŚŝƐǁĂƐĚƵĞƚŽƐƚĂďŝůŝƐĂƚŝŽŶŽĨƚŚĞƉƌŽƚĞŝŶďǇƚŚĞĞǆĐĞƐƐɴ-catenin. However, I then 
measured a significantly higher transcript level of E-cadherin in the PTEN (-/-) null cells, 
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indicating that production of new E-cadherin as opposed to stabilisation is responsible. 
Currently, the mechanism stimulating this increased transcription is unknown. These findings 
support those from Chapter 3, where PTEN depletion led to increased levels of E-cadherin 
protein and transcript in the three PTEN wild-type cells studied. This finding is of relevance to 
tumours. During the process of EMT as tumours progress and invade, E-cadherin is down 
regulated. This contrasts with the high E-cadherin levels in these PTEN (-/-) cells, which one may 
intuitively expect to furnish the cells with less of a migratory phenotype compared with a cell 
with low E-cadherin. PTEN loss has also been associated with increased cell migration, so the 
situation may be more complex. Analysis of migration in these cells may clarify this. 
The PTEN (+/+) and PTEN (-/-ͿĐĞůůƐĞǆƉƌĞƐƐƚŚĞƐĂŵĞɴ-catenin. In both cell lines the proportion 
ŽĨ ɴ-ĐĂƚĞŶŝŶ ĨŽƵŶĚ ŝŶ ĂƐƐŽĐŝĂƚŝŽŶǁĂƐ ƐŝŵŝůĂƌ͕ǁŚŝĐŚ ŝƐ ƵŶƐƵƌƉƌŝƐŝŶŐ͘ dŚĞƌĞǁĂƐ ĨĂƌŵŽƌĞ ɴ-
catenin bound to E-cadherin in the PTEN cells compared with PTEN (+/+). This may be a simple 
ƌĞĨůĞĐƚŝŽŶ ŽĨ ƚŚĞ ĨĂĐƚ ƚŚĂƚ ƚŚĞƌĞ ŝƐ ŵŽƌĞ ɴ-catenin and E-cadherin in these cells so more 
interaction occurs. It cannot be determined from these experiments if the mutant protein 
associates more with APC and the wild type with E-cadherin. Further Co-IP studies of APC and 
E-ĐĂĚŚĞƌŝŶƵƐŝŶŐƚĂŐŐĞĚĞǆŽŐĞŶŽƵƐɴ-catenin could be used to investigate this further. 
I also measured if the re-ŝŶƚƌŽĚƵĐƚŝŽŶŽĨWdEƉƌŽƚĞŝŶĐŽƵůĚĐĂƵƐĞĐŚĂŶŐĞƐŝŶƚŚĞůĞǀĞůƐŽĨɴ-
catenin or E-cadherin. No effects ǁĞƌĞŵĞĂƐƵƌĞĚŽŶƚŚĞůĞǀĞůŽĨĞŝƚŚĞƌɴ-catenin or E-cadherin 
protein. This contrasted with predictions as I expected PTEN with intact lipid phosphatase 
ĂĐƚŝǀŝƚǇƚŽĐĂƵƐĞĂƌĞĚƵĐƚŝŽŶŝŶɴ-catenin. The lipid phosphatase active PTEN proteins did cause 
a significant decrease in levels of Akt, as predicted. 
dŚĞƚƌĂŶƐĐƌŝƉƚůĞǀĞůŽĨɴ-catenin and E-cadherin both decreased in response to all of the PTEN 
vectors. Although reductions in both were statistically significant, E-cadherin transcript showed 
the most dramatic response. For both transcripts these results were surprising. These findings 
support the observation that E-cadherin transcript increases following PTEN depletion of the 
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PTEN (+/+) cells and in the examined cell lines in Chapter 3. The fact that transcriptional 
repression followed transfection of all of the PTEN proteins suggests that the physical presence 
of PTEN is important as opposed to a specific phosphatase function of PTEN. The exact 
mechanism here is unclear from these experiments. 
I have also established that absence of PTEN does not alter the cells’ response to APC depletion. 
In both the PTEN (+/+) and PTEN (-/-ͿĐĞůůƐ͕WŬŶŽĐŬĚŽǁŶĐĂƵƐĞĚĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin 
to the cell cytoplasm with an associated increase in AXIN2 transcription. AXIN2 transcription is 
already elevated in PTEN (-/-ͿĐĞůůƐ͕ƉƌĞƐƵŵĂďůǇƐĞĐŽŶĚĂƌǇƚŽĞůĞǀĂƚĞĚɴ-catenin. APC depletion 
further amplifies this. These data highlight how the accumulation of mutations in a tumour has 
the potential to influence cell behaviour aŶĚ ƚƵŵŽƵƌ ƉƌŽŐƌĞƐƐŝŽŶ͘ dŚĞ ĞůĞǀĂƚĞĚ ɴ-catenin 
transcriptional output following loss of either APC or PTEN may not be sufficient to cause a major 
ŝŶƐƵůƚƚŽƚŚĞĐĞůů͘>ŽƐƐŽĨďŽƚŚ͕ŚŽǁĞǀĞƌ͕ĂƵŐŵĞŶƚƐƚŚŝƐƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨɴ-catenin and 
could potentially create an environment that predisposes the cell to a more malignant 
phenotype. 
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ϱ&ƵŶĐƚŝŽŶĂůŽŶƐĞƋƵĞŶĐĞƐŽĨ^ƚĂďŝůŝƐŝŶŐɴ-Catenin Mutations in HCT116 
Cells 
5.1 Introduction 
/ŶƚŚĞƉƌĞĐĞĚŝŶŐĐŚĂƉƚĞƌƐ͕/ŚĂǀĞĞƐƚĂďůŝƐŚĞĚƚŚĂƚŵĂŶŝƉƵůĂƚŝŽŶŽĨɴ-catenin, PTEN or APC can 
ĐĂƵƐĞ ĐŚĂŶŐĞƐ ŝŶ ƚŚĞ ƌĞůĂƚŝǀĞ ŝŶƚĞƌĂĐƚŝŽŶƐ ŽĨ ɴ-catenin with either APC or E-cadherin. 
Dysfunction of this triad of proteins is centrally implicated in the pathogenesis of colorectal 
cancer. Specifically, in Chapter 3, I established that ĂƉŽŝŶƚŵƵƚĂƚŝŽŶĐĂƵƐŝŶŐƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-
catenin causes it to associate more with APC but much less with E-cadherin than wild-ƚǇƉĞɴ-
catenin. In contrast, I identified that absence of PTEN is associated with a higher level of E-
cadherin and more associĂƚŝŽŶŽĨɴ-catenin with E-cadherin in HCT116 colorectal cancer cells. 
ůůĐĞůůƐƐƚƵĚŝĞĚ͕ ŝƌƌĞƐƉĞĐƚŝǀĞŽĨƚŚĞƉƌĞƐĞŶĐĞŽĨƐƚĂďŝůŝƐĞĚɴ-catenin or PTEN, responded in a 
ƐŝŵŝůĂƌĨĂƐŚŝŽŶƚŽĚĞƉůĞƚŝŽŶŽĨW͘/ŶĂůůĐĞůůƐ͕ƚŚŝƐƌĞƐƵůƚĞĚŝŶĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from 
the plasma membrane to the cytoplasm and was accompanied by a significant increase in 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin measured by an increase in AXIN2 transcription. 
dŚĞƐĞ ĨŝŶĚŝŶŐƐ ŝŶĚŝĐĂƚĞƚŚĂƚ ƚŚĞĐŽŶƚƌŝďƵƚŝŽŶɴ-catenin makes to its roles in cell adhesion or 
transcription can be affected by defects implicated in cancer. However, these molecular findings 
have more relevance if they can be translated into effects on cell function. Aberrations in cell 
function or behaviour is key to driving cancer progression. 
Gut epithelial cells have several functions important in maintaining homeostasis. Stem cells at 
the crypt base must undergo controlled proliferation to produce the specialised cell types that 
populate the crypt (Bjerknes and Cheng 2006, Leushacke and Barker 2012). The differentiated 
cells then migrate in an orderly way up the crypt towards the gut lumen. Cell migration along 
the crypt ends when cells either apoptose or undergo anoikis and are shed into the gut lumen. 
From birth of a cell to its loss takes approximately three days (van der Flier, 2009). This rapid 
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turnover of cells should ensure that cells with oncogenic mutations are usually quickly lost from 
the tissue, minimising chances of acquiring further defects. Following tumour development, it 
can metastasise to distant organs. To do this it must be able to invade surrounding tissues. 
/ŶƚŚŝƐĐŚĂƉƚĞƌ͕/ǁŝůůŵĞĂƐƵƌĞƚŚĞĞĨĨĞĐƚƐŽĨŵƵƚĂƚŝŽŶƐŝŶɴ-catenin and PTEN as well as loss of 
APC on cell function and morphology. 
Specifically, I will: 
1) ĞƚĞƌŵŝŶĞŝĨŵƵƚĂƚŝŽŶƐŝŶɴ-catenin or PTEN affect cell size and proliferation. 
2) ĞƚĞƌŵŝŶĞŝĨŵƵƚĂƚŝŽŶƐŝŶɴ-catenin or PTEN as well as depletion of APC can cause 
changes in cell migration and invasion. 
5.2 Results 
ϱ͘Ϯ͘ϭ^ƚĂďŝůŝƐŝŶŐƉŽŝŶƚŵƵƚĂƚŝŽŶŽĨɴ-catenin reduces cell size 
Cell size and morphology in normal epithelial tissue is uniform and consistent. This uniformity 
can be lost in tumours with cell shape and size being more variable. To measure the impact of 
ƐƚĂďŝůŝƐŝŶŐɴ-catenin mutations on cell size, I used fluorescence-activated cell sorting (FACS) to 
measure cell size based on forward scatter. This provided a basic morphological characterisation 
of the cells and determined how this was influenced by ƐƚĂďŝůŝƐŝŶŐ ɴ-catenin mutations or 
depletion of APC, E-catenin or PTEN (Figure 5.1). 
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Figure 5.1: Cells expressing stabilised E-catenin are smaller than those expressing only wild-type 
E-catenin. Cells were treated as control (scrambled siRNA) or had APC, E-catenin or E-cadherin 
depleted prior to analysis of cell size using FACS based on forward scatter. Plots indicate forward 
scatter as compared between cell lines under control conditions (a) or following depletion of 
proteins outlined in the parental (b), mutant (c), wild type (d) and PTEN (-/-) (e). Plotted data are 
representative. The experiment was performed on at least three separate occasions. 
 
ĞůůƐĞǆƉƌĞƐƐŝŶŐŵƵƚĂŶƚɴ-catenin were consistently smaller compared with cells expressing only 
wild-type ɴ-catenin (i.e. no stabilised E-ĐĂƚĞŶŝŶͿ͘ĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin or PTEN did not 
affect cell size in any of the cells studied. 
Cell size has been linked to cell cycle progression and rates of proliferation, which co-operate to 
proportion organs at the appropriate size (Ginzberg, 2015, Su, 1998). Studies in Drosophila have 
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shown that genetic manipulation of mitosis resulting in an inhibition of proliferation leads to an 
increase in the size of cells (Weigmann, 1997). Similarly, cell cycle arrest in Drosophila results in 
an increase in cell size whereas increased expression of cell cycle regulators increases 
proliferation rate with an accompanying decrease in cell size (Neufeld, 1998). Results here may 
be related to differences in proliferation rates. 
5.2.1 Summary of Key Finding: 
x ĞůůƐĐŽŶƚĂŝŶŝŶŐĂŵƵƚĂŶƚɴ-catenin protein are smaller than cells with only wild-type 
ɴ-catenin protein. 
 
ϱ͘Ϯ͘Ϯ ^ƚĂďŝůŝƐŝŶŐ DƵƚĂƚŝŽŶ ŝŶ ɴ-Catenin and PTEN Loss Increase the Proliferation Rate of 
HCT116 Cells 
I next aimed to detĞƌŵŝŶĞƚŚĞŝŶĨůƵĞŶĐĞŽĨƐƚĂďŝůŝƐĞĚɴ-catenin on the rate of cell proliferation. 
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Figure 5.2: Proliferation is fastest in PTEN (-/-) followed by parental, mutant and wild-type cells. 
Cells were seeded at approximately 10% confluence in a 96-well plate and incubated in the 
incucyte zoom system. Each well was imaged every 24 hours for 96 hours and the surface covered 
by cells calculated by the incucyte software. Confluence shown at 0 (a–d), 51 (e–f) and 92 hours 
is highlighted in gold and was used to calculate percentage confluence. Consistency of replicates 
between wells is plotted in (m) showing real time percentage confluence for the duration of the 
experiment for each well analysed. The mean and standard deviation of percentage confluence 
from 16 separate wells is plotted in (n). 
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PTEN (-/-) cells proliferated at the fastest rate followed by the parental, mutant and wild-type 
cells. In addition to expressing both stabilised and wild-ƚǇƉĞɴ-catenin, the PTEN (-/-) cells may 
have a proliferative advantage due to activation of the Akt pathway. The order of proliferation 
ƌĂƚĞŝŶƚŚĞŽƚŚĞƌĐĞůůůŝŶĞƐĨŽůůŽǁĞĚƚŚĞƉĂƚƚĞƌŶŽĨɴ-catenin expression. The parental cells with 
one mutant and one wild-ƚǇƉĞɴ-catenin were fastest followed by the mutant cells, with only 
mutant non-ĚĞŐƌĂĚĂďůĞɴ-catenin and lastly the wild-type cells, which only express wild-ƚǇƉĞɴ-
catenin. The differences were statistically significant between the PTEN (-/-) cells and the other 
cell lines (p<0.05). The parental and mutant cells proliferated significantly faster than the wild 
type (p<0.05) but there was no difference between them (p>0.05). 
dŚĞƐĞĚĂƚĂƐŚŽǁƚŚĂƚƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶƐŝŶɴ-catenin provide a proliferative advantage. The 
ƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-catenin in these cells is caused by a mutation that renders it non-degradable. 
This is mechanistically slightly different to the scenario in APC-deficient cells in colorectal cancer. 
The outcome, i.e. increased proliferation, appears to be similar. 
 
5.2.2 Summary of Key Findings: 
x Cells expressing ŵƵƚĂŶƚɴ-catenin protein proliferate faster than those with only wild-
ƚǇƉĞɴ-catenin 
x PTEN (-/-) cells proliferate faster than PTEN (+/+) cells 
 
ϱ͘Ϯ͘ϯ͘ϭĞůůƐǁŝƚŚƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶƐŝŶɴ-catenin migrate faster than cells expressing only 
wild-ƚǇƉĞɴ-catenin 
Cell migration is vital for normal function of the gut epithelium. Cells migrate upwards in the 
crypt prior to extrusion into the gut lumen. To occur normally, cells must migrate at the 
appropriate rate and in the correct direction. Experimental elimination of mitosis does not 
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prevent the upward translocation of cells, indicating that migration is an active process and can 
be uncoupled from proliferation {Kaur, 1986). Migration defects could potentially predispose to 
both the initiation and progression of cancer. 
/ŵĞĂƐƵƌĞĚŚŽǁƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶƐŝŶɴ-catenin affected the migration rate of HCT116 cells 
into an artificially generated ‘wound’ (Figure 5.3). 
 
Figure 5.3: HCT116 cells expressing stabilised E-catenin migrate faster than those expressing only 
wild-type E-catenin and PTEN (-/-) cells migrate faster than PTEN wild-type cells. Confluent cell 
monolayers were ‘scratched’ to create an empty space and migration of cells into the space was 
measured. Images of the scratch wound are shown at 0 hours (a–d) and 24 hours (e–h) for each 
cell line. Migration rate is quantified based on the relative area of the wound covered by cells. 
The gold overlay represents the ‘mask’ that marks the surface covered by cells and is used to 
quantify relative wound space. Purple shading shows the area of the wound covered in 24 hours. 
Relative wound space covered is plotted against time in (i). Each data point represents the mean 
and standard deviation of six replicate wells. 
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PTEN (-/-) cells migrated significantly faster (p<0.05), followed by the mutant parental then wild-
ƚǇƉĞĐĞůůƐ͘ůů ĐĞůů ůŝŶĞƐĞǆƉƌĞƐƐŝŶŐ ƐƚĂďŝůŝƐĞĚɴ-catenin migrated significantly faster than cells 
containing only wild-ƚǇƉĞɴ-catenin. The PTEN (-/-ͿĐĞůůƐŚĂǀĞƚŚĞƐĂŵĞĐŽŵƉůĞŵĞŶƚŽĨɴ-catenin 
as the pĂƌĞŶƚĂůĐĞůůůŝŶĞ;ѐϰϱͬнͿ͘ The absence of PTEN augmented the rate of migration, which 
is consistent with previous findings (Raftopoulou, 2004, Leslie, 2007, Davidson, 2010). Cells 
ĞǆƉƌĞƐƐŝŶŐƐƚĂďŝůŝƐĞĚɴ-catenin also proliferated faster than cells with only wild-ƚǇƉĞɴ-catenin. 
A degree of proliferation at the wound edge may contribute to the distance the cells moved into 
the wound. Limiting the experiment to 24 hours sought to minimise this effect. 
ϱ͘Ϯ͘ϯ͘ϮWĚĞƉůĞƚŝŽŶƐůŽǁƐŵŝŐƌĂƚŝŽŶŝƌƌĞƐƉĞĐƚŝǀĞŽĨɴ-catenin 
APC loss is an early and common event in colorectal cancer. It serves an important function in 
ƚŚĞ ƌĞŐƵůĂƚŝŽŶ ŽĨ ɴ-catenin but also has multiple other roles, including those related to 
microtubules and cell migration (Näthke, 1996, Mimori-Kiyosue, 2000, Nelson, 2013). Previous 
studies have suggested that APC loss may negatively affect cell migration (Nelson, 2012). I aimed 
to determine if APC depletion impacted on the migration of HCT116 cells and if any measured 
effects were dependent on the expressiŽŶƉĂƚƚĞƌŶŽĨɴ-catenin. In addition, I measured the 
ĞĨĨĞĐƚŽĨĚĞƉůĞƚŝŶŐɴ-catenin or PTEN on cell migration (Figure 5.4). 
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Figure 5.4: APC depletion causes a reduction in migration rate irrespective of E-catenin status. 
Cells were depleted of APC, E-catenin or PTEN. A scrambled siRNA was used as a control. Cells 
were then plated in a 96-well plate and allowed to reach confluence overnight. The confluent 
monolayer of cells was scratched and incubated in the incucyte zoom system. Images of the cells 
were captured every 2 hours for 24 hours. The area of the wound covered by the migrating edge 
of the cells was used to calculate migration rate. Relative wound confluence for parental (a), 
mutant (b), wild-type (c) and PTEN (-/-) cells (d) is plotted against time. Comparison between 
relative wound confluence at 24 hours in the control versus APC knockdown conditions are 
plotted in (e–f). Data presented are representative of two independent experiments with six 
replicates in each for each treatment condition. 
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WĚĞƉůĞƚŝŽŶƌĞĚƵĐĞƐŵŝŐƌĂƚŝŽŶŽĨ,dϭϭϲĐĞůůƐŝŶĚĞƉĞŶĚĞŶƚůǇŽĨɴ-catenin status. The rate of 
migration was less in all cell lines following APC knockdown. This reached statistical significance 
in all cell lines (p < 0.005). 
Depletion of PTEN did not cause an increase in migration rate, which may have been expected 
given that PTEN null cells migrated faster than PTEN wild-type cells. Although siRNA directed 
towards PTEN achieved a good knockdown on western blotting, the knockdown may have been 
heterogeneous in the migration assay. Cells with incomplete knockdown may migrate at a 
slower rate than cells that are completely devoid of PTEN. Cells were treated for 48 hours with 
siRNA prior to commencement of the migration assay. Perhaps changes required to increase 
migration speed in response to PTEN absence require a longer time period to produce a 
detectable phenotype. 
There are two possible effects that could account for the reduction in migration in APC-depleted 
cells. Either reduced migration speed, or a loss in directionality. I aimed to distinguish between 
these possibilities 
5.2.3.3 APC depletion reduces total distance migrated by a cell but also causes loss of 
ĚŝƌĞĐƚŝŽŶĂůŝƚǇ͘dŚŝƐŽĐĐƵƌƐŝŶĚĞƉĞŶĚĞŶƚůǇŽĨɴ-catenin 
To assess if reduced migration following APC depletion was secondary to a reduction in total 
distance travelled by the cell or loss of directionality, I tracked cells migrating across a wound. 
/Ŷ ƚŚŝƐ ƐĞĐƚŝŽŶ͕ / ĐŽŵƉĂƌĞ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ŽŶůǇ ƐƚĂďŝůŝƐĞĚ ɴ-catenin (mutant cells) and those 
expressing only wild-ƚǇƉĞ ɴ-catenin (wild-type cells). Cells were tracked for 48 hours while 
migrating across a wound. The total distance travelled between the start and end point was 
measured. In addition, the distance separating the position of the start and end point was also 
noted to determine the net displacement over 48 hours (Figure 5.5). 
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Figure 5.5: APC depletion causes a reduction in total distance travelled and also in the degree of 
displacement, indicating a loss of direction. Cells were tracked migrating across a wound for 48 
hours. The total distance travelled was calculated in addition to the displacement from the start 
point at 48 hours. A representative image shows the start location and migration path for five 
separate cells in the control versus APC knockdown conditions (a–d). Total migration distance is 
plotted against displacement for 15 separate mutant (e) and wild-type (f) cells to compare the 
migration pattern in the control versus APC-deplete conditions. Red represents the control and 
blue the APC-deplete conditions. A comparison between migration patterns in mutant versus 
wild-type cells under control (g) and APC-deplete (h) conditions was made. Red represents 
mutant and blue the wild-type cells. 
 
In both cell lines, APC depletion causes a reduction in total migration distance and in 
displacement. This indicates that the ability to migrate is negatively affected following APC loss, 
but in addition the cells do not know where they are going. Depletion of APC had similar effects 
on migration in both the mutant and wild-type cells. These data indicate that the effects of APC 
depletion on cell migration occur independently of whether mutant or wild-ƚǇƉĞɴ-catenin is 
expressed. Loss of directional migration is represented schematically (Figure 5.6). 
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Figure 5.6: A schematic representation of the effects of APC depletion on cell migration. The 
upper cells represent the control and the lower cells APC-deplete conditions. Total distance 
travelled is shown by the black arrows. The distance from the start to finish point is shown by the 
red lines. 
 
5.2.3 Summary of Key Findings: 
x ĞůůƐĞǆƉƌĞƐƐŝŶŐŵƵƚĂŶƚɴ-catenin migrate faster than those with only wild-ƚǇƉĞɴ-
catenin. 
x PTEN (-/-) cells migrate faster that PTEN (+/+) cells. 
x APC depletion reduces rate of migration in all cell lines and this is due mainly to loss of 
directionality. 
5.Ϯ͘ϰĞůůƐǁŝƚŚƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶƐŝŶɴ-catenin are less invasive than cells with only wild-
ƚǇƉĞɴ-catenin 
Invasion is an important step in the progression of cancer and advanced invasive lesions are 
associated with a worse outcome than earlier lesions. I assessed whether stabilising mutations 
ŝŶ ɴ-catenin influence this process by measuring the invasion of HCT116 cells and I also 
ĐŽŵƉĂƌĞĚƚŚĞĞĨĨĞĐƚŽĨĚĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin or PTEN. 
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I again used the incucyte zoom imaging system (Essen Bioscience). A scratch wound assay is set 
up, then a layer of matrigel is placed on top of the wound and allowed to set. Growth medium 
is then placed on top and the assay is allowed to run as a normal migration experiment. The 
matrigel barrier means that to migrate into an empty space cells invade through the matrigel. A 
schematic of this experimental set up is shown (Figure 5.7). 
Figure 5.8: Schematic of invasion assay set-up. A wound is made in a cell monolayer. Matrigel is 
placed on top, allowed to set, and then growth medium is placed on top. The matrigel provides 
a physical barrier for the cells to invade. 
 
Data showing comparisons between cell lines under control conditions are shown (Figure 5.9). 
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Figure 5.9: PTEN (-/-) cells invade through a matrigel barrier faster than PTEN (+/+) cells and cells 
expressing only wild-type E-catenin invade faster than cells with stabilised E-catenin. A confluent 
monolayer of cells was scratched and a layer of matrigel placed on top and allowed to set. Cells 
were then incubated in the incucyte zoom system. Images of the cells were captured every two 
hours for 24 hours. Relative wound density is plotted against time in (i). Each data point 
represents the mean and standard deviation of six replicate wells. 
 
PTEN (-/-) null cells invade faster than PTEN wild-type cells (p <0.05). Cells expressing only wild-
ƚǇƉĞɴ-ĐĂƚĞŶŝŶŝŶǀĂĚĞĨĂƐƚĞƌƚŚĂŶĐĞůůƐǁŝƚŚƐƚĂďŝůŝƐĞĚɴ-catenin. Differences in relative wound 
density at 24 hours were significant when comparing parental (p <0.05) and mutant (p <0.05) 
with wild type. 
The findings in the PTEN (-/-) cells reflect their high rate of cell migration. The invasion patterns 
of the other three cell lines are the opposite of their order of migration speeds, where mutant 
was fastest over parental then wild-type cells. The reasons for this could be multiple as migration 
and invasion are two different processes. 
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/ŶĞǆƚŵĞĂƐƵƌĞĚƚŚĞĞĨĨĞĐƚƐŽĨĚĞƉůĞƚŝŶŐW͕ɴ-catenin and PTEN on invasion rate (Figure 5.10). 
 
 
 
Figure 5.10: Depletion of E-catenin, APC or PTEN slows invasion rate in all cell lines. APC, E-
catenin or PTEN were depleted from cells. Control cells were targeted with scrambled siRNA. A 
confluent monolayer of the cells was scratched and a layer of matrigel placed on top. Cells were 
then incubated in the incucyte zoom system. Images were captured every two hours for 24 hours. 
Invasion rate was quantified based on relative wound density (or area covered by cells). Change 
in wound density over 24 hours is plotted for parental (a), mutant (b), wild-type (c) and PTEN (-
/-) cells (d). Each data point represents the mean and standard deviation from six replicate wells. 
 
ĞƉůĞƚŝŽŶŽĨW͕ɴ-catenin or PTEN in all four cell lines caused a reduction in invasion. The 
greatest and most consistent effects were detected following APC or PTEN knockdown. 
Invasion at 24 hours was significantly lower in all four cell lines following APC depletion 
compared with the control (p < 0.005 for all cells compared with the control). The reduction in 
ŝŶǀĂƐŝŽŶĨŽůůŽǁŝŶŐWĚĞƉůĞƚŝŽŶŵŝƌƌŽƌƐƚŚĞƌĞĚƵĐĞĚĐĞůůŵŝŐƌĂƚŝŽŶƌĂƚĞ͘ĞƉůĞƚŝŽŶŽĨɴ-catenin 
and PTEN also slowed the rate of invasion. 
I feel the invasion data should be interpreted with caution. Although two repeats of the 
experiment were performed each with six wells per cell line, the cells were “unhappy” in the 
matrigel. This is an anecdotal observation and I have no quantitative data pertaining to this. 
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Even during trial growth periods in matrigel in preparation for the invasion the cells did not seem 
to enjoy being grown under these conditions. I think there is a possibility that some of the data 
may be skewed by growth conditions of the cells. 
5.2.4 Summary of Key Findings: 
x PTEN (-/-) cells invade at a faster rate than PTEN wild-type cells. 
x Cells with only wild-ƚǇƉĞɴ-catenin protein invade faster than cells expressing mutant 
ɴ-catenin. 
x APC depletion reduces invasion in all cell lines studied. 
5.3 Discussion 
In this chapter, I aimed to relate some of the changes I discovered at the molecular level in 
Chapters 3 and 4 to cell function and phenotype. I have established that cells expressing mutant 
ɴ-catenin proliferate faster than cells expressing only wild-ƚǇƉĞɴ-catenin. Intuitively this may 
ďĞĞǆƉĞĐƚĞĚ͘,ŽǁĞǀĞƌ͕ŝŶŚĂƉƚĞƌϯ/ƐŚŽǁĞĚƚŚĂƚɴ-catenin transcriptional output measured by 
AXIN2 transcription was not significantly different between the cell lines. This may indicate that 
ŽƚŚĞƌɴ-catenin target genes are responsible for the observed effects on proliferation. The wild-
type cell line had the lowest rate of proliferation. I also showed that the wild-type cells were 
ůĂƌŐĞƌƚŚĂŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐŵƵƚĂŶƚɴ-catenin. The proliferation assay measures area covered by 
the cells as an indicator of proliferation. The rate in the wild-type cells may therefore have been 
exaggerated by their greater size. Differences in cell size may in fact be due to differences in the 
rate of proliferation. Cells lacking PTEN proliferated fastest of all. Their proliferation rate is likely 
to be augmented by activation of the Akt pathway. 
PTEN (-/-) cells also migrated fastest. Loss of PTEN has been linked to increased migration 
previously and is related to absence of its protein phosphatase activity. Cells expressing mutant 
ɴ-catenin migrated faster than those with only wild-ƚǇƉĞɴ-catenin. Some degree of proliferation 
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at the migrating cell edge may have contributed to this, but the experiment was limited to 24 
hours, minimising effects. A more rapid cell migration in the mutant cells may be aided by low 
expression levels of E-cadherin. Down regulation of E-cadherin is known to contribute to the 
migratory phenotype associated with the process of EMT. The increased migration rate in cells 
ǁŝƚŚŵƵƚĂŶƚɴ-catenin could potentially impact on tumour development. Ordered directional 
migration up the colonic crypt prior to shedding of cells into the lumen is required for gut 
ŚŽŵĞŽƐƚĂƐŝƐ͘ĐĞůůǁŝƚŚĂƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶŝŶɴ-catenin may migrate up the crypt faster than 
normal cells. This could minimise the time the cell has to acquire further mutations, reducing 
the chance of tumour development. 
I also determined that APC depletion reduces cell migration significantly irrespective of whether 
mutant or wild-ƚǇƉĞɴ-catenin is expressed. This finding indicates that the observed effects of 
WĚĞƉůĞƚŝŽŶŽĐĐƵƌŝŶĚĞƉĞŶĚĞŶƚůǇŽĨɴ-catenin. Two aspects of cell migration were affected by 
APC loss. The total distance travelled by the cell was reduced but the displacement of the cell 
over the time course of the experiment was also significantly less. This indicates that the cells 
have lost their sense of direction and they do not know where they are going. In all cell lines APC 
ĚĞƉůĞƚŝŽŶĐĂƵƐĞĚĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin to the cytoplasm with only modest increases in 
total cell levels. This was also accompanied by an increase in AXIN2 transcription. I hypothesise 
ƚŚĂƚƚŚĞŵŝŐƌĂƚŽƌǇĚĞĨĞĐƚƐĂƌĞŶŽƚ͕ŚŽǁĞǀĞƌ͕ƌĞůĂƚĞĚƚŽƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin. Observed 
effects may be due to loss of APC from its role related to microtubules and cell movement. This 
hypothesis could be tested in several ways. Depolymerisation of microtubules may be expected 
to produce similar results to APC loss. Measurement of migration could also be undertaken 
following overĞǆƉƌĞƐƐŝŽŶŽĨɴ-catenin. If my hypothesis that migratory defects following APC 
ůŽƐƐĂƌĞƵŶƌĞůĂƚĞĚƚŽɴ-catenin is correct, then overexpression would not be expected to impact 
on migration. 
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WĚĞƉůĞƚŝŽŶĂŶĚƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶƐŽĨɴ-catenin have opposite effects on cell migration. 
dŚĞƐĞĞĨĨĞĐƚƐŵĂǇďĞƚŚĞƌĞƐƵůƚŽĨĚŝƐƚŝŶĐƚŵĞĐŚĂŶŝƐŵƐ͘ɴ-Catenin mutations could result in an 
increased migration rate due to low expression levels of E-cadherin. In addition, transcriptional 
ĂĐƚŝǀŝƚǇ ŽĨ ƚŚĞ ƐƚĂďŝůŝƐĞĚ ɴ-catenin could also have effects on genes other than AXIN2 that 
influence migration. APC loss, on the other hand, may negatively impact cell migration due to 
loss of function in its role associated with microtubules. Migratory defects have relevance to 
colorectal tumours. If APC loss results in a cell losing its sense of direction, instead of the cell 
being expelled into the intestinal lumen, its residence in the crypt may be prolonged. This could 
provide an opportunity for the cell to acquire further mutations necessary for tumour 
ƉƌŽŐƌĞƐƐŝŽŶ͘dŚĞĨƵŶĐƚŝŽŶĂůƌĞĂĚŽƵƚŝƐĚŝĨĨĞƌĞŶƚĨƌŽŵƚŚĂƚƌĞƐƵůƚŝŶŐĨƌŽŵƐƚĂďŝůŝƐŝŶŐɴ-catenin 
mutations, which increase migration rate. Increased expulsion of a cell from the crypt that 
retains a sense of direction may reduce the risk of the cell acquiring further defects. 
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ϲɴ-Catenin Localisation in Gut Organoids and Human Intestinal Polyps 
6.1 Introduction 
/ŚĂǀĞĞƐƚĂďůŝƐŚĞĚƚŚĂƚƐƚĂďŝůŝƐŝŶŐɴ-catenin mutations influences its interaction with APC and E-
cadherin, and that PTEN depletion is associated with increased E-cadherin expression. APC 
ĚĞƉůĞƚŝŽŶŝŶĂůůĐĞůůůŝŶĞƐƐƚƵĚŝĞĚĐĂƵƐĞĚĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the plasma membrane 
to the cytoplasm and was associated with an increase in AXIN2 transcription. APC depletion also 
caused defective cell migration. 
I wanted to establish if previous findings in cells could be repeated in a more physiologically 
ƌĞůĞǀĂŶƚƐǇƐƚĞŵďǇƵƐŝŶŐŐƵƚŽƌŐĂŶŽŝĚƐ͘/ĂůƐŽĂŝŵĞĚƚŽĂƐƐĞƐƐŝĨɴ-catenin was retained at the 
plasma membrane or enriched in the nucleus of human colorectal polyps. PTEN loss has been 
implicated in the serrated pathway of colorectal carcinogenesis. I intended to establish if 
serrated polyps also expressed higher levels of E-cadherin that characterised HCT116 cells 
following PTEN depletion. 
Organoids are self-organising three-dimensional epithelial structures. These “mini guts” can be 
cultured and grown in vitro. They contain stem cells, Paneth cells and all the specialised 
differentiated cell lineages that populate the in vivo crypt–villous structure. They provide an 
experimental system that is physiologically closer to in vivo gut tissue than cultured cell lines. 
Organoids initially form rounded structures, which then form buds that elongate to form the 
crypt unit. Stem cells resident at the crypt base give rise to all specialised types of terminally 
differentiated epithelial cells, which migrate up the crypt and are shed into the central lumen of 
the organoid. The morphology of organoids derived from APC Min/+ mouse gut differs from the 
branched wild-type structure. APC Min/+ organoids form round cyst-like structures upon loss of 
the second Apc allele. This phenotypic change is thought to result from overstimulation of the 
Wnt pathway following APC loss. A similar cyst structure is characteristic of organoids derived 
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from APC fl/fl tissue (Figure 6.1). Assessment of both wild-type and APC Min/+ organoids provides 
the opportunity to measure the influence of different levels of Wnt pathway activation on the 
ůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin. 
 
 
Figure 6.1: The characteristic branching structure of a wild-type organoid is shown in (A). The 
typical phenotypic change following APC loss (B) shows loss of architecture and the development 
of a cyst. Organoids are stained with phalloidin (red) to visualise F-actin and DAPI (blue) to 
visualise nuclei. (Image courtesy of Dr Paul Appleton). 
6.2 Results 
6.2.1 LocalisĂƚŝŽŶŽĨɴ-catenin in wild-type and APC Min organoids 
/ŵĞĂƐƵƌĞĚƚŽƚĂů ůĞǀĞůƐŽĨWĂŶĚɴ-catenin in wild-type organoids and made comparison to 
transformed cyst organoids derived from APC min/+ ƚŝƐƐƵĞ͘/ƚŚĞŶŵĞĂƐƵƌĞĚƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-
catenin in wild-type organoids in comparison to organoids derived from APC Min/+ mice. The 
organoids derived from APC Min/+ tissue in this experiment had already transformed into cysts at 
the time of lysis. This phenotypic change is thought to coincide with loss of APC heterozygosity 
(Figure 6.2). 
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Figure 6.2: E-Catenin in wild-type organoids is located at the plasma membrane and expressed 
at a lower level than E-catenin from APC min/+ organoids. Organoids lysates were prepped whole 
or fractionated into cytoplasmic, membrane, nuclear and cytoskeletal fractions. Lysates were 
subjected to western blotting. Proteins were detected with antibodies against APC, E-catenin, E-
cadherin and actin. Localisation of E-cadherin (c & d) and E-catenin (e & f) is plotted as a 
percentage of cell total. For this experiment, n = 1. Organoids and the whole-lysate western blot 
were provided by Dr Alistair Langlands. 
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Transformed organoids from APC min/+ ƚŝƐƐƵĞ ŚĂǀĞ ŚŝŐŚĞƌ ůĞǀĞůƐ ŽĨ ɴ-catenin than wild-type 
ŽƌŐĂŶŽŝĚƐ͘ɴ-Catenin localises predominantly at the membrane in wild-type organoids, as does 
E-cadherin. In the APC min/+ ŽƌŐĂŶŽŝĚƐ͕ ƚŚĞƌĞ ŝƐ ŵŽƌĞ ĐǇƚŽƉůĂƐŵŝĐ ɴ-catenin, although the 
membrane remains the main site of localisation. 
>ŽƐƐ ŽĨ W ŝŶ ƚŚĞŽƌŐĂŶŽŝĚ ĞůŝŵŝŶĂƚĞƐ ƚŚĞ ĂďŝůŝƚǇ ƚŽ ĚĞŐƌĂĚĞɴ-catenin, consistent with the 
higher expresƐŝŽŶ ůĞǀĞůƐŽĨɴ-catenin in the APC min/+ ŽƌŐĂŶŽŝĚ͘dŚŝƐ ƐƵƉƉŽƌƚƐ ƚŚĞĞůĞǀĂƚĞĚɴ-
catenin levels following APC depletion in the parental and wild-type cells in Chapter 3. 
WĚĞƉůĞƚŝŽŶůĞĚƚŽĂƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin from the plasma membrane to the cytoplasm 
in all cell lines studied in Chapter 3. These findings are reaffirmed in the APC min/+ organoid, which 
ŚĂƐĂŐƌĞĂƚĞƌƉƌŽƉŽƌƚŝŽŶŽĨĐǇƚŽƉůĂƐŵŝĐɴ-catenin than the wild type, where the cytoplasm is 
ǀŝƌƚƵĂůůǇ ĚĞǀŽŝĚ ŽĨ ɴ-catenin. Measurement of AXIN2 transcription would be an additional 
experiment here and I suspect the APC min/+ organoids would have a higher transcript level. 
E-cadherin was predominantly located at the cell membrane, as expected in both the wild-type 
and APC min/+ organoids. 
6.2.1: Summary of Key Findings: 
x /Ŷ ŽƌŐĂŶŽŝĚƐ ůĂĐŬŝŶŐ ĨƵůů ůĞŶŐƚŚ W͕ ƚŚĞƌĞ ŝƐ ŵŽƌĞ ɴ-catenin and it localises in the 
cytoplasm more than in organoids with full length APC. 
x Transformed APC Min/+ ŽƌŐĂŶŽŝĚĐǇƐƚƐŚĂǀĞƐůŝŐŚƚůǇŚŝŐŚĞƌůĞǀĞůƐŽĨƚŽƚĂůɴ-catenin than 
wild type. 
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ϲ͘Ϯ͘Ϯ ɴ-catenin and E-cadherin localise predominantly to the plasma membrane in 
adenomatous and serrated polyps 
/ ŚĂǀĞ ĞƐƚĂďůŝƐŚĞĚ ƚŚĂƚ W ĚĞƉůĞƚŝŽŶ ĐĂƵƐĞƐ ɴ-catenin to move to the cytoplasm from the 
membrane in HCT116 cells. APC loss is an early initiating event in lesions arising via the 
conventional pathway of colorectal carcinogenesis. I also measured increases in the transcript 
and protein level of E-cadherin following PTEN loss in HCT116 cells. PTEN loss has been 
associated with both the conventional and serrated pathways of colorectal cancer development. 
I wanted to investigate whether E-cadherin levels were different in conventional versus serrated 
polyps. 
Polyps arising via the conventional pathway of colorectal carcinoma are characterised by loss of 
APC and mutations in genes such as P53 and Kras. They are commonly referred to as 
adenomatous polyps or adenomas. 
Serrated adenocarcinomas represent an alternative pathway of carcinogenesis and account for 
approximately 10% of colorectal cancers (Makinen, 2007). Serrated polyps differ from 
conventional adenomas in their typical mutation profile. The commonest defects are in the BRAF 
gene, present in an estimated 80% of serrated cancers (O'Brien, 2006). In addition, the CpG–
Island methylator phenotype (CIMP) is also common in proximal serrated lesions (Leggett, 
2010). PTEN mutation has also been associated with serrated lesions in murine models (Davies, 
2014) and humans (Day, 2013). 
There is a paucity of reliable predictive criteria that can identify polyps that will progress to 
invasive cancers. This poses challenges in determining the appropriate management and 
surveillance, with an estimated 35% of patients developing further adenomas within five years 
of removal (Winawer, 1993, Neugut, 1985). Only a small percentage of these will progress to 
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carcinoma. Characterising the expression patterns of proteins implicated in colorectal cancer 
has the potential to reveal useful tools for predicting prognosis and guiding management. 
I next assessed the disƚƌŝďƵƚŝŽŶŽĨɴ-catenin and E-cadherin in a series of human colorectal polyp 
biopsies using immunohistochemical staining. The samples were all human colorectal polyps. 
The polyps were characterised by differences in histological classification. Some polyps were 
conventional adenomas, some were serrated adenomas and some were of mixed histology. No 
details of genetic or clinical characteristics were available. I aimed to determine if the cellular 
distribution of these proteins was comparable between conventional colorectal adenomas and 
serrated polyps. 
A semiquantitative method was used to assess the slides. The predominant localisation of 
ƉƌŽƚĞŝŶǁĂƐ ĐůĂƐƐŝĨŝĞĚĂƐDĞŵďƌĂŶĞ͕ǇƚŽƉůĂƐŵŝĐŽƌEƵĐůĞĂƌ͘EƵĐůĞĂƌɴ-catenin staining was 
scored as positive or negative. Slides were reviewed in conjunction with a consultant 
pathologist. Polyp scoring is displayed in Table 6.2a. Representative images of 
immunohistochemical slides are shown in Figure 6.3. 
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Slide Number Location of stain (E-
cadherin) 
Location of stain(E-
catenin) 
Nuclear Staining Polyp Type 
1 Membrane Membrane Negative Mixed 
2 Membrane Membrane Negative Mixed 
3 Membrane Membrane Negative Mixed 
4 Membrane Membrane Negative Conventional adenoma 
5 Membrane Membrane Negative Conventional adenoma 
6 Membrane Membrane Negative Conventional adenoma 
7 Membrane Membrane Negative Conventional adenoma 
8 Membrane Membrane Negative Conventional adenoma 
9 Membrane Membrane Negative Conventional adenoma 
10 Membrane Membrane Negative Conventional adenoma 
11 Membrane Membrane Negative Conventional adenoma 
12 Membrane Membrane Negative Conventional adenoma 
13 Membrane Membrane Negative Conventional adenoma 
14 Membrane Membrane Negative Conventional adenoma 
15 Membrane Membrane Negative Serrated adenoma 
16 Membrane Membrane Negative Serrated adenoma 
17 Membrane Membrane Negative Serrated adenoma 
18 Membrane Membrane Negative Serrated adenoma 
19 Membrane Membrane Negative Serrated adenoma 
20 Membrane Membrane Negative Serrated adenoma 
21 Membrane Membrane Negative Serrated adenoma 
22 Membrane Membrane Negative Serrated adenoma 
 
Table 6.1: The predominant localisation of E-cadherin and E-catenin was the cell membrane in 
conventional, serrated and mixed adenomas. Nuclear E-catenin staining was negative in all 
samples studied. 
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Figure 6.3: E-Catenin and E-cadherin are localised at the plasma membrane in adenomatous and 
serrated colorectal polyps. Polyp biopsies were probed with antibodies targeting E-catenin or E-
cadherin using immunohistochemistry. Example (20u) immunohistochemical images are shown 
with antibodies against E-catenin (a, c & e) or E-cadherin (b, d & f). Panels show control (a & b), 
a conventional adenoma (c & d) and a serrated polyp (e & f). 
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In all examined slides, the predominant location of E-cadherin was the cell membrane. This was 
unaltered between adenomas of different histological classifications. The level of E-cadherin 
appeared to be similar in conventional and serrated polyps. 
/ŶĂůůƐůŝĚĞƐ͕ƚŚĞƉƌĞĚŽŵŝŶĂŶƚůŽĐĂƚŝŽŶŽĨɴ-catenin was the cell membrane. This was consistent 
ŝŶ ďŽƚŚ ĐŽŶǀĞŶƚŝŽŶĂů ĂŶĚ ƐĞƌƌĂƚĞĚ ƉŽůǇƉƐ͘ /Ŷ Ăůů ĐĂƐĞƐ͕ ŶƵĐůĞĂƌ ƐƚĂŝŶŝŶŐ ĨŽƌ ɴ-catenin was 
ŶĞŐĂƚŝǀĞ͘/ŶƚŚĞƉŽůǇƉƐĂŵƉůĞƐƚŚĞŝŶƚĞŶƐŝƚǇŽĨɴ-catenin appeared increased. This was secondary 
to the tight packing of neighbouring cells. This packing results in the staining pattern appearing 
ŵŽƌĞĚŝĨĨƵƐĞ͘,ŽǁĞǀĞƌ͕ŽŶĐůŽƐĞƌĞǆĂŵŝŶĂƚŝŽŶƚŚĞŵĂŝŶůŽĐĂƚŝŽŶŽĨɴ-catenin is indeed the cell 
membrane. The control slides came from normal colonic mucosa. 
/ŶĂĚĚŝƚŝŽŶƚŽŝŵŵƵŶŽŚŝƐƚŽĐŚĞŵŝĐĂůƐƚĂŝŶŝŶŐ͕/ĂůƐŽĂƐƐĞƐƐĞĚƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin and E-
cadherin using immunofluorescent microscopy (Figure 6.4). 
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Figure 6.4: E-Catenin and E-cadherin are located at the plasma membrane in areas of 
conventional and serrated adenoma in a polyp of mixed histology. A human colorectal polyp of 
mixed histology was probed for DAPI (a), E-catenin (b) and E-cadherin (c). The polyp has areas of 
both conventional adenoma (upper single headed arrow) and serrated histology (lower, double 
headed arrow). 
 
dŚĞƉƌĞĚŽŵŝŶĂŶƚůŽĐĂƚŝŽŶŽĨƚŚĞɴ-catenin signal was at the cell membrane, although a diffuse 
ɴ-ĐĂƚĞŶŝŶƐŝŐŶĂůŝƐǀŝƐŝďůĞƚŚƌŽƵŐŚŽƵƚƚŚĞĐǇƚŽƉůĂƐŵ͘EƵĐůĞĂƌůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin was not 
detected in any slides. The E-cadherin signal was primarily located at the cell membrane in all 
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ƐůŝĚĞƐ͘dŚĞ ůŽĐĂůŝƐĂƚŝŽŶĂŶĚƐŝŐŶĂůůŝŶŐ ŝŶƚĞŶƐŝƚǇŽĨɴ-catenin and E-cadherin was similar in the 
areas of adenomatous and serrated histology. 
6.2.2 Summary of Key Finding: 
x ɴ-Catenin and E-cadherin are predominantly localised to the plasma membrane in both 
ĐŽŶǀĞŶƚŝŽŶĂůĂŶĚƐĞƌƌĂƚĞĚĂĚĞŶŽŵĂƐǁŝƚŚŶŽĞŶƌŝĐŚŵĞŶƚŽĨɴ-catenin in the nucleus. 
 
6.2.3 In polyps of mixed histology, the PTEN signal is different in areas of conventional 
compared with serrated histology 
I next aimed to determine if the intensity or distribution of antibody detected PTEN signal was 
different in conventional adenomas compared with serrated polyps. Conventional adenomas 
are thought to arise via the conventional adenoma–carcinoma sequence. Early mutations in 
these lesions include loss of APC. Serrated polyps are thought to arise via an alternative pathway 
and differ in their mutation signature. These lesions have been associated with loss of PTEN 
tumour suppressor function. 
A semiquantitative approach was used to assess PTEN signal: low, medium or high. The same 22 
ďŝŽƉƐǇƐĂŵƉůĞƐǁĞƌĞƵƐĞĚĨŽƌWdEĂƐƐĞƐƐŵĞŶƚƐƚŚĂƚǁĞƌĞƵƐĞĚĨŽƌɴ-catenin and E-cadherin 
assessment (Figure 6.5). Slides were scored in conjunction with a consultant pathologist. 
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Figure 6.5 PTEN signal intensity is higher in areas of conventional adenoma compared with areas 
of serrated histology. Polyp biopsies were probed with antibodies targeting PTEN using 
immunohistochemistry. Example images of polyps with mixed histology are shown (c–f) with the 
control in (a). Single headed arrows indicate conventional adenoma while double headed arrows 
show areas of serrated adenoma. PTEN signal is brown. A solid black line indicates the 
demarcation between normal (lighter signal) tissue on the right and conventional adenoma 
(higher signal) to the left of the line (c & d). 
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In polyps of mixed histology, the PTEN signal was higher in the adenomatous compared with 
normal tissue and lower in regions of serrated histology. The PTEN signal in the majority of slides 
examined was of medium intensity and localised diffusely in the cytoplasm. In two of the eleven 
conventional adenomas, PTEN signal was higher in the adenomatous region compared with 
normal tissue. In four of eight serrated polyps, the PTEN signal was low in the serrated region 
compared with normal tissue. 
The mixed polyps proved useful for comparing PTEN signal intensity in areas of conventional 
adenoma with regions with a serrated morphology. The PTEN signal was higher in areas of 
conventional compared with areas of serrated histology. Compared with normal tissue, the 
region of conventional adenomas had a more intense PTEN signal. This change occurred with a 
sharp demarcation (c & d). The demarcation point is indicated by the solid black line. 
Slides were also probed with antibody against PTEN and examined using immunofluorescent 
microscopy. An example of a slide displaying mixed histology is shown in Figure 6.6. 
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Figure 6.6: No visible difference in the signal intensity of antibody directed against E-catenin or 
PTEN exists between areas of conventional and serrated adenoma in a polyp of mixed histology 
on immunofluorescent microscopy. A human colorectal polyp of mixed histology was stained 
with DAPI (a), and probed with antibodies against E-catenin (b) & PTEN (c). A merged image is 
in (d). The polyp has areas of both conventional adenoma (lower single headed arrow) and 
serrated histology (upper, double headed arrow). 
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The pattern of PTEN signals between conventional and serrated polyps was consistent, with no 
discernible difference between polyps of different histology. The example in Figure 6.6 shows a 
mixed polyp with a conventional adenoma at the lower right region (single headed arrow) with 
an area of ƐĞƌƌĂƚĞĚ ŚŝƐƚŽůŽŐǇ ŝŶ ƚŚĞ ƵƉƉĞƌ ůĞĨƚ ƌĞŐŝŽŶ ;ĚŽƵďůĞ ŚĞĂĚĞĚ ĂƌƌŽǁͿ͘ ɴ-Catenin is 
predominantly localised to the cell membrane. The PTEN stain is diffuse and similar in both the 
conventional and serrated regions. 
6.2.4 Summary of Key Finding: 
x PTEN is reduced in some serrated adenomas, while some conventional adenomas 
show a higher PTEN signal compared with normal tissue. 
 
6.3 Discussion 
APC loss is a very common and early event in the process of colorectal carcinogenesis. Its 
absence leads to deregulation of ƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨɴ-catenin, often associated with 
ŶƵĐůĞĂƌĞŶƌŝĐŚŵĞŶƚŽĨɴ-ĐĂƚĞŶŝŶ͘/ĚĞƚĞĐƚĞĚĂƐŚŝĨƚŽĨɴ-catenin from the plasma membrane to 
the cytoplasm in colorectal cancer cell lines and aimed to establish if a similar shift was 
detectable in APC deplete mouse gut organoids and early stage human colorectal polyps. 
Organoids derived from Apc min/+ mice transform into cystic structures coinciding with loss of 
ƚŚĞŝƌ ƐĞĐŽŶĚ W ĂůůĞůĞ͘ / ŝĚĞŶƚŝĨŝĞĚ Ă ŚŝŐŚĞƌ ůĞǀĞů ŽĨ ĐǇƚŽƉůĂƐŵŝĐ ɴ-catenin in transformed 
compared with wild-type organoids, supporting observations in cell lines. Interestingly, the wild-
type ŽƌŐĂŶŽŝĚ ŚĂĚ ǀŝƌƚƵĂůůǇ ŶŽ ɴ-catenin. I would expect significant differences in the 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin between the two and would examine transcript levels of 
target genes such as AXIN2 or c-myc as a next step. 
dŚĞƉƌŝŵĂƌǇůŽĐĂƚŝŽŶŽĨɴ-catenin and E-cadherin in the human polyp samples was the plasma 
membrane on examination of the immunohistochemistry slides. The primary locatiŽŶ ŽĨ ɴ-
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catenin in the polyps examined with an immunofluorescence microscopy was also the plasma 
ŵĞŵďƌĂŶĞ͘ dŚĞƌĞ ǁĂƐ ĂůƐŽ ĚŝĨĨƵƐĞ ĐǇƚŽƉůĂƐŵŝĐ ƉƌĞƐĞŶĐĞ ŽĨ ɴ-catenin, although no nuclear 
enrichment was evident. These were early stage polyps and perhaps a more robust translocation 
ŽĨɴ-catenin to the cytoplasm or nucleus would be detectable in more advanced lesions. 
PTEN loss is implicated in both the conventional and serrated pathways of colorectal cancer. I 
examined the level of PTEN signal in polyps of both serrated and adenomatous histology to 
determine if any differences were apparent in these early stage lesions. I previously identified a 
higher level of E-cadherin transcript and protein expression in following PTEN depletion in 
HCT116 cells and aimed to assess if the E-cadherin signal differed in serrated versus 
adenomatous polyps. 
No difference was detectable in the semiquantitative analysis of E-cadherin signal using either 
immunohistochemistry or immunofluorescence. PTEN signal was diffuse in both histological 
polyp categories. Signal intensity did appear to differ in some cases. Several serrated lesions had 
a light PTEN stain compared with areas of normal tissue. Mixed polyps provided an opportunity 
for comparison on the same slide. Serrated regions had a lower signal intensity compared with 
normal tissue and the adenomatous regions were characterised by a more intense PTEN signal. 
PTEN loss has been associated with the serrated pathway of colon cancer. This is the reason why 
I wanted to compare PTEN and E-cadherin signal in conventional and serrated polyps to assess 
if some of my cell line results could be reproduced in human tissue. The polyp classification was 
based purely on histological features and no details regarding either PTEN or APC status were 
known. Further examination of the reduced PTEN signal in the serrated lesions could involve 
assessment of PTEN gene expression. Signal was not absent, simply reduced. It is unclear if this 
relates to defects in the PTEN protein or other factors and further experiments are required. 
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7 Discussion 
In this thesis I have identified that a point mutation in residue serine 45 results in the increased 
ŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and APC. This is associated with lower levels of E-cadherin protein 
and transcript ŝŶ ƚŚĞɴ-catenin mutant cells and a corresponding decrease in the interaction 
ďĞƚǁĞĞŶɴ-catenin and E-ĐĂĚŚĞƌŝŶ͘/ŚĂǀĞĂůƐŽƐŚŽǁŶƚŚĂƚƐƚĂďŝůŝƐĞĚɴ-catenin as a result of APC 
ůŽƐƐŽƌĚŝƌĞĐƚŵƵƚĂƚŝŽŶŽĨɴ-catenin has distinct functional consequences for the cell and this 
may have relevance for tumour behaviour and progression.  I also measured increased levels of 
E-ĐĂĚŚĞƌŝŶ ĂŶĚ ɴ-catenin in cells lacking PTEN. This indicates cross talk between pathways 
involving two important tumour suppressor genes, APC and PTEN. I will focus further discussion 
of the findings of this thesis on three areas. Specifically I will discuss: 
1) dŚĞ ĞĨĨĞĐƚƐ ŽĨ Ă ƐŝŶŐůĞ ƉŽŝŶƚ ŵƵƚĂƚŝŽŶ ŝŶ ɴ-catenin on its presence in complexes 
containing APC or E-cadherin, the functional consequences for the cell and implications 
for colorectal carcinogenesis. 
2) The effects of PTEN loss on E-cadherin. 
3) WĂƐĂƐƚŽƌĂŐĞĂŶĚƚƌĂŶƐƉŽƌƚƉƌŽƚĞŝŶĨŽƌɴ-catenin. 
 
ϳ͘ϭƉŽŝŶƚŵƵƚĂƚŝŽŶŽĨƌĞƐŝĚƵĞƐĞƌŝŶĞϰϱĐĂŶĐŚĂŶŐĞƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin between 
complexes containing APC and those containing E-cadherin.  
ɴ-catenin is centrally implicated in colorectal cancer with vital roles in cell adhesion and 
transcriptional activation. Dysfunction in either role is linked with cancer. E-cadherin forms 
adhesion junctions ǁŝƚŚɴ-catenin at points of cell-cell contact and APC negatively regulates the 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin by targeted degradation.  Individually, APC or E-cadherin 
ĐĂŶŶŽƚŽƌĐŚĞƐƚƌĂƚĞƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin. The coordinated interplay of both is required to 
ŵĂŝŶƚĂŝŶƚŚĞĨƵŶĐƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin within normal limits. How the relationships between 
ɴ-catenin, APC and E-cadherin can be changed in colorectal cancer by different mutations is 
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unclear. My study provides new insights into how the dŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin between its two 
main binding partners is altered by a mutation that affects its turnover and how this affects cell 
function.    
/ŚĂǀĞƐŚŽǁŶŚŽǁĂŵƵƚĂƚŝŽŶŝŶĂƐŝŶŐůĞƌĞƐŝĚƵĞ;ƐĞƌŝŶĞϰϱͿŽĨɴ-catenin causes its increased 
association with APC and decreased association with E-cadherin. To the best of my knowledge, 
ƚŚŝƐŝƐƚŚĞĨŝƌƐƚƚŝŵĞƚŚĞŝŵƉĂĐƚŽĨĂƉŽŝŶƚŵƵƚĂƚŝŽŶŝŶɴ-catenin on its relative interactions with 
both APC and E-cadherin in tandem has been measured in a colorectal cancer cell line (HCT116). 
I found the mutated, 'ϰϱɴ-catenin was sequestered by APC. These cells also had very low levels 
of E-cadherin and correspondingly the 'ϰϱɴ-catenin associated much less with E-cadherin. In 
contrast, wild-ƚǇƉĞ ɴ-catenin was bound to E-cadherin most dominantly and only little was 
found associated with APC.  
I propose that the sequestration function performed by APC acts as a sink to limit levels of free 
ɴ-catenin. This function is especially important in when E-catenin is more stable and abundant. 
/ƚŝƐƵŶĐůĞĂƌŝĨƚŚĞƐĞƋƵĞƐƚƌĂƚŝŽŶŽĨɴ-catenin by APC directly impacts on its association with E-
ĐĂĚŚĞƌŝŶŽƌŝĨŵƵƚĂŶƚɴ-catenin is impaired in its ability to bind E-cadherin. The distribution of 
ɴ-catenin with either E-cadherin or APC, which can either sequester (mutant) or degrade (wild-
ƚǇƉĞͿɴ-ĐĂƚĞŶŝŶĂƉƉĞĂƌƐƚŽďĞĂďůĞƚŽƌĞŐƵůĂƚĞƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶĂůĂĐƚŝǀŝƚǇŽĨɴ-catenin. Despite, 
differences in total levels of APC, E-ĐĂĚŚĞƌŝŶĂŶĚɴ-catenin, or its susceptibility to degradation 
did not correlate with significant differences in transcription of AXIN 2 between the cell lines 
studied. 
ŶƵŵďĞƌŽĨƉĂƐƚƐƚƵĚŝĞƐŚĂǀĞĐŽŶƐŝĚĞƌĞĚƚŚĞĞĨĨĞĐƚƐŽĨƐƚĂďŝůŝƐĞĚɴ-catenin on the interaction 
with E-cadherin in HCT116 cells. Chan and colleagues (Chan et al. 2002) found an increased 
association of wild-ƚǇƉĞ ɴ-catenin with E-cadherin compared to a low level of interaction 
ďĞƚǁĞĞŶ ŵƵƚĂŶƚ ɴ-catenin and E-cadherin. These findings are in accordance with mine. 
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Measurements ŽĨƚŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨɴ-catenin with APC was not made. In addition, they found 
wild-ƚǇƉĞɴ-ĐĂƚĞŶŝŶƚŽďĞĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞĐĞůůŵĞŵďƌĂŶĞďƵƚŵƵƚĂŶƚɴ-catenin to have a 
diffuse cytosolic localisation on immuno-fluorescence microscopy. These findings are in contrast 
to mine. I found both mutant and wild-ƚǇƉĞ ɴ-catenin to be predominantly located at the 
membrane under control conditions using immuno-fluorescence microscopy and biochemical 
cell fractionation. I believe the discordance between my results and those of Chan could be 
ƌĞůĂƚĞĚ ƚŽ ĐĞůů ĚĞŶƐŝƚǇ͘ >ŽĐĂůŝƐĂƚŝŽŶ ŽĨ ɴ-catenin was assessed using microscopy of very low 
ĚĞŶƐŝƚǇĐĞůůƐďǇŚĂŶ͕ǁŚŝĐŚĐĂŶŝŶĨůƵĞŶĐĞɴ-ĐĂƚĞŶŝŶůŽĐĂůŝƐĂƚŝŽŶ͘dŚĞǇĚĞƚĞĐƚĞĚŵŽƌĞŶƵĐůĞĂƌɴ-
catenin in a nuclear fraction of mutant compared to wild-type cells based on absolute levels. My 
ƌĞƐƵůƚƐŵĞĂƐƵƌŝŶŐƚŚĞƌĞůĂƚŝǀĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin in the cytosol, membrane, nucleus and 
ĐǇƚŽƐŬĞůĞƚŽŶƐŚŽǁĞĚŶŽĚŝĨĨĞƌĞŶĐĞŝŶƚŚĞƌĞůĂƚŝǀĞĂŵŽƵŶƚŽĨŶƵĐůĞĂƌɴ-catenin between all cell 
lines. It is ůŝŬĞůǇƚŚĂƚƚŚĞŵƵƚĂŶƚĐĞůů ůŝŶĞŚĂƐĂŐƌĞĂƚĞƌĂďƐŽůƵƚĞĂŵŽƵŶƚŽĨŶƵĐůĞĂƌɴ-catenin 
because the overall levels are higher than in the wild-type cells. Nonetheless, this did not cause 
a detectable difference in transcription of AXIN 2. 
Atomic force microscopy measurements showed that E-cadherin bond strength is lower in 
,dϭϭϲĞǆƉƌĞƐƐŝŶŐŵƵƚĂŶƚɴ-catenin compared to those expressing wild-ƚǇƉĞɴ-catenin and this 
correlated with lower levels of E-cadherin (Bajpai et al. 2013) although they determined that 
ŵƵƚĂŶƚɴ-catenin was capable of binding E-cadherin. This is in agreement with my findings but 
ƚŚĞĂƵƚŚŽƌƐĚŝĚŶŽƚŵĞĂƐƵƌĞƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶŽĨɴ-catenin with APC. An increased association 
ďĞƚǁĞĞŶɴ-catenin and APC has beĞŶŝĚĞŶƚŝĨŝĞĚŝŶD<ĐĞůůƐƵƐŝŶŐĞǆŽŐĞŶŽƵƐůǇĞǆƉƌĞƐƐĞĚɴ-
catenin with N-terminal deletions that include Ser45 (Barth et al. 1997). In this study E-cadherin 
levels were found to change little in response to expressŝŽŶŽĨƚŚĞŵƵƚĂŶƚɴ-catenin proteins. In 
a similar study using AtT20 cells, N-ƚĞƌŵŝŶĂůůǇĚĞůĞƚĞĚɴ-catenin was also found to be bound 
more to APC than wild-ƚǇƉĞɴ-catenin. (Munemitsu et al. 1994).  
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A recent study by Huels and colleagues made interesting discoveries relating to the interactions 
ďĞƚǁĞĞŶ ɴ-catenin and E-ĐĂĚŚĞƌŝŶ ŝŶ ƚŚĞŵŽƵƐĞ ŝŶƚĞƐƚŝŶĞ͘DŝĐĞǁŝƚŚ ĞǆŽŶ ϯ ĚĞůĞƚŝŽŶ ŽĨ ɴ-
catenin were generated. This region contains the phosphorylation sites required for APC 
ƚĂƌŐĞƚĞĚ ĚĞƐƚƌƵĐƚŝŽŶ ƐŽ ƚŚĞ ɴ-ĐĂƚĞŶŝŶ ŝƐ ŶŽƚ ĚĞŐƌĂĚĂďůĞ͘ dŚĞƐĞ ɴ-catenin mutant mice took 
longĞƌƚŽĚĞǀĞůŽƉƐŵĂůůŝŶƚĞƐƚŝŶĂůůĞƐŝŽŶƐƚŚĂŶƚŚŽƐĞǁŝƚŚɴ-ĐĂƚĞŶŝŶŵƵƚĂƚŝŽŶƐŝŶĞŝƚŚĞƌɴ-catenin 
ĂůůĞůĞƐ Žƌ W ůŽƐƐ͘  ƐŝŶŐůĞ ĂĐƚŝǀĂƚŝŶŐ ɴ-catenin mutation was not enough to trigger 
transformation of the colon, which had higher levels of E-cadherin than the small intestine. A 
ŐƌĞĂƚĞƌůĞǀĞůŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and E-cadherin was found in the colon and this 
was true for the mutated (stabilised) and wild-ƚǇƉĞɴ-catenin. The authors proposed that E-
ĐĂĚŚĞƌŝŶĐĂŶĂĐƚĂƐĂ ƐŝŶŬ ĨŽƌŵƵƚĂŶƚɴ-catenin and ƚŚŝƐ ůŝŵŝƚƐ ƚŚĞƉŽƚĞŶƚŝĂů ĨŽƌɴ-catenin to 
induce transformation (Huels et al. 2015). However, there was no assessment of the interaction 
ŽĨɴ-catenin with APC.    These findings support my hypothesis that APC and E-cadherin can bind 
ĂŶĚƐĞƋƵĞƐƚĞƌɴ-catenin to maintain its transcriptional output within set limits. Importantly, I 
ĨŽƵŶĚƚŚĂƚWŝƐĂŵŽƌĞĞĨĨĞĐƚŝǀĞƐŝŶŬĨŽƌɴ-catenin than E-cadherin.  
A common result from my studies and those by Barth and Munemitsu is that N-terminal deletion 
ŽƌƉŽŝŶƚŵƵƚĂƚŝŽŶŽĨɴ-catenin that cause its stabilisation leads to its increased association with 
APC. More specifically, I have shown that a single point mutation of serine 45 is enough to cause 
this effect. The N-terminus contains a number of key phosphorylation sites essential for the 
ĚĞŐƌĂĚĂƚŝŽŶ ŽĨ ɴ-catenin. Serine 45 is phosphorylated as a priming step for sequential 
phosphorylation at residues 44, 37 and 33 prior to ubiquitination and proteosomal degradation 
(Yost et al. 1996, Hart et al. 1999, Liu et al. 2002). Absence of serine 45 does not appear to 
ƉƌĞĐůƵĚĞďŝŶĚŝŶŐŽĨɴ-catenin to APC but it does it non-degradable. The mechanism responsible 
for sequestration cannot be determined from my experiments.  
KŶĞƉŽƐƐŝďŝůŝƚǇŝƐƚŚĂƚŽŶĐĞďŽƵŶĚƚŽWƚŚĞŵƵƚĂŶƚɴ-catenin becomes physically “stuck” and 
cannot be released creating sequestration effect by default. An alternative is that APC assumes 
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an active role in regulating E-catenin when degradation is not possible. Although these two 
ƐĐĞŶĂƌŝŽƐďŽƚŚƌĞƐƵůƚŝŶƚŚĞƐĞƋƵĞƐƚƌĂƚŝŽŶŽĨɴ-catenin by APC they are different. The first implies 
ƚŚĂƚƉŚŽƐƉŚŽƌǇůĂƚŝŽŶŽĨƐĞƌŝŶĞϰϱŝƐĂŶĞƐƐĞŶƚŝĂůƉƌĞƌĞƋƵŝƐŝƚĞƚŽƚƌŝŐŐĞƌƚŚĞƌĞůĞĂƐĞŽĨɴ-catenin 
from APC so once bound they cannot be separated. The second implies that APC can take on a 
ĨŽƌŵĂů ƌŽůĞ ŝŶ ƚŚĞ ƐĞƋƵĞƐƚƌĂƚŝŽŶ ŽĨ ɴ-ĐĂƚĞŶŝŶ ƚŽ ŵĂŝŶƚĂŝŶ ůĞǀĞůƐ ŽĨ ĨƌĞĞ ɴ-catenin within 
ĂĐĐĞƉƚĂďůĞůŝŵŝƚƐ͘,ĞƌĞ͕ƚŚĞƌĞůĞĂƐĞŽĨɴ-catenin from APC is physically possible but in order to 
ĂĐƚĂƐĂƐŝŶŬWŝƐĂĐƚŝǀĞůǇŚŽůĚŝŶŐŽŶƚŽƚŚĞɴ-catenin.    Rather than enforced sequestration 
ƚŚŝƐƌĞƉƌĞƐĞŶƚƐĂĚĞůŝďĞƌĂƚĞ͕ĨƵŶĐƚŝŽŶĂůƐĞƋƵĞƐƚƌĂƚŝŽŶƌĞƐƵůƚŝŶŐŝŶƚŚĞĂďŝůŝƚǇƚŽĐŽŶƚƌŽůĨƌĞĞɴ-
catenin levels within acceptable limits. 
 I wŽƵůĚŝŶǀĞƐƚŝŐĂƚĞƚŚŝƐĨƵƌƚŚĞƌďǇĞǆƚĞŶĚŝŶŐŵǇɴ-catenin overexpression experiments. I would 
ĞǆƉƌĞƐƐŵƵƚĂŶƚƚĂŐŐĞĚɴ-ĐĂƚĞŶŝŶŝŶƚŚĞŵƵƚĂŶƚĐĞůů ůŝŶĞ͕ǁŚŝĐŚĂůƌĞĂĚǇŚĂƐĂůĂƌŐĞƉŽŽůŽĨɴ-
catenin sequestered by APC. I would then perform an APC IP at staggered time points. I would 
ĂŝŵƚŽŵĞĂƐƵƌĞŝĨƚŚĞĞǆŽŐĞŶŽƵƐƚĂŐŐĞĚɴ-catenin becomes increasingly associated with APC 
ŽǀĞƌ ƚŝŵĞ͕ĂƚƚŚĞĞǆƉĞŶƐĞŽĨ ƚŚĞĞŶĚŽŐĞŶŽƵƐŵƵƚĂŶƚɴ-catenin. If so, this would signify that 
ŵƵƚĂŶƚɴ-catenin could indeed cycle off APC and the relationship was therefore deliberate as 
ŽƉƉŽƐĞĚ ƚŽĞŶĨŽƌĐĞĚďǇ ƚŚĞɴ-catenin becoming “stuck”. As a further extension of the over 
expression experiments I would over express E-cadherin in the cell lines studied to assess if a 
ŐƌĞĂƚĞƌƉŽŽůŽĨɴ-catenin associated with it. This is especially relevant in the mutant cell line, 
which had very low levels of E-cadherin.  
dŚĞŵƵƚĂŶƚĐĞůůƐŝŶŵǇƐƚƵĚǇŚĂĚŚŝŐŚĞƌĞǆƉƌĞƐƐŝŽŶůĞǀĞůƐŽĨďŽƚŚɴ-catenin and APC. It is unclear 
ĨƌŽŵŵǇ ĞǆƉĞƌŝŵĞŶƚƐ ŝĨ ŚŝŐŚĞƌ ɴ-catenin can lead to more APC. Logically this would seem 
ĂƉƉƌŽƉƌŝĂƚĞĂƐŚŝŐŚĞƌůĞǀĞůƐŽĨɴ-catenin may require more APC to regulate it. I also found that 
ƵƉŽŶ ĚĞƉůĞƚŝŽŶ ŽĨ ɴ-catenin, APC levels fell. The two appear to be linked however further 
experiments would be required to clarify this relationship. 
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/ĂůƐŽĚĞƚĞĐƚĞĚůŽǁĞƌůĞǀĞůƐŽĨŵƵƚĂŶƚɴ-catenin in association with E-cadherin than wild-type in 
agreement with previous findings (Chan et al. 2002). I investigated this further and found that 
this correlated with low transcript levels of E-ĐĂĚŚĞƌŝŶ͘/ŝĚĞŶƚŝĨŝĞĚĂĨƵƌƚŚĞƌĞĨĨĞĐƚŽĨŵƵƚĂŶƚɴ-
catenin on E-ĐĂĚŚĞƌŝŶƚƌĂŶƐĐƌŝƉƚŝŽŶ͘ǆƉƌĞƐƐŝŶŐĞǆŽŐĞŶŽƵƐŵƵƚĂŶƚɴ-catenin led to a reduction 
in E-cadherin transcripts regardless of whetheƌƚŚĞĞŶĚŽŐĞŶŽƵƐɴ-catenin was mutant or wild-
type.  Expressing exogenous wild-ƚǇƉĞɴ-catenin on the other hand, caused an increase in E-
ĐĂĚŚĞƌŝŶ ƚƌĂŶƐĐƌŝƉƚƐ͘ůƚŚŽƵŐŚ ƚŚĞƐĞ ĨŝŶĚŝŶŐ ƌĞǀĞĂů ĐŽŵƉůĞǆ ƌĞůĂƚŝŽŶƐŚŝƉƐďĞƚǁĞĞŶɴ-catenin 
and E-cadherin at the transĐƌŝƉƚĂŶĚƉƌŽƚĞŝŶůĞǀĞů͕ƚŚĞǇĚŽŶŽƚĞǆƉůĂŝŶǁŚǇŵƵƚĂŶƚɴ-catenin 
does not appear to bind E-cadherin as well as wild-ƚǇƉĞ͘&ŽůůŽǁŝŶŐŝŶĚƵĐƚŝŽŶŽĨŵƵƚĂŶƚɴ-catenin 
ŝŶƚŚĞŵŽƵƐĞĐŽůŽŶ͕ŵƵƚĂŶƚɴ-catenin was increasingly bound to E-cadherin over wild-ƚǇƉĞɴ-
catenin over time when assessed by co-immunoprecipitation at staggered time points. This 
implies that binding in vivo, ĐĂŶŽĐĐƵƌ͘hŶĨŽƌƚƵŶĂƚĞůǇ͕ĐŽŶĐƵƌƌĞŶƚŵĞĂƐƵƌĞŵĞŶƚƐŽĨɴ-catenin 
interaction with APC were not made making it difficult to compare these results to mine (Huels 
et al. 2015)͘/ĨŽƵŶĚŵŽƌĞŵƵƚĂŶƚɴ-catenin in association with APC but not E-cadherin. In both, 
my study and that of Huels, either APC or E-cadherin preferentially sequester the mutant non-
degrĂĚĂďůĞɴ-catenin. It is unclear if this is due to some structural consequence of the mutation 
ƚŚĂƚƌĞƐƵůƚƐŝŶŝŶĐƌĞĂƐĞĚďŝŶĚŝŶŐŽĨŵƵƚĂŶƚɴ-catenin to either APC or E-cadherin.  
&ŝŶĚŝŶŐƐĨƌŽŵŵǇƐƚƵĚǇĂŶĚƚŚĂƚŽĨŚĞŶĨŽƵŶĚŵƵƚĂŶƚɴ-catenin less able to bind to E-cadherin 
ĂŶĚ,dϭϭϲĐĞůůƐ͘ ŽƌƌĞƐƉŽŶĚŝŶŐůǇ͕ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐŽŶůǇŵƵƚĂŶƚɴ-catenin exhibit weaker E-
cadherin bond strength than those expressing only wild-ƚǇƉĞɴ-catenin (Bajpai et al. 2013).. This 
could potentially be related to structural changes induced by deletion of serine 45 that in turn 
could reduce the ability to bind E-ĐĂĚŚĞƌŝŶ͘DƵƚĂƚŝŽŶƐĂĨĨĞĐƚŝŶŐɴ-catenin in tumours tend to 
impact on specific residues in the N-terminal region or involve deletion of exon 3, which contains 
these residues (Ilyas et al. 1997, Morin et al. 1997, Johnson et al. 2005, Segditsas and Tomlinson 
2006)͘/ŵƉŽƌƚĂŶƚůǇƚŚŝƐƌĞŐŝŽŶŽĨɴ-catenin is distinct form the armadillo region that binds to E-
cadherin and is not expected to directly impact on E-cadherin binding. Phosphorylation sites in 
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ɴ-catenin that are involved in regulating its binding to E-cadherin are at the opposite, C-terminal 
end of the protein. Specifically, phosphorylation of Serines 686 and 692 increases the stability 
ŽĨ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ ɴ-catenin and E-cadherin (Huber and Weis 2001), while 
phosphorylation of Tyrosine 654 ĚĞĐƌĞĂƐĞƐƚŚĞĂĨĨŝŶŝƚǇŽĨɴ-catenin for E-cadherin, which may 
ĞŶŚĂŶĐĞ ɴ-catenin transcriptional activity. (Piedra et al. 2001). The C-ƚĞƌŵŝŶĂů ĚŽŵĂŝŶ ŽĨ ɴ-
catenin is known to affect its ability to participate in either transcriptional regulation or 
adhesion. Back folding of the C-terminus blocks the armadillo region compromising binding to 
E-cadherin. In this state, ɴ-catenin is transcriptionally active whereas when bound to alpha-
catenin its C-terminal region is not folded back permitting binding to E-cadherin (Gottardi and 
Gumbiner 2004)͘/ƚŝƐĐŽŶĐĞŝǀĂďůĞƚŚĂƚĚĞůĞƚŝŶŐ^ĞƌŝŶĞϰϱĐĂƵƐĞƐĂĐŽŶĨŽƌŵĂƚŝŽŶĂůĐŚĂŶŐĞŝŶɴ-
catenin that also impedes E-cadherin binding.  However, it is not at all clear how interfering with 
the N-terminal domain can block the armadillo region and reduce binding to E-cadherin to 
produce an effect similar to the back folding of the C-terminus.  Similarly, whether deleting 
entire stretches from the N-ƚĞƌŵŝŶĂůĚŽŵĂŝŶŽĨɴ-catenin causes the changes in the stability of 
interactions with E-cadherin in a similar manner to point deletion of Serine 45 will require 
detailed structural analysis.  
ŶŽƚŚĞƌƌĞŐƵůĂƚŽƌǇƐƚĞƉƚŚĂƚĂĨĨĞĐƚƐ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and E-cadherin is the 
phosphorylation of E-cadherin, ǁŚŝĐŚĐĂŶŝŶĐƌĞĂƐĞĂƐǁĞůůĂƐĚĞĐƌĞĂƐĞŝƚƐĂĨĨŝŶŝƚǇĨŽƌɴ-catenin 
(Gottardi and Gumbiner 2004) (Piedra et al. 2001). An important kinase that facilitates these 
events it GSK3EThe strength of E-cadherin bonds in HCT116 cells expressing wild-ƚǇƉĞ ɴ-
ĐĂƚĞŶŝŶ ĚĞĐƌĞĂƐĞĚ ƚŽ Ă ůĞǀĞů ĐŽŵƉĂƌĂďůĞ ƚŽ,dϭϭϲ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐŵƵƚĂŶƚ ɴ-catenin upon 
depletion of GSK3Ewhereas there was no change when GSK3 was depleted from cells 
expressing only mutant ɴ-catenin (Bajpai et al. 2013). This observation and my own preliminary 
ŽďƐĞƌǀĂƚŝŽŶƐ ůĞĂĚŵĞ ƚŽ ƐƉĞĐƵůĂƚĞ ĂďŽƵƚǁŚǇŵƵƚĂŶƚ ɴ-catenin associates less well with E-
cadherin than wild-type. Preliminary ĞǆƉĞƌŝŵĞŶƚƐ ƐŚŽǁĞĚ ƚŚĂƚ ǁŚĞŶ ŵƵƚĂŶƚ ɴ-catenin is 
sequestered by APC, Axin could be co-immunoprecipitated by APC (data not shown) suggesting 
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ƚŚĂƚ ŽƚŚĞƌ ĐŽŵƉŽŶĞŶƚƐ ŽĨ ƚŚĞ ĚĞƐƚƌƵĐƚŝŽŶ ĐŽŵƉůĞǆ ĂƌĞ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ƚŚĞ ƐĞƋƵĞƐƚĞƌĞĚ ɴ-
catenin. If GSK3Eis one of these, its availability to phosphorylate E-cadherin may be reduced so 
that E-ĐĂĚŚĞƌŝŶŚĂƐƌĞĚƵĐĞĚĂĨĨŝŶŝƚǇĨŽƌɴ-ĐĂƚĞŶŝŶ͘dŚŝƐĐŽƵůĚĞǆƉůĂŝŶǁŚǇŵƵƚĂŶƚɴ-catenin binds 
poorly to E-cadherin. At present this is merely speculation. To test this theory I would compare 
the presence of GSK3E ŝŶĂŶWĂŶĚɴ-catenin IP in mutant versus wild-type cells. 
^ƚĂďŝůŝƐĞĚɴ-catenin can result from either N-ƚĞƌŵŝŶĂůɴ-catenin deletions or of a point mutation 
ŝŶ ƐĞƌŝŶĞ ϰϱǁŚŝůĞ W ůŽƐƐ ĂůƐŽ ƌĞƐƵůƚƐ ŝŶ ƐƚĂďŝůŝƐĞĚ ɴ-catenin.  Mutations of APC or direct 
ŵƵƚĂƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶĐĂŶďŽƚŚůĞĂĚƚŽƐƚĂďŝůŝƐĞĚɴ-catenin but the functional consequences of 
ĞŝƚŚĞƌŵƵƚĂƚŝŽŶĂƌĞĚŝĨĨĞƌĞŶƚ͘/ŚĂǀĞƐŚŽǁŶƚŚĂƚŵƵƚĂŶƚ͕ƐƚĂďŝůŝƐĞĚɴ-catenin can be sequestered 
by APC and has little interaction with E-cadherin.  That can explain why AXIN 2 transcription is 
equivalent in cells expressing only wild-type or mutant E-catenin. In both of these cell types, the 
ƉƌĞĚŽŵŝŶĂŶƚ ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ ɴ-catenin is the cell membrane.  This is consistent with the 
observaƚŝŽŶ ƚŚĂƚ W ĚĞƉůĞƚŝŽŶ ĐĂƵƐĞƐ Ă ƌĞĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ ɴ-catenin to the cytoplasm and a 
ĐŽŶĐŽŵŝƚĂŶƚ ƐŝŐŶŝĨŝĐĂŶƚ ŝŶĐƌĞĂƐĞ ŝŶ y/E Ϯ ƚƌĂŶƐĐƌŝƉƚŝŽŶ͕ ƌĞŐĂƌĚůĞƐƐ ŽĨ ǁŚĞƚŚĞƌ ɴ-catenin is 
mutant or wild-ƚǇƉĞĂŶĚǁŝƚŚŽƵƚŽƌŽŶůǇŵŽĚĞƐƚŝŶĐƌĞĂƐĞƐŝŶƚŽƚĂůɴ-catenin levels. I also showed 
that depleting E-ĐĂĚŚĞƌŝŶĐĂƵƐĞĚĂƐŝŵŝůĂƌƌĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin but was accompanied by 
a less dramatic effect on transcription of Axin. These findings indicate that the localisation of 
ĂŶĚͬŽƌƚŚĞĂǀĂŝůĂďŝůŝƚǇŽĨĨƌĞĞɴ-catenin is more important than total abundance for stimulating 
transcriptional activation. This is consistent with the idea that elevated levels of E-cadherin 
found in the mouse colon (compared to small intestine) can limit transformation caused by an 
ĂĐƚŝǀĂƚŝŶŐɴ-catenin mutation (Huels et al. 2015). Huels’ study suggests that E-cadherin provides 
Ă ďƵĨĨĞƌŝŶŐ ĞĨĨĞĐƚ ŽĨ ƚŚĞ ɴ-catenin mutation. My findings show APC can also perform this 
ďƵĨĨĞƌŝŶŐĨƵŶĐƚŝŽŶ͘dŚĞďŝŶĚŝŶŐŽĨɴ-catenin to either APC or E-cadherin limits the levels of free, 
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůůǇ ĂĐƚŝǀĞ ɴ-catenin, which I have shown accumulates in the cytoplasm.  This 
ƐƵƉƉŽƌƚƐƚŚĞŝĚĞĂƚŚĂƚƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin by both APC and E-cadherin is critical and impacts 
on cancer progression. 
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ůƚŚŽƵŐŚĂ^ĞƌŝŶĞϰϱƉŽŝŶƚŵƵƚĂƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶĂŶĚWůŽƐƐďŽƚŚůĞĂĚƚŽƐƚĂďŝůŝƐĂƚŝŽŶŽĨɴ-
ĐĂƚĞŶŝŶ͕ƚŚĞĐŽŶƐĞƋƵĞŶĐĞƐŽŶƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚŽĨɴ-catenin are different due to the ability 
ŽĨWƚŽƐĞƋƵĞƐƚĞƌɴ-catenin. The cells expressinŐŵƵƚĂŶƚɴ-catenin proliferated faster but had 
an equivalent level of AXIN 2 transcription compared to cells expressing wild-ƚǇƉĞɴ-catenin. To 
ŝŶǀĞƐƚŝŐĂƚĞƚŚŝƐŵŽƌĞĐůŽƐĞůǇ/ǁŽƵůĚŵĞĂƐƵƌĞƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶůĞǀĞůƐŽĨŽƚŚĞƌɴ-catenin/Wnt 
target genes and also dissect in more detail the relative abundance of binding partners in 
complexes formed by mutant versus wild-ƚǇƉĞ ɴ-catenin (for instance using Mass 
Spectrometry). 
Loss of APC has additional functional consequences. APC depletion in all cells examined leads to 
a reduction in cell migration and this was mainly due to a loss of direction. The overall negative 
effect ton migration may increase the residency time of an APC mutant cell within a crypt, 
increasing its likelihood of further accumulation of mutations. . Thus it is not only loss of the 
ĂďŝůŝƚǇŽĨWƚŽƌĞŐƵůĂƚĞɴ-catenin that has relevance in cancer but also functions related to 
interactions facilitated by its C-terminus, for instance its effect on microtubules. 
These findings provide insight into ǁŚǇWůŽƐƐŝŶĐŽůŽƌĞĐƚĂůƚƵŵŽƵƌƐŝƐǀĞƌǇĐŽŵŵŽŶǁŚŝůĞɴ-
catenin mutations are comparatively rare. APC loss is a very common finding in both colorectal 
tumours and early stage lesions indicating that it is an early event. Some tumours lacking APC 
mutatioŶŚĂǀĞďĞĞŶĨŽƵŶĚƚŽŚĂǀĞĂĐƚŝǀĂƚŝŶŐŵƵƚĂƚŝŽŶƐŽĨɴ-catenin (Miyaki et al. 1999, Johnson 
et al. 2005) and it has been suggested that  WĂŶĚɴ-catenin mutations in tumours are mutually 
exclusive (Morin et al. 1997) (Sparks et al. 1998). Recent data challenge this assertion by 
identifying mutations in multiple Wnt pathway genes in tumours that harbour APC mutation 
(Cancer Genome Atlas 2012). This suggests multiple abnormalities affecting the Wnt pathway 
may act synergistically to provide the selective advantage necessary to facilitate tumour 
progression. 
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 E-catenin mutations are far less common than loss of APC and are characterised by point 
mutation of N-terminal residues or deletion of exon 3 (Ilyas et al. 1997, Morin et al. 1997, 
Johnson et al. 2005, Segditsas and Tomlinson 2006).  They are particularly associated with 
Hereditary non-polyposis coli (HNPCC) (Miyaki et al. 1999) but far less common in sporadic 
cancers (Johnson et al. 2005). E-catenin mutation in HNPCC may result from the mutator 
phenotype that characterises these lesions due to defects in mismatch repair genes. In addition 
ƐŽŵĞĂƵƚŚŽƌƐŚĂǀĞŝĚĞŶƚŝĨŝĞĚĂŚŝŐŚĞƌŶƵŵďĞƌŽĨƐŵĂůůƐƉŽƌĂĚŝĐĂĚĞŶŽŵĂƐƚŽŚĂƌďŽƵƌɴ-catenin 
mutations than sporadic cancers  (Samowitz et al. 1999). This suggests that lesions with 
ŵƵƚĂƚŝŽŶƐŝŶɴ-catenin may be less likely to progress than those with loss of APC.  
dŚŝƐƚŚĞŽƌǇĨŝƚƐǁŝƚŚƐŽŵĞŽĨŵǇĨŝŶĚŝŶŐƐ͘>ĞƐŝŽŶƐǁŝƚŚƐƚĂďŝůŝƐŝŶŐŵƵƚĂƚŝŽŶƐŽĨɴ-catenin may be 
less likely to progress if APC remains intact and sequesters the mutanƚɴ-catenin thus limiting 
transcriptional activation. Loss of APC or mutations that produce APC protein unable to bind and 
ƐĞƋƵĞƐƚĞƌɴ-ĐĂƚĞŶŝŶ͕ŽŶƚŚĞŽƚŚĞƌŚĂŶĚƌĞƐƵůƚŝŶŝŶĐƌĞĂƐĞĚɴ-catenin transcriptional activation 
together with migration defects. Both could increase the risk of cancer progression. It is unclear 
ŝĨŵƵƚĂŶƚɴ-catenin has altered interaction with APC in vivo. This could be investigated further 
ďǇƉƌŽĚƵĐŝŶŐŽƌŐĂŶŽŝĚƐ ĨƌŽŵŵŝĐĞǁŝƚŚĂŶĂĐƚŝǀĂƚŝŶŐɴ-catenin mutation and measuring the 
interactŝŽŶďĞƚǁĞĞŶŵƵƚĂŶƚɴ-catenin and APC using Co-IP to allow comparing their relative 
association with that in wild-ƚǇƉĞŽƌŐĂŶŽŝĚƐ͘DƵƚĂƚŝŽŶŽĨɴ-catenin is more common in other 
tumour types such as hepatocellular carcinoma or pseudo papillary pancreatic tumours than in 
colorectal cancer. In these tumours reduced E-cadherin levels are associated with increased 
ƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨɴ-ĐĂƚĞŶŝŶƚĂƌŐĞƚŐĞŶĞƐ͘DƵƚĂƚŝŽŶŽĨɴ-catenin and loss of E-cadherin may act 
synergistically here to promote tumour progression. (Huels et al. 2015). In colorectal cancer 
down regulation of E-cadherin has been associated with late stage lesions and the EMT process.  
dŚĞ ĨŝŶĚŝŶŐ ƚŚĂƚ ɴ-catenin transcriptional output in HCT116 cells with activating ɴ-catenin 
mutation only increases following APC depletion is consistent with the “just right” hypothesis. 
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This theory relates to different levels of Wnt signalling produced by different APC mutations and 
proposes that there is an optimal amount of Wnt signalling for cells to have the growth 
advantage required to form a tumour (Fodde and Brabletz 2007, Buchert et al. 2010). My 
ĨŝŶĚŝŶŐƐŝŶĚŝĐĂƚĞƚŚĂƚĂƐƚĂďŝůŝƐŝŶŐɴ-catenin mutation alone may not be sufficient to stimulate 
ɴ-catenin transcriptional output but that additional changes such as loss of APC are required to 
produce significant increases in transcription of target genes, such as AXIN 2. This increased 
transcriptional output combined with the consequences of APC loss on cell migration, may 
ŚĂƐƚĞŶ ƚŚĞ ƉƌŽŐƌĞƐƐŝŽŶ ŽĨ ƚƵŵŽƵƌƐ͘ dŚŝƐŵĂǇ ĞǆƉůĂŝŶǁŚǇ ɴ-catenin mutations in colorectal 
tumours are less common than those harbouring APC mutations. 
With further refinement, these findings have important implications for the management of 
patients with cancer. For example if a patient has a polyp removed a conundrum exists as to 
whether they enter a surveillance programme or require formal surgical resection to enable full 
pathological staging by removing both the lesion site and lymph nodes. Such a radical procedure 
may however be unnecessary and poses significant risk to the patient.  Analysis of the lesion for 
ƚŚĞƉƌĞƐĞŶĐĞŽĨŵƵƚĂƚŝŽŶƐŽĨWŽƌɴ-ĐĂƚĞŶŝŶĐŽŵďŝŶĞĚǁŝƚŚĂŶĂůǇƐŝƐŽĨɴ-catenin localisation 
ŽƌƚƌĂŶƐĐƌŝƉƚŝŽŶĂůŽƵƚƉƵƚĐŽƵůĚďĞƵƐĞĚƚŽŐƵŝĚĞƚŚĞƌĂƉǇŽƌƐƵƌǀĞŝůůĂŶĐĞŝŶƚĞŶƐŝƚǇ͘ƐƐŚŽǁŶ͕ɴ-
catenin mutations may be less likely to progress in the absence of additional mutations whereas 
an APC mutation may immediately cause more functional aberrations making progression more 
likely. Of course I am extrapolating my findings here but with continued technological 
progression and understanding of molecular defects in cancer such targeted treatments may 
one day be possible to match the patient and their tumour. 
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7.2 The effects of PTEN on E-cadherin 
I have shown that PTEN can cause changes in the lĞǀĞůƐŽĨďŽƚŚɴ-catenin and E-cadherin. I 
believe two separate mechanisms are responsible for this. The lipid phosphatase activity of PTEN 
ŝƐ ůŝŬĞůǇ ƚŽďĞƌĞƐƉŽŶƐŝďůĞĨŽƌĐŚĂŶŐŝŶŐ ůĞǀĞůƐŽĨɴ-catenin while the physical presence of the 
PTEN protein appears to impact on the level of E-cadherin. 
I have shown that PTEN (-/-) cells express higher amounts of E-cadherin protein and transcripts 
than PTEN (+/+) cells. I have also shown that depletion of PTEN from PTEN (+/+) cells causes 
increases in the transcription and protein level of E-cadherin. These data were supported by the 
observation that expression of exogenous PTEN protein in PTEN (-/-) cells leads to reactivation 
of E-cadherin transcription.   
These findings are in contrast to a number of previous studies that associate down regulation of 
PTEN with decreased E-cadherin expression in a number of tumour types including ovarian, 
melanoma and nasopharyngeal (Hao et al. 2012, Zhang et al. 2013, Huang et al. 2014).   
There is evidence that PTEN associates with adherens junctions.  Studies using MDCK cells found 
that PTEN stabilised E-ĐĂĚŚĞƌŝŶĂƚĂĚŚĞƌĞŶƐ ũƵŶĐƚŝŽŶƐďƵƚ ŝƚĚŝĚŶŽƚĂůƚĞƌŽǀĞƌĂůů ůĞǀĞůƐŽĨɴ-
catenin or E-cadherin (Kotelevets et al. 2001). A further study by the same group showed that 
PTEN could be co-immunoprecipitated with E-ĐĂĚŚĞƌŝŶ ĂŶĚ ɴ-catenin. Here, PTEN had an 
ŝŶĚŝƌĞĐƚ ůŝŶŬƚŽɴ-catenin via the scaffold protein MAG1-1b (Kotelevets et al. 2005). Similarly, 
both PTEN and PI3K were identified in association with E-ĐĂĚŚĞƌŝŶĂŶĚɴ-catenin at adherens 
junctions in a pancreatic cancer cell line. In this case the phosphatase activity of PTEN was shown 
to play a role in the phospŚŽƌǇůĂƚŝŽŶŽĨɴ-catenin (Vogelmann et al. 2005). 
Although the exact role of PTEN in the regulation of adhesion junction components E-cadherin 
ĂŶĚɴ-catenin is unclear, there is evidence suggesting that these proteins co-localise in some 
cells. I found transcriptional repression of E-cadherin by PTEN in HCT116 cells. Interestingly the 
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transcriptional repression of E-cadherin was produced by transfection of a panel of PTEN 
proteins, including those no phosphatase function. This suggests that the physical presence of 
the PTEN protein is important rather than a specific enzymatic function. To establish a 
mechanism that explains these observations will require further experiments. A first step would 
be to identify the presence of PTEN in a complex with E-ĐĂĚŚĞƌŝŶ ĂŶĚ ɴ-catenin using co-
ŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚŝŽŶ͘/ƚŝƐƉŽƐƐŝďůĞƚŚĂƚƚŚĞŝŶƚĞƌĂĐƚŝŽŶŽĨWdEĂŶĚɴ-catenin via MAGI-1b may 
be dependent on a PDZ domain.  In that case, expression of a PTEN protein lacking a PDZ domain 
may be expected to affect its relationship with E-ĐĂĚŚĞƌŝŶŽƌɴ-catenin. Measuring E-cadherin 
ĂŶĚɴ-catenin levels following introduction of such a PTEN mutant protein could confirm this 
idea. I hypothesised that the relationship between PTEN and E-cadherin may involve Snail but I 
could not detect any change in the amount of Snail in response to PTEN expression. To take this 
further I would also assess other relatives of Snail involved in the EMT process such as Slug and 
Twist. 
The mechanism mediating the influence of PTEN on E-cadherin transcription may also involve a 
feedback loop regulating adherens junctions. A close association with the adhesion junction 
complex may place PTEN in a position to indirectly regulate transcription of some of the 
junctional components. Close association of PTEN with the junctional complex may act as a 
platform to recruit other proteins to the adherens junction that are released when the junction 
disassembles or is not fully functional.  This in turn may act as a signal for the requirement for 
more E-cadherin.  Release of PTEN and such additional proteins may stimulate E-cadherin 
transcription to maintain junctions. In the PTEN (-/-) cells such ‘transcription activating agents’ 
are unable to associate with PTEN or the adherens junction and therefore can stimulate 
transcription of E-cadherin. This speculative hypothesis will have to be tested by further 
experiments.   
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/ŚĂǀĞƐŚŽǁŶƚŚĂƚWdEĂĨĨĞĐƚƐƚŚĞůĞǀĞůƐŽĨďŽƚŚɴ-catenin and E-cadherin identifying potential 
cross talk between two common tumour suppressor genes, PTEN and APC. 
This is potentially important in cancer and several studies have shown combinations of 
mutations in these two tumour suppressor genes can enhance cancer progression. Loss of APC 
alone caused uterine hyperplasia but no malignant transformation in a mouse model of 
endometrial cancer. PTEN loss could initiate invasive lesions and loss of both tumour suppressor 
genes together hastened progression and caused more aggressive lesions than loss or mutation 
of either alone (van der Zee et al. 2013). In murine models of colorectal cancer, PTEN loss alone 
caused no alteration of epithelial architecture but in combination with APC loss mice developed 
adenocarcinoma (Marsh et al. 2008). This indicates that effects of PTEN loss may require 
adĚŝƚŝŽŶĂůĚǇƐĨƵŶĐƚŝŽŶŝŶɴ-catenin transcriptional activity to cause tumour genesis. A separate 
study by the same group found that in mice predisposed to adenoma development (APC fl/+) with 
PTEN and KRAS mutations developed adenocarcinoma with no metastasis. In contrast, APC wild-
type mice carrying mutation in PTEN and KRAS developed invasive metastatic cancers with a 
serrated histology. These findings indicate that the relationships between combinations of 
mutations and there functional consequences are complex. In addition, the effects of specific 
mutational signatures may act in a tissue dependent manner given the findings in endometrial 
versus colon cancer in mouse models described above.  
These studies indicate that crosstalk exists between the APC and PTEN pathways in tumours. My 
data support this at a molecular level. I have shown that changes in the amounts of E-cadherin 
ĂŶĚɴ-catenin occur in response to PTEN depletion. These two proteins are also implicated in 
colorectal cancer following APC loss. Further  characterisation of the of the cross talk at the 
molecular level will help elucidate how mutations in PTEN and APC can synergise to influence 
tumour characteristics.  
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PTEN mutations in human cancers have been associated with serrated lesions (Day et al. 2013). 
Consistently, I found lower PTEN signal in areas of serrated histology in some early stage human 
colorectal polyps. Analysis of a larger number of polyps and a broader range of tumour stages is 
required to characterise this further. In addition, the corresponding levels and localisation of E-
cadherin and E-catenin and mutational status of APC will need to be measured to determine 
how the findings in cell lines relate to situations in tumours. 
My data shoǁĞĚƚŚĂƚWdEĐĂŶĂĨĨĞĐƚůĞǀĞůƐŽĨďŽƚŚɴ-catenin and E-cadherin in HCT116 cells. 
The effects on E-cadherin appear to be dependent on the physical presence of PTEN protein to 
repress E-cadherin transcription. The link between PTEN and adherens junctions is important in 
cancers as adherens junctions are often down regulated during the process of EMT and cancer 
progression. I have shown an increase in E-cadherin when PTEN is depleted. Clarification of the 
mechanism responsible may allow development of strategies to manipulate E-cadherin levels in 
tumours, dampening the process of EMT and halting tumour progression. 
In the cell lines studied I measured effects of loss or re-expression of PTEN. This all or nothing 
approach may not reflect the situation in tumours, where mutations in the protein or post 
translational modifications may influence the protein activity as opposed to a complete absence 
of the protein. Modifications to the protein could potentially influence tumour progression or 
influence association with a particular histological category. Further work is required to assess 
ŝĨƐƉĞĐŝĨŝĐŵƵƚĂƚŝŽŶƐĐĂŶŝŵƉĂĐƚŽŶɴ-catenin and E-cadherin in a similar manner to complete 
loss of the PTEN protein 
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ϳ͘ϯƌŽůĞŽĨWŝŶ͚ƐƚŽƌŝŶŐ͛ĂŶĚƚƌĂŶƐƉŽƌƚŝŶŐɴ-catenin 
I hĂǀĞ ƐŚŽǁŶ ƚŚĂƚ W ĐĂŶ ƐĞƋƵĞƐƚĞƌ ƐƚĂďŝůŝƐĞĚ ɴ-catenin. This can regulate transcriptional 
ŽƵƚƉƵƚŽĨɴ-catenin. Similar attributes have been assigned to E-cadherin in mouse colon and this 
has been shown to limit tumour genesis (Huels et al. 2015). The coordinated actions of APC and 
E-ĐĂĚŚĞƌŝŶƚŚƵƐĐĂŶƌĞŐƵůĂƚĞɴ-catenin and help to maintain intestinal homeostasis. Dysfunction 
of any component of this triad can predispose to cancer. 
APC has many functions and targeting for degradation is usually considered its primary function 
ŝŶ ƚŚĞ ƌĞŐƵůĂƚŝŽŶ ŽĨ ɴ-catenin. I propose that APC potentially has as a primary role in the 
ƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin that involves storage and transport and that under certain conditions 
targeting for degradation is secondary. This is a speculative hypothesis and further experiments 
would be required to clarify this. But I will outline some justification for this proposal. 
^ƚĂďŝůŝƐĞĚɴ-catenin is sequestered by APC. If this sequestration is active and serves as functional 
ƐĞƋƵĞƐƚƌĂƚŝŽŶƚŽƌĞŐƵůĂƚĞɴ-ĐĂƚĞŶŝŶĂƐŽƉƉŽƐĞĚƚŽĞŶĨŽƌĐĞĚĚƵĞƚŽƚŚĞŵƵƚĂŶƚɴ-catenin being 
physically “stuck”, then this would provide a second method whereby APC can control free levels 
ŽĨĐĞůůƵůĂƌɴ-catenin. When precipitating AW͕ŵŽƌĞŵƵƚĂŶƚɴ-catenin was bound to APC than 
wild-type. Nonetheless, there was a significant amount of wild-ƚǇƉĞ ɴ-catenin found in 
ĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚW͘/ĨƚŚĞƌĞůĂƚŝŽŶƐŚŝƉďĞƚǁĞĞŶWĂŶĚɴ-ĐĂƚĞŶŝŶƐĞƌǀĞƐŽŶůǇƚŽĚĞŐƌĂĚĞɴ-
catenin, one would assume it ǁĂƐƚƌĂŶƐŝĞŶƚƐŽƚŚĂƚƌĞůĂƚŝǀĞůǇůŝƚƚůĞɴ-catenin is bound to APC at 
ĂŶǇŽŶĞƚŝŵĞ͘/ŶĂĚĚŝƚŝŽŶ͕ƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ-catenin levels is maintained within tight limits to 
ensure normal cell function and deviations from this caused by stabilising mutations or APC loss 
ĐĂŶƉƌĞĚŝƐƉŽƐĞƚŽĐĂŶĐĞƌ͘/ŶĚĞĞĚ͕ƚƌĂŶƐĐƌŝƉƚůĞǀĞůƐŽĨɴ-catenin in the mutant and wild-type cell 
ůŝŶĞƐǁĞƌĞǀĞƌǇƐŝŵŝůĂƌ͘/ĨĂůĂƌŐĞĂŵŽƵŶƚŽĨɴ-catenin was bound to APC for degradation, this 
could suggest that the cell has somehow “over shot” iƚƐĂĐĐĞƉƚĂďůĞĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨɴ-catenin, 
necessitating large scale degradation. Given the potential consequences of over stimulation of 
ɴ-catenin transcriptional activity this seems like a risky strategy for the cell.  
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If the primary function of APC is reůĂƚĞĚƚŽƐƚŽƌĂŐĞ͕ŝƚǁŽƵůĚƉƌŽǀŝĚĞƚŚĞĐĞůůǁŝƚŚĂƉŽŽůɴ-catenin 
that can be released should it be required by the cell. A Wnt signal can then provide an additional 
ŵĞĐŚĂŶŝƐŵƚŽƚŽƉƵƉƚŚŝƐɴ-catenin pool should the cell require it, by inhibiting the destruction 
complex.  
/ĨŽƵŶĚƚŚĂƚƚŚĞŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶɴ-catenin and APC takes place at the membrane of the cell. 
This is in keeping with previous findings that the destruction complex is associated with the 
membrane following inhibition by Wnt signalling (Li et al. 2012). If indeed APC performs a role 
ŝŶƚŚĞƚƌĂŶƐƉŽƌƚĂŶĚƐƚŽƌĂŐĞŽĨɴ-catenin, a plasma membrane associated location would seem 
logical as it is in close proximity to E-cadherin. This would allow exchanŐĞŽĨ ƐĞƋƵĞƐƚĞƌĞĚɴ-
catenin from APC to E-cadherin and vice versa.  A study by Klingelhofer and colleagues support 
ƚŚŝƐŝĚĞĂ͘dŚĞǇƐŚŽǁĞĚƚŚĂƚɴ-catenin can cycle on and off E-cadherin at the membrane but this 
process is impaired in APC deficient cells (Klingelhofer et al. 2003). Further support for a role of 
APC in the regulation of adherens junctions was identified following expression of full length 
WŝŶ^tϰϴϬĐĞůůƐ͘dŚŝƐƐƚŝŵƵůĂƚĞĚĂƚƌĂŶƐůŽĐĂƚŝŽŶŽĨɴ-catenin from the nucleus to the plasma 
membrane. In addition, E-cadherin also moved to the membrane. This is consistent with a role 
for APC in the transport of components of the adhesion complex (Faux et al. 2004).   
I alƐŽĨŽƵŶĚƚŚĂƚɴ-catenin redistributed to the cytoplasm following APC depletion but was not 
enriched in the nuclear.  However, AXIN 2 transcription increased under these conditions. 
Previous authors have identified a role for APC in the nuclear export of E-catenin (Rosin-
Arbesfeld et al. 2000, Rosin-Arbesfeld et al. 2003). APC lacking a nuclear export signal remained 
ĐĂƉĂďůĞ ŽĨ ƌĞŐƵůĂƚŝŶŐ ɴ-catenin transcriptional activity indicating a role for APC ion the 
sequestratŝŽŶŽĨŶƵĐůĞĂƌɴ-catenin (Neufeld et al. 2000). This supports a role for APC in both the 
ĂĐƚŝǀĞƚƌĂŶƐƉŽƌƚĂŶĚƐƚŽƌĂŐĞŽĨɴ-catenin as a means of regulating transcriptional output. 
This theory is speculative but my results and those of others indicate that APC could potentially 
ƌĞŐƵůĂƚĞɴ-ĐĂƚĞŶŝŶďǇŝƚƐĚĞůŝďĞƌĂƚĞƐĞƋƵĞƐƚƌĂƚŝŽŶ͘/ƚĐŽƵůĚĂůƐŽĨƵůĨŝůĂƌŽůĞŝŶƚŚĞƚƌĂŶƐƉŽƌƚŽĨɴ-
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ĐĂƚĞŶŝŶďĞƚǁĞĞŶĐĞůůƌĞŐŝŽŶƐƚŽďƌŝŶŐɴ-catenin in close proximity to E-cadherin while limiting 
the free pool available to activate transcription. Additional layers of regulation are added by the 
ƚĂƌŐĞƚĞĚ ĚĞŐƌĂĚĂƚŝŽŶ ŽĨ ɴ-catenin if levels are too high and by inhibition of the destruction 
complex in response to a Wnt ligand. The presence of an APC-ĂƐƐŽĐŝĂƚĞĚ͕ ƐƚŽƌĞĚ ƉŽŽůŽĨ ɴ-
ĐĂƚĞŶŝŶŵĂǇĂůůŽǁĨŝŶĞƌƚƵŶŝŶŐŽĨɴ-catenin levels than a simple model with and on and off state 
ĨŽƌƚŚĞĚĞŐƌĂĚĂƚŝŽŶĐŽŵƉůĞǆ͘&ŝŶĞƚƵŶŝŶŐǁŽƵůĚĨŝƚǁŝƚŚƚŚĞƚŚĞŽƌǇƚŚĂƚƚŚĞĐŽƌƌĞĐƚůĞǀĞůŽĨɴ-
catenin transcriptional output is required for carcinogenesis, in keeping with the “just right” 
model. Such tight regulation is likely also required for normal homeostasis. A role for APC as 
ďŽƚŚ Ă ƐƚŽƌĂŐĞ ĚĞƉŽƚ ĂŶĚ ƚƌĂŶƐƉŽƌƚĞƌ ƚŚĂƚ ĐĂŶ ƐŚƵƚƚůĞ ɴ-catenin between different 
compartments could be an effective mechanism to achieve this fine tuning. 
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8 Future Experiments 
This project has raised a number of questions that I would like to investigate in more detail. I 
ǁŽƵůĚůŝŬĞƚŽĚĞƚĞƌŵŝŶĞŝĨŵƵƚĂŶƚɴ-catenin was capable of cycling on and off of APC or if it is 
simply physically “stuck”. This could potentially distinguish between a passive role of APC in 
sequestering E-catenin statically (indicated by slow cycling) or a more active role in dynamically 
sequestering E-catenin so that can be regulated independently (indicated by more rapid cycling). 
dŽ ĚŽ ƚŚŝƐ / ǁŽƵůĚ ĞǆŽŐĞŶŽƵƐůǇ ĞǆƉƌĞƐƐ ƚĂŐŐĞĚŵƵƚĂŶƚ ɴ-catenin in cells expressing either 
mutant or wild-type E-catenin that can be induced rapidly. Performing APC 
immunoprecipitations at different times after inducing expression of the exogenous E-catenin 
ǁŽƵůĚƌĞǀĞĂůŚŽǁƋƵŝĐŬůǇ ƚĂŐŐĞĚɴ-catenin replaced the endogenous wild-ƚǇƉĞŽƌŵƵƚĂŶƚɴ-
catenin bound to APC over time.  Similarly, investigating the E-catenin that can be co-
immunprecipiated with E-cadherin would reveal the relative interactions of wild-ƚǇƉĞɴ-catenin 
and mutant E-catenin with E-cadherin. 
/ ǁŽƵůĚ ƌĞƉĞĂƚ ƚŚĞ ŵŽůĞĐƵůĂƌ ĂŶĂůǇƐŝƐ ŽĨ ƚŚĞ ƌĞůĂƚŝŽŶƐŚŝƉƐ ďĞƚǁĞĞŶ W͕ ɴ-catenin and E-
cadherin in organoids. They represent a more physiologically relevant system and initially I 
ǁŽƵůĚĐŽŵƉĂƌĞůĞǀĞůƐĂŶĚŝŶƚĞƌĂĐƚŝŽŶƐďĞƚǁĞĞŶɴ-catenin, E-cadherin and APC from wild-type 
and APC Min/+ mice. I would also like to carry this out on organoids from mice carrying a stabilising 
ɴ-catenin mutation. Ultimately I would like to investigate these relationships in organoids 
ĚĞƌŝǀĞĚĨƌŽŵŚƵŵĂŶƚŝƐƐƵĞ͘dƵŵŽƵƌƐĂŵƉůĞƐǁŝƚŚĞŝƚŚĞƌWŽƌɴ-catenin mutations would be 
compared to clarify differences at the molecular level. This system would also provide a platform 
for drug screening studies. 
I would also investigate the relationship between E-cadherin and PTEN in more detail. I would 
start by attempting to Co-/WWdEǁŝƚŚɴ-catenin and E-cadherin. If this was successful I would 
express a mutant PTEN protein lacking a PDZ domain to measure if this region was necessary for 
ƚŚĞŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶWdE͕ɴ-catenin and E-ĐĂĚŚĞƌŝŶ͘/Ĩ/ǁĂƐĂďůĞƚŽƉƌŽǀĞŝŶƚĞƌĂĐƚŝŽŶŽĨɴ-
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catenin, E-cadherin and PTEN in HCT116 cells I would analyse a Co-IP study using mass 
spectrometry to highlight any other proteins present in the complex. These proteins would then 
be candidates for involvement in the transcriptional repression of E-cadherin and would be 
studied further.  
A larger scale mass spectrometry based screen of the wild-type and mutant cells would also be 
undertaken. Multiple differences exist between these cells in morphology, function and 
biochemical properties. The only genetic difference between the cells is that one expresses 
mutant and the other wild-ƚǇƉĞɴ-catenin. One may assume that much of the functional and 
ďŝŽĐŚĞŵŝĐĂů ĚŝĨĨĞƌĞŶĐĞƐ ďĞƚǁĞĞŶ ƚŚĞ ĐĞůůƐ ƌĞƐƵůƚ ĨƌŽŵ ĚŝĨĨĞƌĞŶƚŝĂů ŽƵƚƉƵƚ ŽĨ ɴ-catenin 
transcriptional activity.  A screen to determine differences in protein expression between the 
cells could then be used to focus a more specific analysis. For example if proteins known to be 
involved in cell adhesion were enriched more in the wild-type than the mutant cells then these 
ĐŽƵůĚ ďĞ ĐŽŶƐŝĚĞƌĞĚ ĨƵƌƚŚĞƌ ǁŝƚŚ ƚŚĞ Ăŝŵ ŽĨ ĞǆƉůĂŝŶŝŶŐ ĚŝĨĨĞƌĞŶƚŝĂů ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ ɴ-
catenin  and E-cadherin. A similar approach could be taken to other cell functions. This would 
provide more insight into how molecular differences influence their relevant signalling pathways 
and in turn, cell function. 
I would extend my experiments to include a broader assessment of Wnt target genes and assess 
differences between the mutant and wild type cell lines. I examined Axin 2 which is a recognised 
tŶƚ ƚĂƌŐĞƚ  ŐĞŶĞ ĂŶĚ ŝƐ ĨƌĞƋƵĞŶƚůǇ ƵƐĞĚ ƚŽ ĂƐƐĞƐƐ ɴ-catenin transcriptional activity. I would 
measure transcription of ĂƉĂŶĞůŽĨŽƚŚĞƌɴ-catenin target genes using qPCR. Other reporter 
systems exist such as TOP flash. This represents a more basic determination of an either on or 
off state. I feel that qPCR measurements of target genes is more sensitive given the complexities 
ŽĨɴ-catenin transcriptional activity. 
I would also carry out sequencing of the mutant and wild type cells I have used. Although these 
ĐĞůůƐĂƌĞŝƐŽŐĞŶŝĐĂŶĚĚŝĨĨĞƌŽŶůǇŝŶƚŚĞŝƌĞǆƉƌĞƐƐŝŽŶŽĨɴ-catenin it must be borne in mind that 
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they are cancer cells of the mutator phenotype. Sequencing would clarify if the existence of 
further mutations are contributing to experimental findings. 
Lastly I would extend my analysis of human polyps to include a variety of stages as opposed to 
only early stage lesions that I studied. Detailed information about the mutations in the samples 
in APC, PTEN or KRAS would also allow comparison of the findings to those identified in the cell 
line studies. This may highlight opportunities for new diagnostic or therapeutic approaches. 
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Appendix 1 
 
ŶĂůǇƐŝƐŽĨɴ-catenin distribution using immunofluorescence microscopy 
Introduction 
The initial approach in my project involved using immunofluorescence microscopy to measure 
ƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin within the cell. By determining location I hoped to be able to infer 
which of its most common binding partners it was likely to be associated with and the function 
ƚŚĂƚŝƚǁĂƐƉůĂǇŝŶŐ͘&ŽƌĞǆĂŵƉůĞɴ-catenin at the membrane may signify a role in cell adhesion 
ǁŚŝůĞŶƵĐůĞĂƌɴ-catenin may imply a signalling function. I aimed to assess if the distribution of 
ɴ-catenin was responsive to biochemical manipulation of the levels of its binding partners. I 
ƉůĂŶŶĞĚƚŽŵĞĂƐƵƌĞƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin in both HCT116 colorectal cancer cells and in 
mouse gut tissue. 
 
Cell compartment identification and image analysis 
dŽ ĂĚĚƌĞƐƐŵĞĂƐƵƌĞŵĞŶƚ ŽĨ ŝŶƚƌĂĐĞůůƵůĂƌ ĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ ɴ-catenin using immunofluorescent 
imaging, I had to establish a method of visually identifying the cell membrane and nucleus using 
markers so that I could extract the relevant data from the images. Numerous methods were 
attempted and failed. I found DAPI to be a suitable stain to identify the cell nucleus. I tried 
several aproaches to identifying the cell membrane. The best visual representation of the cell 
ŵĞŵďƌĂŶĞǁĂƐĂĐŚŝĞǀĞĚƵƐŝŶŐĂŶƚŝďŽĚǇĚŝƌĞĐƚĞĚĂŐĂŝŶƐƚɴ-ĐĂƚĞŶŝŶ͘ŽŶƐŝĚĞƌŝŶŐƚŚĂƚɴ-catenin 
was to be the focus of my measurements, I deemed it inapproprate to use this to identify the 
cell membrane compartment. I compared phalloidin stain with an antibody directed against 
Na+/K+ ATPase. Both of these prodced a good representation of the cell membrane. Phalloidin 
was a better choice as it is a stain as opposed to an antibody. This resulted in more flexibility 
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when using other antibodies as more options would be available for the specific species of 
secondary antibodies. 
Alternative membrane stains such as wheat germ agglutinin were unsuccesful as it stained the 
nuclear membrane as opposed to the plasma membrane. I also attempted to use cytoplasmic 
stains to identify the cytoplasm. These were unsuccesful as they produced a diffuse non-specific 
staining pattern. I therefore decided to use DAPI to identify nuclei and phalloidin to mark the 
cell membrane. 
Using these markers to identify visually the relevant cell compartments, a threshold can be 
applied to their signal intensity using image analysis software. This allows the creation of a 
“mask”, representing an area overlaying the region of interest. In this way, masks representing 
the membrane and nuclear compartments can be created. Combining these two masks and 
inverting creates a mask for the remaining cytoplasmic compartment. Examples of these 
“masks” can be seen below in Figure A1 and show good correlation with regions identified 
visually with the phalloidin and DAPI stains, respectively. Using image analysis software the 
masks can be overlain on the original image. The signal intensity from the protein of interest 
within the area covered by the overlying “masked” region can then be calculated. 
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Figure A1.1: Shows visual identification of the membrane compartment using Alexa-fluor 568 
phalloidin in a) and identification of the nuclear compartment using DAPI in b) in HCT116 (wild-
type) cells. Figure 1c) shows E-catenin stain in HCT116 (wild-type) cells. The corresponding 
threshold “masks” can be seen below to represent the membrane compartment in 1d), the 
nuclear compartment in 1e) and the cytoplasmic compartment in 1g). 
Once markers of the cellular compartments were identified, I aimed to assess whether their use 
could produce reliable and consistent measurement of my target proteins between different 
samples. To quantify the intracellular distribution of my target proteins, the quantity at the 
membrane region was assigned a value 1. Protein levels in the cytoplasmic and nuclear regions 
were then calculated relative to levels at the membrane. 
This method of image analysis produced inconsistent quantification of relative intracellular 
distribution of proteins of interest. Figure A2 shows the distribution of E-catenin in untreated 
HCT116-HaB92 (wild-type) cells taken from five separate slides. 
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Figure A1.2: Shows relative intracellular distribution of E-catenin in HCT116-(wild-type) cells 
taken from five separate slides. The membrane value is set at 1 and the cytoplasmic and nuclear 
content are measured relative to the membrane. 
 
Several problems were encountered using this method. Accuracy could be improved by selecting 
a single image slice for quantification. This, however, was not representative of the whole cell. 
Analysis of the entire stack was very time consuming if the process was carried out manually. In 
conjunction with image analysis experts, I developed a macro that was capable of automating 
the analysis process on the whole stack. Although this sped up the process, results were variable 
and unreliable. 
dŚĞŵĞƚŚŽĚǁĂƐĐĂƉĂďůĞŽĨĚĞƚĞĐƚŝŶŐůĂƌŐĞĐŚĂŶŐĞƐŝŶƚŚĞůŽĐĂůŝƐĂƚŝŽŶŽĨɴ-catenin. For example 
I treated the cells with Leptomycin B, which ĂĐƚƐƚŽƚƌĂƉɴ-catenin in the cell nucleus. This large 
shift was detectable using the image analysis method described. Subtle changes produced by 
biochemical depletion of proteins of interest were not amenable to accurate measurement. I 
used siRNA to deplete APC. To determine successful transfection of the cell I used fluorescently 
tagged siRNA to provide a visual indication of transfection. The transfection pattern was 
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heterogeneous, so quantification of a whole field of cells was unrepresentative of treatment 
effects. Automated identification and quantification of successfully transfected cells was not 
possible. This added to inaccuracies inherent in the method. 
YƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨɴ-catenin distribution in mouse intestine 
/ĂůƐŽĂƚƚĞŵƉƚĞĚƚŽƋƵĂŶƚŝĨǇƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨɴ-catenin in mouse gut tissue. I had aimed to be 
able to detect and quantify differences in distribution between normal gut tissue and that from 
APC (min/+) mice. Unfortunately, this was also fraught with problems. I tried to make adaptations 
to overcome these, but was ultimately unsuccessful. I will outline some of the issues and 
attempted solutions here. 
Automated identification of cell compartments 
I used actin and DAPI as markers of the cell membrane and nucleus, respectively. I then used 
image analysis programmes to apply a mask automatically to each of these markers based on 
signal intensity from the actin and the DAPI. This mask was then used as a template to represent 
each cellular region of interest. I aimed to quantify the E-catenin intensity contained within each 
region of interest to calculate its relative cellular distribution. The intention of using an 
automated approach was to minimise the inherent bias in delineating cell compartments 
manually. Several problems were encountered. 
The cells in gut tissue are very closely and irregularly packed. Often a region of one cell (e.g. 
membrane) overlaps with nuclear or cytoplasmic regions of neighbouring cells. It was therefore 
impossible accurately to resolve each cellular region, rendering the produced data unreliable. A 
representative image of a mouse gut crypt can be seen in Figure A3. 
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Figure A1.3: Colonic crypt from normal mouse gut tissue stained with actin (yellow), DAPI (blue) 
and E-catenin (green) shows how closely overlapping cells and their components are. 
I attempted using both wax and frozen tissue sections, but this did not improve compartment 
delineation to an extent that made automatic determination of cell compartments feasible. I 
used multiple image analysis software packages including imageJ and Imaris. The new Imaris 
package was purchased to aid automatic analysis. I discussed the issues with all available image 
analysis experts within the College of Life Sciences, including the microscopy department and 
the OMERO team. I also arranged a discussion of possible data analysis solutions with an image 
analysis expert from the Imaris Company. None of these approaches yielded any success for 
tissue analysis. 
Manual Identification of Cell Compartments 
I then attempted manual identification of cell compartments, again using actin and DAPI as 
markers as an automated image analysis method was not possible. This involved drawing around 
the relevant marker and using the image analysis software to calculate E-catenin intensity 
contained within my manually acquired region of interest. A representative image of manually 
compartmentalised regions of interest is shown in Figure A4. 
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Figure A1. 4: Identification of cell regions using manual compartmentalisation. Two Paneth cells 
and two stem cells are shown divided into regions representing nucleus (blue), membrane (red) 
and cytoplasm (yellow) from a colonic crypt in normal mouse gut tissue. 
 
Several problems occurred using this approach also. Frequently, cell regions overlap with other 
regions in neighbouring cells. It is thus very difficult accurately to identify a region of interest, 
even manually and when using whole stacks or individual Z planes. Even in a single Z plane it is 
challenging to unambiguously identify all regions reliably, making data unreliable, and without 
three-dimensional data the results do not represent the cell as a whole. 
 
In tissue sections, in the smaller stem cells the cell volume is almost entirely filled with the 
nucleus. It is therefore difficult to identify a cytoplasmic compartment and identify it as a region 
of interest. Cellular identification was based on gross morphological features. Paneth cells are 
characterised by large empty-looking cytoplasmic regions and stem cells are the small 
intervening cells. The alternative is to use specific cell-type markers such as lysozyme and LGR5. 
However, these then occupy two fluorescent channels, limiting the availability of other 
fluorescent microscope channels required for actin, DAPI and proteins of interest such as E-
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catenin. As the analysis was making use of tissue sections, it is impossible to determine with 
confidence what position in the crypt is being scrutinised. An estimate of this can be made using 
the crypt lumen diameter, but this is open to error. Having an accurate estimate of this is 
important as crypt position could influence the cellular distribution of E-catenin. Another 
consideration in this image analysis was time. To analyse a single crypt in this manner took a 
considerable amount of time. Given the unreliable nature of the data produced and the number 
of crypt measurements that would be required, I abandoned this approach. Not surprisingly, 
analysing the data acquired in this manner showed large inter-crypt variability, consistent with 
the issues raised above, and questioning the robustness of the data (Figure A5). 
 
Figure A1.5: E-Catenin distribution in cells from normal intestinal mouse crypts. Comparison 
between Paneth cells from four different crypts (n = 10 cells per crypt) is shown in a) and between 
stem cells in b). Figure A5c) shows E-catenin distribution between cells from the villous, Paneth 
cells and stem cells (n = 30 cells from each region). 
 
&ƵƌƚŚĞƌ ĂĚǀĂŶĐĞƐ ĂƌĞ ƌĞƋƵŝƌĞĚ ĨŽƌ ĂĐĐƵƌĂƚĞ ƋƵĂŶƚŝĨŝĐĂƚŝŽŶ ŽĨ ɴ-catenin using 
ŝŵŵƵŶŽĨůƵŽƌĞƐĐĞŶĐĞŝŵĂŐŝŶŐ͘ůƚŚŽƵŐŚɴ-catenin has a predominant membrane location, it has 
a diffuse distribution in other cell compartments also. Quantification of protein localisation using 
imaging may be more robust if the protein of interest had a more specific location. Good visual 
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representations of the distribution can be easily achieved, but accurate numerical quantification 
of this is problematic. Given the failure to develop a robust reliable method and the large time 
investment involved, it was decided that the project should be approached from a slightly 
different angle. 
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Appendix 2 
Throughout this thesis I have shown a number of western blots. These have generally been 
shown without an accompanying sizing ladder. Here I will show a few examples of full blots 
including ladders. The blue colour visible on the blots is due to pen used to mark the ladders. 
The first example shows efficiency of target protein knockdown following siRNA treatment 
(Figure A2. 1) 
 
 
a)                                                                  B) 
Figure A2.1: Western blot showing depletion of APC, ɴ-catenin and E-cadherin compared to 
control in (a) and APC, ɴ-catenin and PTEN in (b). Blots were probed with antibody targeting APC, 
E-cadherin, ɴ-catenin, PTEN and GAPDH.  
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Generally a knockdown of approximately 80-90% of control levels were achieved in each 
ƚĂƌŐĞƚĞĚƉƌŽƚĞŝŶ͘dŚŝƐǁĂƐĐŽŶƐŝƐƚĞŶƚĂĐƌŽƐƐĂůůĐĞůůůŝŶĞƐƐƚƵĚŝĞĚ͘/ĂůƐŽŽǀĞƌĞǆƉƌĞƐƐĞĚɴ-catenin 
in the mutant and wild-type cell lines. A whole representative blot including ladder is shown 
(Figure A2. 2) 
 
Figure A2.2: Western blot showing expression of exogenous mutant or wild-type E-catenin in 
mutant (Left) and wild type (right cells). Blots were probed with antibodies against APC, E-
catenin and GAPDH (Top panel). The same blot was also probed against E-cadherin (bottom 
panel). 
I also expressed exogenous PTEN protein in PTEN (-/-) cells. A full size representative western 
blot is shown (Figure A2. 3). 
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Figure A2.3: Western blot showing expression of a series of PTEN proteins in PTEN (-/-) cells 
compared to untreated and control treated cells. Blots were probed with antibodies against APC, 
E-cadherin, Ⱦ-catenin PTEN and GAPDH.  
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I also fractionated cells into cytoplasmic, membrane, nuclear and cytoskeletal compartments. In 
order to assess the efficiency of the fractionation process I blotted against specific 
compartmental markers. I used GAPDH, E-cadherin, TOPO II and Keratin 19 as markers of the 
cytoplasmic, membrane, nuclear and cytoskeletal compartments respectively. After 
determining that the fractionation protocol was robust using these markers I did not blot for 
these four markers on every single blot. If I found an unexpected result I would check the 
fractionation efficiency with compartment markers. I also frequently blotted for E-cadherin, 
TOPO II and GAPDH to mark 3 of the 4 compartments. A representative blot is shown (Figure A2. 
4).  
 
Figure A2.4: Representative western blots showing compartmental markers. In (a) the 
membrane compartment is shown by blot against E-cadherin and the nuclear compartment by 
TOPO II. In (b) GAPDH shows the cytosolic compartment and Keratin 19 the cytoskeletal. In blot 
(c) 2 cell fractionations are shown. The blot is probed against £-catenin and efficiency of 
fractionation is shown by blot against GAPDH, E-cadherin and TOPO II to show the cytosolic, 
membrane and nuclear compartments respectively.   
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